Methods of Treating Neurological and Cardiovascular Conditions

A1R and A3R agonists are used to treat brain and cardiovascular conditions by achieving specific receptor occupancy, addressing the limitations of current treatments and optimizing treatment efficacy through targeted drug delivery and dosing.

JP2024541763APending Publication Date: 2024-11-12ASTROCYTE PHARMACEUTICALS INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024530021
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-22
Filing Date
2022-11-22
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Current treatments for brain injuries, central nervous system injuries, and cardiovascular conditions are limited by the inaccessibility of the brain and the limited regenerative ability of brain cells, with a need for more effective neuroprotective drugs and methods to determine optimal dosing and target engagement.

Method used

The use of A1R and/or A3R agonists to treat conditions such as traumatic brain injury, stroke, and cardiovascular disease by achieving specific receptor occupancy (%RO) between 0.01% to 40% in the brain or central nervous system, optimizing treatment regimens through methods that include administering the compounds and determining receptor occupancy.

Benefits of technology

This approach allows for effective treatment of various injuries and conditions by ensuring the compounds reach the intended target sites, improving neuroprotection and promoting neural repair, and reducing the need for large clinical trial groups by using target occupancy data to guide dosing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541763000052
    Figure 2024541763000052
  • Figure 2024541763000053
    Figure 2024541763000053
  • Figure 2024541763000054
    Figure 2024541763000054
Patent Text Reader

Abstract

The present invention provides nucleoside analog compounds and methods of use thereof for the treatment of certain injuries, diseases, disorders and conditions, such as brain injury, such as stroke or traumatic brain injury.The present invention further provides methods for screening adenosine receptor agonists for efficacy, determining optimal treatment regimens, and evaluating the brain and / or CNS receptor occupancy levels required for efficacy.The present invention relates to compounds and methods of use thereof for treating, improving, or promoting recovery from certain conditions of the brain, central nervous system (CNS), or cardiovascular system, such as brain injury, neurodegenerative conditions, or cardiac ischemia.The present invention also provides methods for determining the effective treatment to administer for such conditions.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 63 / 264,424, filed November 22, 2021, the entirety of which is incorporated herein by reference.

[0002] FIELD OF THEINVENTION The present invention relates to compounds and methods of use thereof for treating, ameliorating, or promoting recovery from certain conditions of the brain, central nervous system (CNS), or cardiovascular system, such as brain injury, neurodegenerative conditions, or cardiac ischemia. The present invention also provides methods for determining effective treatments to administer for such conditions. [Background technology]

[0003] 2. Background of the Invention Brain injury and damage to the central nervous system (CNS) are substantial causes of death and disability worldwide. Brain and CNS conditions that result in neuronal death and damage range from ischemic episodes (e.g., stroke) and trauma to degenerative disorders (e.g., Alzheimer's disease). Treatment options are limited by factors such as the inaccessibility of the brain and the limited ability of neurons and other brain cells to regenerate. For example, current acute ischemic stroke (AIS) therapies are limited to recanalization by thrombolysis or thrombectomy. These treatments focus on restoring blood flow and oxygenation of hypoperfused tissues. However, thrombolytic agents are only given to less than 5% of AIS patients within a limited time window after occlusion, whereas thrombectomy requires access to the site of occlusion and is currently available in less than 20% of AIS patients.

[0004] There is a major unmet need for pharmacological therapies that are both neuroprotective and administrable for the majority of AIS patients with recanalization. The vast majority of previous preclinical neuroprotection programs have focused on efficacy evaluation in rodent models, with limited insight into drug distribution, target engagement, and pharmacological response, perhaps inevitably resulting in neutral or negative findings during clinical trials. For these reasons, the international Stroke Treatment Academic Industry Roundtable (STAIR) has issued detailed guidelines for preclinical testing of potential AIS therapies, including evaluation of efficacy in both lyssencephalic and gyrencephalic species. To date, there is a lack of options beyond the postsynaptic density protein-95 inhibitor nerinetide and the plasminogen modulator SMTP-7 that meet the STAIR guidelines for evaluation in both rodent and nonhuman primate (NHP) stroke models prior to the initiation of clinical trials. More generally, there is a need for more effective means of determining effective doses, and whether effective doses exist, for candidate compounds under investigation for stroke, TBI, and conditions of the brain, CNS, and cardiovascular system. For example, candidate compounds may need to cross the blood-brain barrier and engage target receptors with sufficient efficiency to be effective.

[0005] There is an urgent and compelling unmet medical need for more effective treatments for brain injury, CNS injury, heart and cardiovascular disease, and related conditions, as well as for promoting neuronal repair in patients with neurodegenerative conditions, such as Alzheimer's disease. Summary of the Invention [Means for solving the problem]

[0006] Summary of the Invention In some embodiments, the present invention provides methods for evaluating the efficacy of new drug candidates, selecting clinical doses, improving efficacy, and treating various injuries, diseases, disorders, and conditions. Such drug candidates include the compounds described herein. In one embodiment, the compounds for use in the provided methods are A1R and / or A3R agonists.

[0007] In some embodiments, the compound acts as an agonist of the A3 adenosine receptor (A3R). In some embodiments, the compound is a partial A3R agonist. In some embodiments, the compound is a biased A3R agonist. In some embodiments, the compound acts by dual agonism at the A3 adenosine receptor and the A1 adenosine receptor (A1R). In some embodiments, the compound acts as an agonist of the A1 adenosine receptor (A1R). In some embodiments, the compound is a partial A1R agonist. In some embodiments, the compound is a biased A1R agonist. [Brief description of the drawings]

[0008] [Figure 1] Figure 1A-C shows the effect of initiation of I-1 treatment on the slope of DWI lesion growth following tMCAO in non-human primates. (A) Slope of MCAO lesion growth prior to initiation of vehicle or I-1 treatment. (B) Slope of MCAO lesion growth following vehicle or I-1 treatment. (C) Comparison of the slope of lesion growth before and after initiation of vehicle or I-1 treatment 2 hours after occlusion. Results represent mean ± SEM, n = 4 / dosage group, and n = 16 for groups treated with all I-1 complexes combined ("Comp"). Pre-treatment slopes of lesion growth were determined for each subject from 0.5-1.8 hours after occlusion. Initial post-treatment slopes were determined from 1.8-6.0 hours after occlusion to provide sufficient time points for slope determination. Unpaired t-tests comparing each I-1 treatment group to the vehicle group (Panels A, B) and paired t-tests comparing each group to itself, before and after treatment.

[0009] [Diagram 2] Figure 2 shows the percent change in penumbra volume following tMCAO and treatment with vehicle or I-1. Penumbra volume was calculated from the difference between cerebral perfusion defect and lesion volume at a threshold of less than 30% of contralateral cerebral blood flow from 0.5 to 3.5 hours after occlusion. Results represent mean ± SEM, n = 4 / dosage group, and n = 16 for all I-1 complex-treated groups. Unpaired t-test comparing each I-1 treatment group to the vehicle group.

[0010] [Diagram 3] FIG. 3A-D shows a comparison of DWI lesion volume growth between vehicle and I-1 treated subjects following tMCAO. (A) Comparison of DWI lesion size and growth between vehicle and all I-1 complex treated subjects. (B) Comparison of DWI lesion size and growth between vehicle and each I-1 treated dose group. (C) Comparison of percent inhibition of DWI lesion volume 24 hours after occlusion. (D) Comparison of percent inhibition of DWI lesion volume 120 hours after occlusion. Results represent mean ± SEM, n=4 / dose group, and n=16 for all I-1 complex treated groups. Unpaired t-test.

[0011] [Figure 4] 4A-B show a comparison of representative DWI and HE stained images of lesions from vehicle and I-1 treated subjects. (A) Representative DWI images of lesions at 0.5 and 120 hours post-occlusion in each vehicle and I-1 dosing group. (B) Representative HE stained brain section at 120 hours post-occlusion. Shaded areas indicate infarcted areas.

[0012] [Figure 5-1]Figure 5A-E shows I-1 plasma and CSF pharmacokinetics in non-human primates following MCAO, as well as the relationship between DWI lesion volume inhibition and mean I-1 unbound plasma concentration, CSF total concentration and estimated A1R / A3R brain receptor occupancy. (A) Plasma and (B) CSF pharmacokinetics. (C) Correlation between CSF concentration and unbound plasma concentration. Pharmacokinetics were determined following initiation of the bolus / infusion regimen and compared to a reference intravenous bolus dose. (D) Relationship between % inhibition of lesion volume at final DWI measurement (120 hours) and unbound plasma concentration (red), CSF total concentration (blue). (E) Relationship between % inhibition of lesion volume at final DWI measurement and estimated I-1 brain receptor occupancy for adenosine A1 and A3 receptors (green). Results represent mean ± SEM, n=4 / dosing group. [Figure 5-2] Figure 5A-E shows I-1 plasma and CSF pharmacokinetics in non-human primates following MCAO, as well as the relationship between DWI lesion volume inhibition and mean I-1 unbound plasma concentration, CSF total concentration and estimated A1R / A3R brain receptor occupancy. (A) Plasma and (B) CSF pharmacokinetics. (C) Correlation between CSF concentration and unbound plasma concentration. Pharmacokinetics were determined following initiation of the bolus / infusion regimen and compared to a reference intravenous bolus dose. (D) Relationship between % inhibition of lesion volume at final DWI measurement (120 hours) and unbound plasma concentration (red), CSF total concentration (blue). (E) Relationship between % inhibition of lesion volume at final DWI measurement and estimated I-1 brain receptor occupancy for adenosine A1 and A3 receptors (green). Results represent mean ± SEM, n=4 / dosing group.

[0013] [Figure 6] FIG. 6 shows the change in neurological deficit scores from day 1 to day 5 following middle cerebral artery occlusion in non-human primates. Neurological deficit was assessed using the neurological deficit score (NDS). Results are expressed as mean ± SEM, n=4 per dose group, and n=16 for groups treated with all I-1 complexes combined. Statistical analysis was an unpaired t-test comparing each I-1 treatment group to the vehicle group.

[0014] [Figure 7] FIG. 7 shows that R-PIA at a dose of 0.02 mg / kg showed partial reversal of the decrease in ATP during ischemia in rats. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] Detailed Description of the Invention Summary of Certain Aspects of the Invention Many drugs are ultimately targeted to specific binding sites at receptors, ion channels, transporters, or enzymes. Recent investigations have revealed the level of drug occupancy required at some target sites, with the level of drug or ligand occupancy required to activate a biological response in animal studies to achieve therapeutic efficacy in humans. Non-invasive methodologies, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) tracer studies, are particularly useful as they have the sensitivity required to perform target occupancy studies in both humans and animals, allowing quantification of specifically bound compounds in both normal and diseased tissues. Clinical and preclinical assays of target site occupancy by drugs and new drug candidates may provide the potential to reorient drug discovery and development toward optimal dosing of desired target sites while minimizing side effects, as well as achieving specific levels of target occupancy that can most effectively stimulate or inhibit specific receptors, ion channels, transporters, and enzymes. Similarly, measurements of target occupancy can improve animal research studies by optimizing efficacy at desired target sites while minimizing off-target effects.

[0016] Although some general insights have been elucidated regarding the degree of in vivo target occupancy required for effective activation or blocking of physiological and behavioral responses by drugs, ligands, and endogenous agonists, there are no available studies that allow the skilled artisan to determine the receptor occupancy (RO)% required for therapeutic efficacy at adenosine 1 and 3 receptors (A1R and A3R), particularly in brain and CNS targets. Human target occupancy data (from PET and SPECT) are now available for many G protein-coupled receptors (GPCRs), selected neurotransmitter transporters, and some enzymes and ion channels, providing valuable information regarding the target occupancy required for efficacy at precedent targets. Due to the multiple variables that affect the RO% required for therapeutic efficacy, initial studies must be expanded to build a rationale for predicting clinical efficacy for precedent targets as well as novel chemical entities acting on unprecedented targets, such as both A1R and A3R.

[0017] As described in Grimwood et al., Pharmacology & Therapeutics 122 (2009) 281-301, incorporated herein by reference in its entirety, the required target occupancy will depend on the molecular class of both the target and the ligand, and will be similar to both patient treatment and human or animal physiology. For antagonists, approximately 60-90% target occupancy is required for G protein-coupled receptors, neurotransmitter transporters, and ligand-gated ion channels. In contrast, the RO% (receptor occupancy%) required for an effective dose of an agonist may range more widely, depending on the intrinsic activity of the agonist, the reserve of the receptor or ion channel at the target site, and the response being measured. Agonists with low efficacy generally require a higher degree of occupancy, and agonists with high efficacy generally require a lower degree of occupancy. Target desensitization, competition by endogenous ligands, and regional target differences all affect the target occupancy requirements. Measurement of target occupancy can help ensure proper dosing and targeting of compounds in preclinical and clinical drug development and basic research. Generalization of target occupancy can be particularly important in establishing early dosing recommendations for many new drug targets provided by the onset of genomic and proteomic approaches, for which little data is available on their functional response.

[0018] For example, early dose-ranging studies in early clinical trials often require large group sizes to obtain statistically significant results using symptom assessment as the primary outcome. If the primary outcome measurement is changed to a surrogate marker defined by the target occupancy level that is required to affect preclinical disease models or activate preclinical biological responses, the group size of these early dose-ranging clinical trials can be reduced and development timelines shortened. In addition, many clinical trials end with no evidence of efficacy, and even worse, many also end without knowing whether the drug has the appropriate level to reach the intended target site. As provided in the present invention, the target occupancy guided method provides evidence that the target site is occupied to the intended extent by the drug candidate, and therefore has performed an appropriate test of its therapeutic potential.

[0019] Improved guidance of both the discovery and development process by target occupancy data could significantly shorten and improve new drug development. Molecular target occupancy data also provide important insights into physiological activation by endogenous agonists and quantitative requirements for ligand dosing in basic animal studies. In vivo target occupancy measurements can also help resolve critical issues regarding brain activation, such as the effect of receptor reserve, regional differences in target site response, the effect of disease processes and disease progression at receptors, possible differences in the degree of target occupancy between clinical responders and non-responders, and the degree of receptor occupancy by endogenous agonists in animals and humans.

[0020] The integration of target occupancy approaches with basic animal research throughout the drug discovery and development process holds great promise for improving dose selection and optimizing on-target versus off-target effects in both types of studies. A unified focus on target occupancy throughout drug discovery and development can also help accelerate the discovery of new drugs, especially for difficult-to-treat diseases in the brain and CNS, where selectively delivering adequate levels of a drug to its intended cellular and molecular target sites presents challenges.

[0021] Thus, the present invention provides methods for evaluating the efficacy of small molecule drug candidates, selecting clinical doses, improving efficacy, and treating various injuries, diseases, disorders, and conditions.Such drug candidates include the compounds described herein.In some embodiments, the compounds for use in the provided methods are A1R and / or A3R agonists.

[0022] In one aspect, the invention provides a method of treating an injury, disease, or disorder, such as traumatic brain injury (TBI), stroke, a neurodegenerative condition, a cardiac or cardiovascular disease, addiction, an addictive disorder, and a condition associated with TBI, stroke, or a neurodegenerative condition, comprising administering to a subject in need thereof an amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising same, effective to reach 0.01-40% receptor occupancy (%RO) at the A1 receptor (A1R) and / or A3 receptor (A3R) in the brain or CNS for a period of time sufficient to treat the condition.

[0023] In another aspect, the present invention provides a method of screening A1R, A3R, or dual A1R / A3R agonists for efficacy in treating an injury, disease, or disorder, such as traumatic brain injury (TBI), stroke, a neurodegenerative condition, a cardiac or cardiovascular disease, and a condition associated with TBI, stroke, or a neurodegenerative condition, comprising administering to a subject in need thereof an amount of an A1R, A3R, or dual A1R / A3R agonist, or a pharma- ceutically acceptable salt thereof or a composition comprising same; and determining receptor occupancy (%RO) at the A1 receptor (A1R) and / or A3 receptor (A3R) in the brain or CNS.

[0024] In some embodiments, the A1R, A3R, or dual A1R / A3R agonist is effective to treat an injury, disease, or disorder if it achieves 0.01-40% RO at the A1R and / or A3R in the brain or CNS. In some embodiments, the A1R, A3R, or dual A1R / A3R agonist is effective to treat an injury, disease, or disorder if it achieves 1-15% RO at the A1R and / or A3R in the brain or CNS. In some embodiments, the agonist is a dual A1R / A3R agonist and is effective to treat an injury, disease, or disorder if it achieves about 1-15% RO at the A1R and / or A3R in the brain or CNS.

[0025] In another aspect, the present invention provides a method for determining an effective dose for treating an injury, disease, or disorder, such as traumatic brain injury (TBI), stroke, a neurodegenerative condition, a cardiac or cardiovascular disease, addiction, an addictive disorder, and a condition associated with TBI, stroke, or a neurodegenerative condition, comprising administering to a subject in need thereof an amount of an A1R, A3R, or dual A1R / A3R agonist, or a pharma- ceutically acceptable salt thereof or a composition comprising same; and determining receptor occupancy (%RO) at the A1 receptor (A1R) and / or A3 receptor (A3R) in the brain or CNS.

[0026] In some embodiments, an effective dose of the A1R, A3R, or dual A1R / A3R agonist treats an injury, disease, or disorder if it reaches 0.01-40% RO at the A1R and / or A3R in the brain or CNS. In some embodiments, an effective dose of the A1R, A3R, or dual A1R / A3R agonist treats an injury, disease, or disorder if it reaches 1-15% RO at the A1R and / or A3R in the brain or CNS. In some embodiments, the agonist is a dual A1R / A3R agonist and an effective dose for treating an injury, disease, or disorder reaches about 1-15% RO at the A1R and / or A3R in the brain or CNS.

[0027] In another aspect, the present invention provides a method of predicting efficacy or predicting an effective dose for treating an injury, disease, or disorder, such as traumatic brain injury (TBI), stroke, a neurodegenerative condition, a cardiac or cardiovascular disease, addiction, an addictive disorder, and a condition associated with TBI, stroke, or a neurodegenerative condition, comprising administering to a subject in need thereof an amount of an A1R, A3R, or dual A1R / A3R agonist, or a pharma- ceutically acceptable salt thereof or a composition comprising same; and determining the receptor occupancy (%RO) at the A1 receptor (A1R) and / or A3 receptor (A3R) in the brain or CNS.

[0028] In some embodiments, an effective dose of the A1R, A3R, or dual A1R / A3R agonist treats an injury, disease, or disorder if it reaches 0.01-40% RO at the A1R and / or A3R in the brain or CNS. In some embodiments, an effective dose of the A1R, A3R, or dual A1R / A3R agonist treats an injury, disease, or disorder if it reaches 1-15% RO at the A1R and / or A3R in the brain or CNS. In some embodiments, the agonist is a dual A1R / A3R agonist and an effective dose for treating an injury, disease, or disorder reaches about 1-15% RO at the A1R and / or A3R in the brain or CNS.

[0029] In some embodiments, the subject is treated with the predicted effective dose determined by the methods described above.

[0030] In another aspect, the present invention provides a method of optimizing a treatment regimen for an injury, disease, or disorder, such as traumatic brain injury (TBI), stroke, a neurodegenerative condition, a cardiac or cardiovascular disease, addiction, an addictive disorder, and a condition associated with TBI, stroke, or a neurodegenerative condition, comprising administering to a subject in need thereof an amount of an A1R, A3R, or dual A1R / A3R agonist, or a pharma- ceutically acceptable salt thereof or a composition comprising same; and determining receptor occupancy (%RO) at the A1 receptor (A1R) and / or A3 receptor (A3R) in the brain or CNS.

[0031] In some embodiments, an effective dose of the A1R, A3R, or dual A1R / A3R agonist treats the injury, disease, or disorder when it reaches 0.01-40% RO at the A1R and / or A3R in the brain or CNS. In some embodiments, an effective dose of the A1R, A3R, or dual A1R / A3R agonist treats the injury, disease, or disorder when it reaches 0.01-30%, such as 1-20%, such as 1-15% RO at the A1R and / or A3R in the brain or CNS. In some embodiments, the agonist is a dual A1R / A3R agonist and an effective dose for treating the injury, disease, or disorder reaches about 1-15% RO at the A1R and / or A3R in the brain or CNS.

[0032] In some embodiments, the method further comprises increasing the dose of the agonist if a %RO of 0.01-40% is not reached at the A1R and / or A3R of the brain or CNS; and decreasing the dose of the agonist if a %RO of greater than 40% is reached. In some embodiments, the method further comprises treating the subject for the injury, disease, or condition based on the optimized treatment regimen determined by the method.

[0033] In some embodiments, the method determines the minimum effective dose of the A1R and / or A3R agonist. In some embodiments, the method determines the maximum effective dose of the A1R and / or A3R agonist.

[0034] In some embodiments, the disclosed methods are performed in an animal subject, such as a mouse, rat, pig, or monkey, and the methods allow for the determination of an effective dose for humans. Thus, in some embodiments, the disclosed methods provide an effective dose for humans based on the effective dose for animals identified by the methods.

[0035] In some embodiments, the compound acts as an agonist of the A3 adenosine receptor (A3R). In some embodiments, the compound is a partial A3R agonist. In some embodiments, the compound is a biased A3R agonist. In some embodiments, the compound acts by dual agonism at the A3 adenosine receptor and the A1 adenosine receptor (A1R). In some embodiments, the compound acts as an agonist of the A1 adenosine receptor (A1R). In some embodiments, the compound is a partial A1R agonist. In some embodiments, the compound is a biased A1R agonist.

[0036] In some embodiments, the compound is administered in an amount effective to achieve about 0.01-30% RO in the subject's brain. In some embodiments, the compound is administered in an amount effective to achieve about 0.1-25% RO in the subject's brain. In some embodiments, the compound is administered in an amount effective to achieve about 1-15% RO in the subject's brain.In some embodiments, the compound is administered to the subject's brain at 0.25-40%, 0.25-35%, 0.25-25%, 0.25-20%, 0.5-20%, 0.5-18%, 0.75-18%, 0.75-16%, 0.9-16%, 0.9-15%, 1.0-15%, 1.0-14%, 1.2-14%, 1.2-13%, 1.4-13%, 1.4-12%, 1.5-12%, 1.5-11%, 1.75-11%, 1.75-10%, 2.0-10%, 2.0-9.0%, 2.5-9.0%, 2.5-8.0%, 3.0-8.0%, 3.0-9.0%, 3.0-10 ... .0-7.0%, 3.5-7.0%, 3.5-6.0%, 4.0-6.0%, 5.0-30%, 6.0-30%, 7.0-30%, 8.0-30%, 9.0-30%, 10-30%, 5.0-25%, 6.0-25%, 7.0-25%, 8.0-25%, 9.0-25%, 10-25%, 5.0-20%, 6.0-20%, 7.0-20%, 8.0-20%, 9.0-20%, 10-20%, 5.0-18%, 6.0-18%, 7.0-18%, 8.0-18%, 9.0-18%, 10-18%, 5.0-15%, 6. 0-15%, 7.0-15%, 8.0-15%, 9.0-15%, or 10-15%; or about 0.01%, about 0.05%, about 0.1%, about 0.2%, about 0.25%, about 0.4%, about 0.5%, about 0.75%, about 0.9%, about 1.0%, about 1.2%, about 1.4%, about 1.5%, about 1.75%, about 2.0%, about 2.25%, about 2.5%, about 2.75%, about 3.0%, about 3.5%, about 4.0%, about 4.5%, about 5.0%, about 5.5%, about 6.0%, about 6.5%, about 7.0%, about 7.5%, about 8.0%, about 8.5%, about 9 The subject is administered an amount effective to achieve about 0.0%, about 9.5%, about 10%, about 10.5%, about 11.0%, about 11.5%, about 12%, about 12.5%, about 13%, about 13.5%, about 14%, about 14.5%, about 15%, about 15.5%, about 16%, about 16.5%, about 17%, about 17.5%, about 18%, about 18.5%, about 19%, about 19.5%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 32%, about 34%, about 36%, about 38%, or about 40% RO. In some embodiments, the aforementioned amounts of %RO refer to the %RO of the A1R. In some embodiments, the aforementioned amounts of %RO refer to the %RO of A3R.In some embodiments, the aforementioned amounts of %RO refer to the total %RO of A1R and A3R combined.

[0037] In some embodiments, the compound is administered in an amount effective to achieve about 0.01-30% RO in the CNS of the subject. In some embodiments, the compound is administered in an amount effective to achieve about 0.1-25% RO in the CNS of the subject. In some embodiments, the compound is administered in an amount effective to achieve about 1-15% RO in the CNS of the subject.In some embodiments, the compound is administered to the CNS of a subject at 0.25-40%, 0.25-35%, 0.25-25%, 0.25-20%, 0.5-20%, 0.5-18%, 0.75-18%, 0.75-16%, 0.9-16%, 0.9-15%, 1.0-15%, 1.0-14%, 1.2-14%, 1.2-13%, 1.4-13%, 1.4-12%, 1.5-12%, 1.5-11%, 1.75-11%, 1.75-10%, 2.0-10%, 2.0-9.0%, 2.5-9.0%, 2.5-8.0%, 3.0-8.0%. ,3.0~7.0%,3.5~7.0%,3.5~6.0%,4.0~6.0%,5.0~30%,6.0~30%,7.0~30%,8.0~30%,9.0~30%,10~30%,5.0~25%,6.0~25%,7.0~25%,8.0~25%,9.0~25%,10~25%,5.0~20%,6.0~20%,7.0~20%,8.0~20%,9.0~20%,10~20%,5.0~18%,6.0~18%,7.0~18%,8.0~18%,9.0~18%,10~18%,5.0~15%,6 0.0-15%, 7.0-15%, 8.0-15%, 9.0-15%, or 10-15%; or about 0.01%, about 0.05%, about 0.1%, about 0.2%, about 0.25%, about 0.4%, about 0.5%, about 0.75%, about 0.9%, about 1.0%, about 1.2%, about 1.4%, about 1.5%, about 1.75%, about 2.0%, about 2.25%, about 2.5%, about 2.75%, about 3.0%, about 3.5%, about 4.0%, about 4.5%, about 5.0%, about 5.5%, about 6.0%, about 6.5%, about 7.0%, about 7.5%, about 8.0%, about 8.5%, about 9 The subject is administered an amount effective to achieve about 0.0%, about 9.5%, about 10%, about 10.5%, about 11.0%, about 11.5%, about 12%, about 12.5%, about 13%, about 13.5%, about 14%, about 14.5%, about 15%, about 15.5%, about 16%, about 16.5%, about 17%, about 17.5%, about 18%, about 18.5%, about 19%, about 19.5%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 32%, about 34%, about 36%, about 38%, or about 40% RO. In some embodiments, the aforementioned amounts of %RO refer to the %RO of the A1R. In some embodiments, the aforementioned amounts of %RO refer to the %RO of A3R.In some embodiments, the aforementioned amounts of %RO refer to the total %RO of A1R and A3R combined.

[0038] In some embodiments, the compound produces a higher %RO at the A1R than at the A3R. In some embodiments, the compound produces a lower %RO at the A1R than at the A3R. In some embodiments, the compound produces about the same %RO at the A1R and A3R.

[0039] In some embodiments, the %RO ratio of A1R to A3R is about 1:50, 1:40, 1:30, 1:20, 1:10, 1:5, 1:2.5, 1:1.5, 1:1, 50:1, 40:1, 30:1, 20:1, 10:1, 5:1, 2.5:1, or 1.5:1.

[0040] In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to reach about 0.01-40% RO at the A1R and about 0.01-40% RO at the A3R. In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to reach about 0.01-30% RO at the A1R and about 0.01-30% RO at the A3R. In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to reach about 0.1-25% RO at the A1R and about 0.01-25% RO at the A3R. In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to reach about 1.0-15% RO at the A1R and about 1.0-15% RO at the A3R. In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to reach about 0.1-10% RO at the A1R and about 1.0-20% RO at the A3R. In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to achieve a 1.0-20% RO at the A1R and about a 0.1-10% RO at the A3R.

[0041] In some embodiments, the compound is administered to the brain or CNS of a subject at about 0.01%, about 0.05%, about 0.1%, about 0.2%, about 0.25%, about 0.4%, about 0.5%, about 0.75%, about 0.9%, about 1.0%, about 1.2%, about 1.4%, about 1.5%, about 1.75%, about 2.0%, about 2.25%, about 2.5%, about 2.75%, about 3.0%, about 3.5%, about 4.0%, about 4.5%, about 5.0%, about 5.5%, about 6.0%, about 6.5%, about 7.0%, about 7.5%, about 8.0%, about 8.5%, about 9.0%, about 9.5%, about 10%, about 10.5%, about 11.0%, about 11.5%, or about 12%RO and A3R: approx. 10%, approx. 10.5%, approx. 11.0%, approx. 11.5%, approx. 12%, approx. 12.5%, approx. 13%, approx. 13.5%, approx. 14%, approx. 14.5%, approx. 15%, approx. 15.5%, approx. 16%, approx. 16.5%, approx. 17%, approx. 17.5%, approx. 18%, approx. 18.5%, approx. 19%, approx. 20% 0.5%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, or about 40% RO. In some embodiments, the compound is administered to the brain or CNS of a subject at about 10%, about 10.5%, about 11.0%, about 11.5%, about 12%, about 12.5%, about 13%, about 13.5%, about 14%, about 14.5%, about 15%, about 15.5%, about 16%, about 16.5%, about 17%, about 17.5%, about 18%, about 18.5%, about 19%, about 19.5%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, or about 30% at the A1RRO and about 0.01%, about 0.05%, about 0.02%, about 0.04%, about 0.06%, about 0.08%, about 0.09%, about 10.10%, about 10.11%, about 10.12%, about 10.13%, about 10.14%, about 10.15%, about 10.16%, about 10.17%, about 10.18%, about 10.19%, about 10.20%, about 10.21%, about 10.22%, about 10.23%, about 10.24%, about 10.25%, about 10.26%, about 10.27%, about 10.28%, about 10.29%, or about 30% at the A1RRO and about 0.01%, about 0.05%, about 0.06%, about 0.08%, about 0.09%, about 10.29%, or about 30% at the A3RRO. and is administered in an amount effective to achieve an RO of about 0.1%, about 0.2%, about 0.25%, about 0.4%, about 0.5%, about 0.75%, about 0.9%, about 1.0%, about 1.2%, about 1.4%, about 1.5%, about 1.75%, about 2.0%, about 2.25%, about 2.5%, about 2.75%, about 3.0%, about 3.5%, about 4.0%, about 4.5%, about 5.0%, about 5.5%, about 6.0%, about 6.5%, about 7.0%, about 7.5%, about 8.0%, about 8.5%, about 9.0%, about 9.5%, about 10%, about 10.5%, about 11.0%, about 11.5%, or about 12%.

[0042] In some embodiments, the injury, disease, or disorder is traumatic brain injury (TBI), concussion, stroke (e.g., acute ischemic stroke (AIS)), partial or complete spinal cord transection, malnutrition, toxic neuropathies, meningoencephalopathy, neurodegeneration caused by genetic disorders, age-related neurodegeneration, vascular disease, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), cardiovascular disease, autoimmune disease, allergic disease, transplant rejection, graft versus host disease, ocular hypertension, glaucoma, odor hypersensitivity, or other conditions. These conditions include but are not limited to: anesthesia, nausea, vomiting, nausea and vomiting (ASL), nausea and vomiting (ASC ...

[0043] In some embodiments, the injury, disease, or disorder is stroke.

[0044] In some embodiments, the stroke is selected from ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, and transient ischemic attack (TIA).In some embodiments, the stroke is ischemic, for example, acute ischemic stroke (AIS).In some embodiments, the stroke is hemorrhagic.

[0045] In some embodiments, the compound is administered within 8 hours, 4 hours, 2 hours, or 1 hour of the stroke, hi some embodiments, the compound is administered for at least the first 1-72 hours after the stroke.

[0046] In some embodiments, the present invention provides a method of treating a brain or central nervous system (CNS) injury or condition selected from traumatic brain injury (TBI) or stroke, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0047] In some embodiments, the injury, disease, or disorder is TBI.

[0048] In some embodiments, the TBI is selected from a concussion, whiplash, motor vehicle accident, blast injury, combat-related injury, or a mild, moderate or severe blow to the head.

[0049] In some embodiments, neuroprotection or neurorepair in the patient is increased compared to an untreated patient.

[0050] In some embodiments, the injury, disease, or disorder is a neurodegenerative disease selected from Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), or a neurodegenerative condition caused by a virus, alcoholism, tumor, toxin, or repetitive brain injury.

[0051] In some embodiments, the injury, disease, or condition is AD or ALS.

[0052] In some embodiments, the injury, disease, or disorder is a cardiac or cardiovascular disease selected from cardiac ischemia, myocardial infarction, cardiomyopathy, coronary artery disease, arrhythmias, myocarditis, pericarditis, angina, hypertensive heart disease, endocarditis, rheumatic heart disease, congenital heart disease, and atherosclerosis.

[0053] In some embodiments, the cardiac or cardiovascular disease is cardiac ischemia or myocardial infarction.

[0054] In some embodiments, the compound or composition is administered chronically to treat stroke, cardiac ischemia, or myocardial infarction, for the period after the injury has occurred until it has resolved.

[0055] In some embodiments, the compound or composition is administered within 24 hours of the TBI or stroke.

[0056] In some embodiments, the compound or composition is administered within 4 hours or 8 hours of the TBI or stroke.

[0057] In some embodiments, the compound or composition is administered during at least the first 4-48 hours after TBI or stroke.

[0058] In some embodiments, the condition associated with brain injury or neurodegenerative condition is selected from epilepsy, migraine, collateral brain damage associated with radiation cancer treatment, depression, mood or behavioral changes, dementia, erratic behavior, suicidality, tremors, Huntington's disease, loss of motor coordination, hearing loss, speech disorders, dry eyes, masked facies, attention deficit, memory loss, cognitive difficulties or impairments, defects in CNS function, learning disabilities, vertigo, dysarthria, dysphagia, eye abnormalities, or disorientation.

[0059] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered orally, intravenously, or parenterally. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered orally. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered intravenously. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered parenterally. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered as a continuous intravenous (IV) infusion. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered, for example, as an IV bolus initially, followed by a continuous IV infusion to maintain a desired plasma concentration. In some embodiments, the compound or a pharma- ceutical acceptable salt thereof is administered as a slow bolus / rapid infusion. In some embodiments, the slow bolus / rapid infusion comprises IV administration over a period of about 5 to 60 minutes, for example, 5 to 30, 5 to 20, 10 to 20, or about 10 minutes.

[0060] In some embodiments, the compound is I-1, or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound is one of the compounds listed in Table 1 below, or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound is I-25, or a pharma- ceutically acceptable salt thereof.

[0061] In another aspect, the present invention provides a method of treating stroke comprising administering to a subject in need thereof an effective amount of the following compound(s) to achieve 0.01-40% receptor occupancy (%RO) at A1 receptors (A1R) and / or A3 receptors (A3R) in the brain or CNS for a period sufficient to treat the stroke: [ka] or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0062] In some embodiments, the stroke is selected from ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, and transient ischemic attack (TIA).

[0063] In some embodiments, the stroke is ischemic, for example, acute ischemic stroke (AIS).

[0064] In some embodiments, the stroke is hemorrhagic.

[0065] In some embodiments, the compound is administered within 48 hours of the stroke. In some embodiments, the compound is administered within 24 hours of the stroke. In some embodiments, the compound is administered within 16 hours of the stroke. In some embodiments, the compound is administered within 8 hours, 4 hours, 2 hours, or 1 hour of the stroke.

[0066] In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to achieve about 0.1-25% RO at the A1R and about 0.01-25% RO at the A3R. In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to achieve about 1.0-15% RO at the A1R and about 1.0-15% RO at the A3R. In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to achieve about 0.1-10% RO at the A1R and about 1.0-20% RO at the A3R. In some embodiments, the compound is administered to the subject's brain or CNS in an amount effective to achieve about 1.0-20% RO at the A1R and about 0.1-10% RO at the A3R.

[0067] In some embodiments, the compound is administered to the subject's brain in an amount effective to achieve about 0.1-25% RO at the A1R and A3R (combined). In some embodiments, the compound is administered to the subject's brain in an amount effective to achieve about 1-15% RO at the A1R and A3R (combined). In some embodiments, the compound is administered to the subject's brain in an amount effective to achieve about 5-20% RO at the A1R and A3R (combined).

[0068] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a plasma concentration of about 30±20 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a plasma concentration of about 190±30 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a plasma concentration of about 480±100 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a plasma concentration of about 1100±300 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a plasma concentration of about 2500±400 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a plasma concentration of about 3200±400 ng / mL.

[0069] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is a) a plasma concentration of approximately 32±11 ng / mL; b) a plasma concentration of approximately 186 ± 24 ng / mL; c) a plasma concentration of about 483 ± 23 ng / mL; and d) A plasma concentration of approximately 1127 ± 246 ng / mL The compound is administered in an amount that produces a pharmacokinetic result selected from the group consisting of:

[0070] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 2.0±1.0 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 9.0±3.0 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 17.0±9.0 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 110.0±50.0 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 330.0±75.0 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 50-500 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 70-450 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 80-400 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 90-350 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 100-300 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 110-250 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 120-200 ng / mL. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 50-150 ng / mL. In some embodiments, the compound or pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 10-130 ng / mL. In some embodiments, the compound or pharma- ceutically acceptable salt thereof is administered in an amount that results in a CSF concentration of about 15-150, 20-140, 30-130, 40-120, 50-120, 60-110, or 70-100 ng / mL.

[0071] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is a) CSF concentration of approximately 2.1 ± 0.4 ng / mL; b) CSF concentration of approximately 8.8 ± 2.6 ng / mL; c) a CSF concentration of about 16.8 ± 5.7 ng / mL; and d) CSF concentration of approximately 108 ± 35 ng / mL The compound is administered in an amount that produces a pharmacokinetic result selected from the group consisting of:

[0072] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is a) Approximately 0.05-0.25 mg / kg per day; b) about 0.2-0.8 mg / kg per day; c) about 0.7 to 2.5 mg / kg per day; and d) Approximately 2.3 to 12.0 mg / kg per day The dosage is selected from the group consisting of:

[0073] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is a) approximately 0.11 mg / kg per day; b) approximately 0.47 mg / kg per day; c) about 1.7 mg / kg per day; and d) Approximately 5.2 mg / kg per day The dosage is selected from the group consisting of:

[0074] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is a) Approximately 0.03 to 0.12 mg / kg per hour; b) approximately 0.125-0.50 mg / kg per hour; c) about 0.45 to 1.8 mg / kg per hour; and d) Approximately 1.4 to 5.0 mg / kg per hour The dosage is selected from the group consisting of:

[0075] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is a) approximately 0.06 mg / kg per hour; b) approximately 0.25 mg / kg per hour; c) about 0.9 mg / kg per hour; and d) Approximately 2.8 mg / kg per hour The dosage is selected from the group consisting of:

[0076] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is a) about 0.05-0.25 mg / kg in combination with continuous dosing at about 0.03-0.12 mg / kg per hour; b) about 0.2-0.8 mg / kg in combination with continuous dosing at about 0.125-0.50 mg / kg per hour; c) about 0.7 to 2.5 mg / kg per hour in combination with a continuous dose of about 0.45 to 1.8 mg / kg per hour; and d) about 2.3 to 12.0 mg / kg per hour in combination with continuous dosing at about 1.4 to 5.0 mg / kg per hour The dosage is selected from the group consisting of:

[0077] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is a) about 0.11 mg / kg combined with a continuous dose of about 0.06 mg / kg per hour; b) about 0.47 mg / kg combined with a continuous dose of about 0.25 mg / kg per hour; c) about 1.7 mg / kg per hour in combination with a continuous dose of about 0.9 mg / kg per hour; and d) Approximately 5.2 mg / kg per hour in combination with a continuous dose of approximately 2.8 mg / kg per hour The dosage is selected from the group consisting of

[0078] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is a) about 6.5 mg; b) About 28mg; c) about 102 mg; and d) Approximately 312mg The daily dose is selected from the following:

[0079] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 25-75 mg.In some embodiments, the compound is compound I-1.

[0080] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 1-400 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 6-300 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 10-200 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 20-150 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 25-100 mg.

[0081] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 1-100 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 1-80 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 3-70 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 5-60 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 10-50 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 15-40 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 20-40 mg.

[0082] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 100-800 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 200-400 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 75-250 mg. In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered in a daily dose of about 50-150 mg.

[0083] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered at a concentration of about 1 mg, 3 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, It is administered in a daily dose of 190mg, 200mg, 210mg, 220mg, 230mg, 240mg, 250mg, 260mg, 270mg, 280mg, 290mg, 300mg, 310mg, 320mg, 330mg, 340mg, 350mg, 360mg, 370mg, 380mg, 390mg, 400mg, 425mg, 450mg, 475mg, 500mg, 525mg, 550mg, 575mg, or 600mg.

[0084] In some embodiments, the subject is a mammal. In some embodiments, the subject is a mouse, a rat, a pig, or a primate. In some embodiments, the subject is a human.

[0085] In some embodiments, the compound has formula I [ka] or a pharma- ceutically acceptable salt thereof, R 1 is C 1~8 Alkyl, -(C 1~4 alkylene)-Ar, -(C 1~4 Alkylene)-Cy, C2~8 Alkenyl, -(C 2~4 alkenylene)-Ar, -(C 2~4 Alkenylene)-Cy,C 2~8 Alkynyl, -(C 2~4 alkynylene)-Ar, -(C 2~4 alkynylene)-Cy, phenyl, Cy, or a 5-6 membered monocyclic aromatic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is selected from R 3 or R 1 is a halogen when X is a covalent bond; Ar is phenyl or a 5-6 membered monocyclic aromatic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Cy is a 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7- to 12-membered saturated or partially unsaturated bicyclic carbocyclic ring, or a 3- to 6-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R 2 is hydrogen, C 1~4 Alkyl, halogen and C 1~4 -(C 1~4 Alkylene)-Ar, halogen and C 1~4 -(C 1~4 Alkylene)-Cy, or C 3~5 cycloalkyl, 1~4 Alkyl and C 3~5 cycloalkyl is optionally substituted with 1, 2, or 3 deuterium or halogen atoms; Each R 3 are independently deuterium, halogen, -CN, -O-(C 1~4 alkyl), -OH, -S-(C 1~4 alkyl), or -SH; R 4is -CHOH or -C(O)NHR 5 and R 5 is H or C 1~4 is alkyl, X is a covalent bond, S or O; [n is 0, 1, 2, or 3].

[0086] The definitions of the variables in formula I above encompass multiple chemical groups. The present application contemplates, for example, (i) embodiments in which the definition of a variable is a single chemical group selected from the chemical groups above, (ii) embodiments in which the definition of a variable is a collection of two or more chemical groups selected from those above, and (iii) embodiments in which a compound is defined by a combination of the variables defined by (i) or (ii).

[0087] As broadly defined above, R 1 is C 1~8 Alkyl, -(C 1~4 alkylene)-Ar, -(C 1~4 Alkylene)-Cy, C 2~8 Alkenyl, -(C 2~4 alkenylene)-Ar, -(C 2~4 Alkenylene)-Cy,C 2~8 Alkynyl, -(C 2~4 alkynylene)-Ar, -(C 2~4 alkynylene)-Cy, phenyl, Cy, or a 5-6 membered monocyclic aromatic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is selected from R 3 or R 1 is a halogen when X is a covalent bond.

[0088] In some embodiments, R 1 is R 3 C is substituted n times with 1~8 In some embodiments, R 1 is R 3 -(C 1~4In some embodiments, R 1 is R 3 -(C 1~4 In some embodiments, R 1 is R 3 C is substituted n times with 2~8 In some embodiments, R is alkenyl. 1 is R 3 -(C 2~4 alkenylene)-Ar. In some embodiments, R 1 is R 3 -(C 2~4 alkenylene)-Cy. In some embodiments, R 1 is R 3 C is substituted n times with 2~8 In some embodiments, R is alkynyl. 1 is R 3 -(C 2~4 alkynylene)-Ar. In some embodiments, R 1 is R 3 -(C 2~4 alkynylene)-Cy. In some embodiments, R 1 is R 3 In some embodiments, R is phenyl substituted n times with 1 is R 3 In some embodiments, R is Cy substituted n times with 1 is a 5-6 membered monocyclic aromatic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, said ring being 3 In some embodiments, X is a covalent bond and R 1 is a halogen.

[0089] In some embodiments, R 1 is C 1~8 Alkyl, -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is R 3 is substituted n times with

[0090] In some embodiments, R 1 is C 1~8 Alkyl, -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, or C 2~8 alkynyl, each of which is R 3 In some embodiments, R 1 is C 1~8 Alkyl, -(C 1~2 alkylene)-phenyl, or -(C 1~2 Alkylene)-(C 3~5 cycloalkyl), each of which is R 3 In some embodiments, R 1 is C 1~8 Alkyl, -(C 1~2 alkylene)-phenyl, or -(C 1~2 Alkylene)-(C 3~5 In some embodiments, R 1 is -(C 1~2 alkylene)-phenyl or -(C 1~2 Alkylene)-(C 3~5 cycloalkyl).

[0091] In some embodiments, R 1 is C 1~8 Alkyl, -(C 1~2 alkylene)-phenyl, -(C 1~2 Alkylene)-(C 3~5 cycloalkyl), or C 3~8 cycloalkyl, each of which is R 3is substituted n times with

[0092] In some embodiments, R 1 is C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is R 3 is substituted n times with

[0093] In some embodiments, R 1 is R 3 C is substituted n times with 1~6 In some embodiments, R 1 is R 3 C is substituted n times with 1~4 In some embodiments, R 1 is R 3 C is substituted n times with 3~8 In some embodiments, R 1 is R 3 C is substituted n times with 3~6 In some embodiments, R 1 is R 3 C is substituted n times with 3~4 In some embodiments, R 1 (i) R 3 C substituted 1, 2, or 3 times with 1~2 alkyl; or (ii) R 3 C is substituted n times with 3~8 In some embodiments, R 1 is R 3 C substituted 1, 2, or 3 times with 1~8 In some embodiments, R 1 is R 3 -(C 1~4 In some embodiments, R 1 is R 3 -(C 1~2 In some embodiments, R 1 is R3 -(C 1~4 Alkylene)-(C 3~8 In some embodiments, R 1 is R 3 -(C 1~2 Alkylene)-(C 3~5 In some embodiments, R 1 is R 3 C is substituted n times with 3~8 In some embodiments, R 1 is R 3 C is substituted n times with 3~6 It is cycloalkyl.

[0094] In some embodiments, R 1 is C 1~8 In some embodiments, R 1 is C 1~6 In some embodiments, R 1 is C 1~4 In some embodiments, R 1 is methyl or ethyl. In some embodiments, R 1 is methyl. In some embodiments, R 1 is ethyl. In some embodiments, R 1 is C 3~8 In some embodiments, R 1 is C 3~6 In some embodiments, R 1 is C 3~4 In some embodiments, R 1 is -(C 1~4 In some embodiments, R 1 is -(C 1~2 In some embodiments, R 1 is -(C 1~4 Alkylene)-(C 3~8 In some embodiments, R 1 is -(C 1~2 Alkylene)-(C3~5 In some embodiments, R 1 is C 2~8 In some embodiments, R is alkenyl. 1 is C 2~8 In some embodiments, R is alkynyl. 1 is C 3~8 In some embodiments, R 1 is C 3~6 In some embodiments, R 1 is phenyl. In some embodiments, R 1 is a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0095] In some embodiments, R 1 (i) R 3 C substituted 1, 2, or 3 times with 1~2 alkyl, or (ii) C 3~8 Alkyl, -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is represented by R 3 In some embodiments, R 1 (i) R 3 C substituted 1, 2, or 3 times with 1~8 alkyl, or (ii)-(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is represented by R 3 In some embodiments, R 1 (i) R 3 C substituted 1, 2, or 3 times with 1~2 alkyl, or (ii) C 3~8 Alkyl, -(C 1~2 alkylene)-phenyl, -(C 1~2 Alkylene)-(C 3~5 cycloalkyl), or C 3~8 cycloalkyl, each of which is R 3 In some embodiments, R 1 is C 3~8 Alkyl, -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is R 3 In some embodiments, R 1 is -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is R 3 is substituted n times with

[0096] In some embodiments, X is a covalent bond and R 1 is a halogen selected from F or Cl. In some embodiments, R1 is F. In some embodiments, R 1 is Cl.

[0097] In some embodiments, R 1 is selected from those illustrated in Table 1 below.

[0098] As generally defined above, Ar is phenyl or a 5-6 membered monocyclic aromatic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0099] In some embodiments, Ar is phenyl. In some embodiments, Ar is a 5-6 membered monocyclic aromatic heterocycle having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0100] In some embodiments, Ar is selected from those depicted in Table 1 below.

[0101] As generally defined above, Cy is a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring, or a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0102] In some embodiments, Cy is a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, Cy is a 3-8 membered saturated monocyclic carbocyclic ring. In some embodiments, Cy is a 3-6 membered saturated monocyclic carbocyclic ring. In some embodiments, Cy is a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring. In some embodiments, Cy is a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0103] In some embodiments, Cy is selected from those depicted in Table 1 below.

[0104] As broadly defined above, R 2 is hydrogen, C 1~4 Alkyl, halogen and C 1~4 -(C 1~4 Alkylene)-Ar, halogen and C 1~4 -(C 1~4 Alkylene)-Cy, or C 3~5 cycloalkyl, 1~4 Alkyl and C 3~5 The cycloalkyl is optionally substituted with 1, 2, or 3 deuterium or halogen atoms.

[0105] In some embodiments, R 2 is halogen and C 1~4 -(C 1~4 In some embodiments, R 2 is halogen and C 1~4 -(C 1~4 In some embodiments, R 2 is C 1~4 Alkyl or C 3~5 cycloalkyl, each of which is optionally substituted with 1, 2, or 3 deuterium or halogen atoms. 2 is C optionally substituted with 1, 2, or 3 deuterium or halogen atoms 1~4 In some embodiments, R 2 C substituted with 1, 2, or 3 deuterium or halogen atoms 1~4 In some embodiments, R 2is C optionally substituted with 1, 2, or 3 deuterium or halogen atoms 3~5 In some embodiments, R 2 C substituted with 1, 2, or 3 deuterium or halogen atoms 3~5 It is cycloalkyl.

[0106] In some embodiments, R 2 is hydrogen, C 1~4 Alkyl, or C 3~5 In some embodiments, R 2 is hydrogen or C 1~4 In some embodiments, R 2 is C 1~4 Alkyl or C 3~5 In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is C 1~4 In some embodiments, R 2 is methyl or ethyl. In some embodiments, R 2 is methyl. In some embodiments, R 2 is C 3~5 In some embodiments, R 2 is cyclopropyl.

[0107] In some embodiments, R 2 is selected from those illustrated in Table 1 below.

[0108] As generally defined above, each R 3 are independently deuterium, halogen, -CN, -O-(C 1~4 alkyl), -OH, -S-(C 1~4 alkyl), or -SH.

[0109] In some embodiments, each R 3 are independently halogen, -O-(C 1~4 alkyl), -OH, -S-(C 1~4In some embodiments, each R 3 is deuterium. 3 is independently a halogen. In some embodiments, each R 3 is independently fluoro or chloro. In some embodiments, R 3 is fluoro. 3 In some embodiments, each R 3 are independently -O-(C 1~4 alkyl) or -OH. In some embodiments, each R 3 are independently -O-(C 1~4 In some embodiments, R 3 is -OH. In some embodiments, each R 3 are independently -S-(C 1~4 alkyl) or -SH. In some embodiments, each R 3 are independently -S-(C 1~4 In some embodiments, R 3 is -SH.

[0110] In some embodiments, R 3 is selected from those illustrated in Table 1 below.

[0111] As broadly defined above, R 4 is -CHOH or -C(O)NHR 5 It is.

[0112] In some embodiments, R 4 is -CHOH. In some embodiments, R 4 is -C(O)NHR 5 It is.

[0113] In some embodiments, R 4 is -C(O)NH2. In some embodiments, R 4 is -C(O)NHMe. In some embodiments, R 4 is -C(O)NHEt.

[0114] In some embodiments, R 4 is selected from those illustrated in Table 1 below.

[0115] As broadly defined above, R 5 is H or C 1~4 It is an alkyl.

[0116] In some embodiments, R 5 is selected from those illustrated in Table 1 below.

[0117] In some embodiments, R 5 is H. In some embodiments, R 5 is C 1~4 It is an alkyl.

[0118] As generally defined above, X is a covalent bond, S or O. In some embodiments, X is a covalent bond. In some embodiments, X is S. In some embodiments, X is O. In some embodiments, X is a covalent bond and R 1 is a halogen. In some embodiments, R 1 is selected from those illustrated in Table 1 below.

[0119] As generally defined above, n is 0, 1, 2, or 3. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 0 or 1. In some embodiments, n is 1 or 2. In some embodiments, n is 2 or 3. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 1, 2, or 3. In some embodiments, n is selected from those depicted in Table 1 below.

[0120] The above description describes multiple embodiments for compounds of formula I. The present patent application specifically contemplates all combinations of embodiments.

[0121] In some embodiments, the compound has formula IA [ka] or a pharma- ceutically acceptable salt thereof, R 1 (i) R 3 C substituted 1, 2, or 3 times as appropriate 1~2 alkyl, or (ii) C 3~8 Alkyl, -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is represented by R 3 is replaced n times as necessary by R 2 is hydrogen, C 1~4 Alkyl, or C 3~5 is cycloalkyl, Each R 3 are independently halogen, -O-(C 1~4 alkyl), -OH, -S-(C 1~4 alkyl), or -SH; X is S or O; [n is 0, 1, 2, or 3].

[0122] In some embodiments, the compound has formula IB [ka] or a pharma- ceutically acceptable salt thereof, R 1 is a halogen, R 2 is hydrogen, C 1~4 Alkyl, or C 3~5is cycloalkyl, and X is a covalent bond.

[0123] The definitions of the variables in formulas IA and IB above encompass multiple chemical groups. The present application contemplates, for example, (i) embodiments in which the definition of a variable is a single chemical group selected from the chemical groups above, (ii) embodiments in which the definition of a variable is a collection of two or more chemical groups selected from those above, and (iii) embodiments in which a compound is defined by a combination of the variables defined by (i) or (ii).

[0124] In certain embodiments, the compound is a compound of formula IA. In certain embodiments, the compound is a compound of formula IB.

[0125] As broadly defined above, R 1 (i) R 3 C substituted 1, 2, or 3 times as appropriate 1~2 alkyl, or (ii) C 3~8 Alkyl, -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is R 3 is substituted n times as necessary.

[0126] In some embodiments, R 1 (i) R 3 C substituted 1, 2, or 3 times as appropriate 1~2 alkyl, or (ii) C 3~8 Alkyl, -(C 1~2 alkylene)-phenyl, -(C 1~2 Alkylene)-(C 3~5 cycloalkyl), or C3~8 cycloalkyl, each of which is R 3 is substituted n times as necessary.

[0127] In some embodiments, R 1 is R 3 C substituted 1, 2, or 3 times with 1~2 In some embodiments, R 1 is C 3~8 Alkyl, -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is R 3 is substituted n times with

[0128] In some embodiments, R 1 is -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, or C 2~8 alkynyl, each of which is R 3 In some embodiments, R 1 is -(C 1~2 alkylene)-phenyl or -(C 1~2 Alkylene)-(C 3~5 cycloalkyl), each of which is R 3 In some embodiments, R 1 is -(C 1~2 alkylene)-phenyl or -(C 1~2 Alkylene)-(C 3~5 cycloalkyl).

[0129] In some embodiments, R 1 is C 3~8cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is R 3 is substituted n times with

[0130] In some embodiments, R 1 is R 3 C is substituted n times with 3~8 In some embodiments, R 1 is R 3 C is substituted n times with 3~6 In some embodiments, R 1 is R 3 C is substituted n times with 3~4 In some embodiments, R 1 is R 3 -(C 1~4 In some embodiments, R 1 is R 3 -(C 1~2 In some embodiments, R 1 is R 3 -(C 1~4 Alkylene)-(C 3~8 In some embodiments, R 1 is R 3 -(C 1~2 Alkylene)-(C 3~5 In some embodiments, R 1 is R 3 C is substituted n times with 2~8 In some embodiments, R is alkenyl. 1 is R 3 C is substituted n times with 2~8 In some embodiments, R is alkynyl. 1 is R 3 C is substituted n times with 3~8 In some embodiments, R 1 is R 3 C is substituted n times with3~6 In some embodiments, R 1 is R 3 In some embodiments, R is phenyl substituted n times with 1 is a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, said ring being 3 is substituted n times with

[0131] In some embodiments, R 1 is C 3~8 In some embodiments, R 1 is C 3~6 In some embodiments, R 1 is C 3~4 In some embodiments, R 1 is -(C 1~4 In some embodiments, R 1 is -(C 1~2 In some embodiments, R 1 is -(C 1~4 Alkylene)-(C 3~8 In some embodiments, R 1 is -(C 1~2 Alkylene)-(C 3~5 In some embodiments, R 1 is C 2~8 In some embodiments, R is alkenyl. 1 is C 2~8 In some embodiments, R is alkynyl. 1 is C 3~8 In some embodiments, R 1 is C 3~6 In some embodiments, R 1 is phenyl. In some embodiments, R 1 is a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0132] In some embodiments, R 1 (i) R 3 C substituted 1, 2, or 3 times with 1~8 alkyl, or (ii)-(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is represented by R 3 In some embodiments, R 1 is C 3~8 Alkyl, -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is R 3 In some embodiments, R 1 is -(C 1~4 alkylene)-phenyl, -(C 1~4 Alkylene)-(C 3~8 Cycloalkyl), C 2~8 Alkenyl, C 2~8 Alkynyl, C 3~8 cycloalkyl, phenyl, or a 5-6 membered monocyclic aromatic heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, each of which is R 3 is substituted n times with

[0133] In some embodiments, R 1 is selected from those illustrated in Table 1 below.

[0134] As broadly defined above, R 2 is hydrogen, C 1~4 Alkyl, or C 3~5 It is cycloalkyl.

[0135] In some embodiments, R 2 is hydrogen or C 1~4 In some embodiments, R 2 is C 1~4 Alkyl or C 3~5 In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is C 1~4 In some embodiments, R 2 is methyl or ethyl. In some embodiments, R 2 is methyl. In some embodiments, R 2 is C 3~5 In some embodiments, R 2 is cyclopropyl.

[0136] In some embodiments, R 2 is selected from those illustrated in Table 1 below.

[0137] As generally defined above, each R 3 are independently halogen, -O-(C 1~4 alkyl), -OH, -S-(C 1~4 alkyl), or -SH.

[0138] In some embodiments, each R 3 is independently a halogen. In some embodiments, each R 3 is independently fluoro or chloro. In some embodiments, R 3 is fluoro. 3 are independently -O-(C 1~4 alkyl) or -OH. In some embodiments, each R 3 are independently -O-(C 1~4In some embodiments, R 3 is -OH. In some embodiments, each R 3 are independently -S-(C 1~4 alkyl) or -SH. In some embodiments, each R 3 are independently -S-(C 1~4 In some embodiments, R 3 is -SH.

[0139] In some embodiments, R 3 is selected from those illustrated in Table 1 below.

[0140] As generally defined above, X is S or O. In some embodiments, X is S. In some embodiments, X is O. In some embodiments, R 1 is selected from those illustrated in Table 1 below.

[0141] As generally defined above, n is 0, 1, 2, or 3. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 0 or 1. In some embodiments, n is 1 or 2. In some embodiments, n is 2 or 3. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 1, 2, or 3. In some embodiments, n is selected from those depicted in Table 1 below.

[0142] The above description describes multiple embodiments of the compounds of formula IA. The present patent application specifically contemplates all combinations of embodiments.

[0143] In some embodiments, the compound for use in the methods provided is a compound selected from one of the compounds in Table 1, or a pharma- ceutically acceptable salt thereof.

[0144] R is as generally defined above for formula IB; 1 is a halogen. In some embodiments, R 1 is F. In some embodiments, R 1 is Cl. In some embodiments, R 1 is Br. In some embodiments, R 1 is I.

[0145] R is as generally defined above for formula IB; 2 is hydrogen, C 1~4 Alkyl, or C 3~5 It is cycloalkyl.

[0146] In some embodiments, R 2 is hydrogen or C 1~4 In some embodiments, R 2 is C 1~4 Alkyl or C 3~5 In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is C 1~4 In some embodiments, R 2 is methyl or ethyl. In some embodiments, R 2 is methyl. In some embodiments, R 2 is C 3~5 In some embodiments, R 2 is cyclopropyl.

[0147] In some embodiments, the compound of formula IB is [ka] or a pharma- ceutically acceptable salt thereof.

[0148] U.S. Patent Nos. 9,789,131 and 10,765,693, each of which is incorporated herein by reference in its entirety, describe certain compounds that are useful for treatment. Such compounds include compound I-1. [ka] or a pharma- ceutically acceptable salt thereof.

[0149] Compound I-1 is designated as MRS4322 in U.S. Pat. No. 9,789,131, and the synthesis of compound I-1 is detailed in Example 9 of U.S. Pat. No. 9,789,131. Compound I-1 is designated as Compound A in U.S. Pat. No. 10,765,693, and its synthesis and the preparation of its solid forms are detailed in Example A therein and in the subsequent examples.

[0150] In some embodiments, the compound is selected from one of the compounds described in US Pat. No. 9,789,131, the entirety of which is incorporated herein by reference.In some embodiments, the compound is adenosine, ADP, 2-methylthio-ADP trisodium salt, ATP, ATP disodium salt, α,β-methylene ATP, α,β-methylene adenosine 5′-triphosphate trisodium salt, 2-methylthio adenosine triphosphate tetrasodium salt, 2-MeSATP, BzATP triethylammonium salt, inosine, cytidine, acylated cytidine, cytidine monophosphate (CMP), cytidine diphosphate (CDP), cytidine triphosphate (CTP), CDP-choline, CMP-choline, denuclease inhibitor ... sol, denufozole tetrasodium, GTP, ITP, MRS541, MRS542, MRS1760, MRS2179, MRS2279, MRS2341, MRS2365, MRS2500, MRS2690, MRS2698, MRS3558, MRS4322, MRS5151, MRS5676, MRS5678, MRS5697, MRS5698, MRS5923, MRS5930, Benzyl-NECA, IB-MECA, Cl-IB-MECA, LJ529, DPMA, CCPA, DBXRM, HEMADO, PEM ADO, HENECA, PENECA, CP608,039, CP532,903, CGS21680, AR132, VT72, VT158, VT160, VT163, PSB0474, uridine 5'-diphosphate (UDP), UDP-glucose, uridine β-thiodiphosphate (UDPβS), uridine 5'-triphosphate (UTP), uridine γ-thiophosphate (UTPγS), 2-thioUTP tetrasodium salt, UTPγS trisodium salt, uridine-5'-diphosphoglucose, diuridine triphosphate, 2-(hexylthio)( HT)-AMP, diadenosine pentaphosphate, 2'-deoxy-2'-amino-UTP, 2-thio-UTP, triacetyl uridine, diacetyl / acyluridine, uridine, suramin, dipyridamole analogs, diadenosine tetraphosphate Ap4U, Ap4A, INS365, INS37217, or INS48823; or a pharma- ceutically acceptable salt thereof, wherein the ribo or 2-deoxyribo sugar of any of the foregoing compounds can be replaced with a methanocarba sugar in the north conformation.

[0151] In some embodiments, 2-methylthio-ADP or a pharma- ceutically acceptable salt thereof is useful in the methods of the invention. Without wishing to be bound by theory, it is believed that 2-MeS ADP is rapidly hydrolyzed in vivo to 2-methylthioadenosine, which is a biased agonist, partial agonist, or biased partial agonist of the A1R / or A3R.

[0152] In some embodiments, the compound is an A1R and / or A3R agonist, e.g., N 6 -benzyladenosine-5'-N-methyluronamide, e.g. N 6 -(3-iodobenzyl)-adenosine-5'-N-methyluronamide, also known as IB-MECA or Can-Fite CF-101, or 2-chloro-N 6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (also known as 2-CI-IB-MECA or Can-Fite CF-102); (N)-methanocarbanucleosides, such as (1R,2R,3S,4R)-4-(2-chloro-6-((3-chlorobenzyl)amino)-9H-purin-9-yl)-2,3-di-hydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (CF502, Can-Fite Biopharma, also known as MA; (2S,3S,4R,5R)-3-amino-5-[6-(2,5-dichlorobenzylamino)purin-9-yl]-4-hydroxy-tetrahydrofuran-2-carboxylic acid methylamide (also known as CP532,903); (1'S,2'R,3'S,4'R,5'S)-4-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (also known as MRS3558), 2-(1-hexynyl)-N-methyladenosine; (1S,2R,3S,4R)-2,3-dihydroxy-4-(6-((3-iodobenzyl)amino)-4H-purin-9(5H)-yl) -N-methylcyclopentanecarboxamide (CF101, also known as Can-Fite); (1S,2R,3S,4R)-4-(2-chloro-6-((3-iodobenzyl)amino)-4H-purin-9(5H)-yl)-2,3-dihydroxy-N-methylcyclopentanecarboxamide (CF102, also known as Can-Fite); (1'R,2'R,3'S,4'R,5'S)-4-{2-chloro-6-[(3-iodophenylmethyl)amino]purin-9-yl-}-1-(methylaminocarbonyl)-bicyclo[3.1.0]hexane-2,3-diol (also known as MRS1898); or 2-dialkynyl derivatives of (N)-methanocarbanucleosides; or a pharma-ceutically acceptable salt thereof. In some embodiments, the compound is selected from IB-MECA (also known as CF101), or Cl-IB-MECA (also known as CF102); or a pharma- ceutically acceptable salt thereof.In some embodiments, the compound is selected from (N)-methanocarbanucleosides, such as those disclosed above; or pharmaceutically acceptable salts thereof. In some embodiments, the compound is one of the compounds disclosed in WO2014 / 160502, which is incorporated herein by reference in its entirety.

[0153] Also included are A3R allosteric modulators that enhance receptor activity in the presence of natural ligands, such as 2-cyclohexyl-N-(3,4-dichlorophenyl)-1H-imidazo[4,5-c]quinolin-4-amine (CF602, also known as Can-Fite). However, the A3R agonists listed above are by no means exclusive, and other such agonists can also be used. Administration of A3R agonists covalently bound to polymers is also contemplated. For example, A3R agonists can be administered in the form of conjugates, where the agonist is bound to polyamidoamine (PAMAM) dendrimers.

[0154] In some embodiments, the compound is [ka] (See Beukers MW et al., (2004) "New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine," J. Med. Chem. 47(15):3707-3709); [ka] [ka] (See Devine SM et al., "Synthesis and Evaluation of new A3R agonists," Bioorg Med Chem 18, 3078-3087, 2010; and Muller CE, Jacobson KA, "Recent Developments in adenosine receptor ligands and their potential for novel drugs," Biochimica et Biophysica Acta 1808, 1290-1308, 2011); [Chemical formula] (See Ben DD et al., "Different efficacy of adenosine and NECA derivatives at the human A3 receptor: Insight into the receptor activation switch," Biochem Pharm 87, 321-331, 2014; and Camaioni E, Di Francesco E, Vittori S, Volpini R, Cristalli G, "Adenosine receptor agonists: synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA," Bioorg Med Chem 1997;5:2267-75); [Chemical formula] (See Klotz, K.N. "2-Substituted N-ethylcarboxamidoadenosine derivatives as high-affinity agonists at human A3 adenosine receptors," Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):103-8; and Cristalli G et al. (1995) "2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists," J Med Chem 38 :1462-1472); [Chemical formula] (See Kim S et al. "3D quantitative SAR at A3R," J Chem Inf. Model 47, 1225-1233 2007); [Chemical formula] [Chemical formula] (See Lee, K. et al. "Ring-Constrained (N)-Methanocarba Nucleosides as Adenosine Receptor Agonists," Bioorg Med Chem Lett 2001, 11, 1333-1337); [Chemical formula] (See Kenneth A. Jacobson et al. Chapter 6. A3 Adenosine Receptor Agonists: History and Future Perspectives pp 96-97. Book - Springer: A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics, 2009); [ka] (See Muller CE, Jacobson KA, "Recent Developments in adenosine receptor ligands and their potential for novel drugs," Biochimica et Biophysica Acta 2011, 1808, 1290-1308); [ka] (MRS5930; Jacobson KA et al. "John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors," Comp. and Struct. Biotechnology Jour 13. 286-298. 2015); [ka] (MRS5923; Jacobson KA et al. "John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors," Comp. and Struct. Biotechnology Jour 13. 286-298. 2015); [ka] CP532,903 (see Tracey WR et al., "Novel n6-substitued adenosine 5'-N-methyluronamides with high selectivity for human A3R reduce ischemic myochardial injury," Am J Physiol Heart Circ Physiol 285, 2003; Muller CE, Jacobson KA, "Recent Developments in adenosine receptor ligands and their potential for novel drugs," Biochimica et Biophysica Acta 1808, 1290 - 1308, 2011; and Wan TC et al., "The A3R Agonist CP-532,903 Protects against Myocardial Ischemia / Reperfusion Injury," J. of Pharmacology and Exptl Therapies 324, 1, 2008); [Chemical formula] (see Volpini R et al., "HEMADO as Potent and Selective Agonists of hA3R," J Med Chem 45, 3271 - 3279, 2002; Muller CE et al., "Recent Developments in adenosine receptor ligands and their potential for novel drugs," Biochimica et Biophysica Acta 1808, 1290 - 1308, 2011; and Volpini R et al., "Synthesis and Evaluation of Potent and Highly Selective Agonists for hA3R," J of Med Chem 52, 7897 - 7900, 2009); [ka] (See Muller CE, Jacobson KA. "Recent Developments in adenosine receptor ligands and their potential for novel drugs," Biochimica et Biophysica Acta 1808, 1290-1308. 2011); [ka] (wherein R is H or cyclopentylmethyl); [ka] (wherein R is H, butyl, or pyridin-2-yl) (see Cosyn L. et al., "2-triazole-substituted adenosines," J Med Chem 2006. 49. 7373-7383); [ka] (See Muller CE, Jacobson KA. "Recent Developments in adenosine receptor ligands and their potential for novel drugs," Biochimica et Biophysica Acta 1808, 1290-1308. 2011); [ka] (wherein Ar is selected from phenyl, p-CH3CO-phenyl, p-fluorophenyl, or 2-pyridyl) (see Volpini R et al. "Synthesis and Evaluation of Potent and Highly Selective Agonists for hA3R," J Med Chem 52, 7897-7900. 2009); [ka] (See Pugliese AM et al., "Role of A3R on CA1 hippocampal neurotransmission during OGD," Biochem Pharmacology 74. 2007); [ka] (See Klotz KN "Adenosine receptors and their ligands NS's," Arch Pharmacol. 362. 382-391. 2000); or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is selected from an (N)-methanocarbanucleoside, such as the compounds disclosed above; or a pharmaceutically acceptable salt thereof.

[0155] In some embodiments, the compound is [ka] [ka] [ka] or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is selected from an (N)-methanocarbanucleoside, such as the compounds disclosed above; or a pharmaceutically acceptable salt thereof.

[0156] In some embodiments, the compound is [ka] [ka] [ka] or a pharma- ceutically acceptable salt thereof.

[0157] In some embodiments, the compound is [ka] or a pharma- ceutically acceptable salt thereof.

[0158] In some embodiments, the compound is [ka] or a pharma- ceutically acceptable salt thereof.

[0159] In some embodiments, the compound is [ka] or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound is I-25 or a pharma- ceutically acceptable salt thereof.

[0160] In some embodiments, the compound is MRS5698, MRS5980, or BIO-205. [ka] Or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is MRS5698, MRS5980, or BIO-205, or a pharmaceutically acceptable salt thereof, and the injury, disease, or disorder is pain, a pain condition, or a pain disorder. In some embodiments, the pain, a pain condition, or a pain disorder is neuropathic pain.

[0161] In some embodiments, the compound is selected from one of the compounds in Table 1, or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound is a monophosphate, diphosphate, or triphosphate of a compound of formula I, IA, or IB, such as a compound depicted in Table 1, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof. In some embodiments, the prodrug of the monophosphate, diphosphate, or triphosphate is the corresponding mono-, di-, or triphosphate ester, such as an alkyl ester or a phenyl ester thereof. Exemplary prodrugs of phosphate are described in U.S. Patent No. 9,724,360, the contents of which are incorporated herein by reference. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0162] Compounds and Definitions The compounds of the present invention include those compounds generally described herein and are further described by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise specified. For purposes of the present invention, chemical elements are defined as defined in the Elements, CAS version, Handbook of Chemistry and Physics, 75 th In addition, the general principles of organic chemistry are identified in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999 and "March's Advanced Organic Chemistry", 5 thEd., Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of each of which are incorporated herein by reference.

[0163] The term "aliphatic" or "aliphatic group," as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more units of unsaturation, or a monocyclic or bicyclic hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic (also referred to herein as "carbocyclic" or "alicyclic") and has a single point of attachment to the rest of the molecule. Unless otherwise specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In still other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in still other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In some embodiments, "alicyclic" (or "carbocycle") refers to a monocyclic C3-C6 hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic and has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0164] As used herein, the term "bicyclic ring" or "bicyclic ring system" refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, that is saturated or has one or more units of unsaturation and shares one or more atoms between the two rings of the ring system. Thus, the term includes any permissible ring fusion, e.g., ortho-fused or spirocyclic. As used herein, the term "heterobicyclic" is a subset of "bicyclic" that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present at the attachment point of the ring, are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms, e.g., sulfones and sulfonates), phosphorus (including oxidized forms, e.g., phosphates), boron, and the like. In some embodiments, the bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. As used herein, the term "bridged bicyclic" refers to any bicyclic ring system, saturated or partially unsaturated, i.e., carbocyclic or heterocyclic, having at least one bridge. As defined by IUPAC, a "bridge" is an unbranched chain of atoms, or an atom, or a valence bond, connecting two bridgeheads, where a "bridgehead" is any skeletal atom of the ring system that is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, the bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include the following groups, in which each group is bonded to the remainder of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, bridged bicyclic groups are optionally substituted with one or more substituents as described for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include: [ka] Exemplary bridged bicyclic rings include: [ka] Examples include:

[0165] The term "lower alkyl" means C 1~4 It refers to a straight or branched chain alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0166] The term "lower haloalkyl" refers to a C alkyl group substituted with one or more halogen atoms. 1~4 It refers to a straight or branched chain alkyl group.

[0167] The term "heteroatom" refers to one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (including as in N-substituted pyrrolidinyl).

[0168] The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.

[0169] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2) n -, where n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2, or 2 to 3. A "substituted" alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms have been replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0170] The term "alkenylene" refers to a divalent alkenyl group having at least one carbon-carbon double bond. Unless otherwise specified, the double bond can be cis or trans. In some embodiments, an alkenylene group has a single carbon-carbon double bond. In some embodiments, the double bond is cis. In some embodiments, the double bond is trans. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0171] The term "alkynylene" refers to a divalent alkynyl group having at least one carbon-carbon triple bond. The carbon-carbon triple bond can be located at the internal or terminal position of the alkynylene group, i.e., at either end of the chain or carbon atom or between two carbon atoms within it. A substituted alkynylene chain is a polymethylene group containing at least one triple bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups. In some embodiments, the triple bond is at the terminal position, and the hydrogen of the alkynyl is optionally replaced by a substituent.

[0172] The term "halogen" means F, Cl, Br, or I.

[0173] The term "aryl" used alone or as part of a larger moiety, such as in "aralkyl", "aralkoxy" or "aryloxyalkyl", refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, in which at least one ring in the system is aromatic, and each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring". In certain embodiments of the invention, "aryl" refers to an aromatic ring system that may bear one or more substituents, including, but not limited to, phenyl, biphenyl, naphthyl, anthracyl, and the like. Also included within the scope of the term "aryl" as used herein are groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.

[0174] The terms "heteroaryl" and "heteroar-" used alone or as part of a larger moiety, such as "heteroaralkyl" or "heteroaralkoxy", refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms, having 6, 10, or 14 pi-electrons shared in the cyclic arrangement, and having 1 to 5 heteroatoms in addition to the carbon atoms. The term "heteroatom" refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms "heteroaryl" and "heteroara-" as used herein also include groups in which an aromatic heterocycle is fused to one or more aryl, alicyclic, or heterocyclyl rings, with the attachment radical or point of attachment being on the aromatic heterocycle. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. Heteroaryl groups can be monocyclic or bicyclic. The term "heteroaryl" can be used interchangeably with the terms "heteroaryl ring", "heteroaryl group", or "heteroaromatic", all of which include rings that are optionally substituted.The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, where the alkyl and heteroaryl portions independently are optionally substituted.

[0175] As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic radical" and "heterocyclic ring" are used interchangeably and refer to a stable 5-7 membered monocyclic or 7-10 membered bicyclic heterocyclic moiety that is saturated or partially unsaturated and has, in addition to carbon atoms, one or more, preferably 1-4, heteroatoms as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. By way of example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen can be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or . + It may be NR (as in N-substituted pyrrolidinyl).

[0176] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic radical" are used interchangeably herein and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or alicyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. Heterocyclyl groups can be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by heterocyclyl, where the alkyl and heterocyclyl moieties, independently, are optionally substituted.

[0177] As used herein, the term "partially unsaturated" refers to a ring moiety that contains at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.

[0178] As described herein, the compounds of the present invention may contain "optionally substituted" moieties. In general, the term "substituted," whether preceded by the term "optionally" or not, means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. Unless otherwise specified, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and if more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituents may be the same or different at all positions. The combinations of substituents envisioned by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to compounds that are substantially unchanged when subjected to conditions that allow for their production, detection, and in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0179] Each optional substituent on a substitutable carbon is selected from the group consisting of halogen, -(CH2), 0~4 R°;-(CH2) 0~4 OR°;-O(CH2) 0~4 R°;-O-(CH2) 0~4 C(O)OR°;-(CH2) 0~4 CH(OR°)2;-(CH2) 0~4 SR°;-(CH2) 0~4 Ph (can be substituted by R°); -(CH2) 0~4 O(CH2) 0~1 Ph (can be substituted with R°); -CH=CHPh (can be substituted with R°); -(CH2) 0~4 O(CH2) 0~1 -pyridyl (can be substituted by R°); -NO2; -CN; -N3; ​​-(CH2) 0~4 N(R°)2;-(CH2) 0~4 N(R°)C(O)R°;-N(R°)C(S)R°;-(CH2) 0~4 N(R°)C(O)NR°2;-N(R°)C(S)NR°2;-(CH2) 0~4N(R°)C(O)OR°;-N(R°)N(R°)C(O)R°;-N(R°)N(R°)C(O)NR°2;-N(R°)N(R°)C(O)OR°;-(CH2) 0~4 C(O)R°;-C(S)R°;-(CH2) 0~4 C(O)OR°;-(CH2) 0~4 C(O)SR°;-(CH2) 0~4 C(O)OSiR°3;-(CH2) 0~4 OC(O)R°;-OC(O)(CH2) 0~4 SR-, SC(S)SR°;-(CH2) 0~4 SC(O)R°;-(CH2) 0~4 C(O)NR°2;-C(S)NR°2;-C(S)SR°;-SC(S)SR°, -(CH2) 0~4 OC(O)NR°2;-C(O)N(OR°)R°;-C(O)C(O)R°;-C(O)CH2C(O)R°;-C(NOR°)R°;-(CH2) 0~4 SSR°;-(CH2) 0~4 S(O)2R°;-(CH2) 0~4 S(O)2OR°;-(CH2) 0~4 OS(O)2R°;-S(O)2NR°2;-(CH2) 0~4 S(O)R°;-N(R°)S(O)2NR°2;-N(R°)S(O)2R°;-N(OR°)R°;-C(NH)NR°2;-P(O)2R°;-P(O)R°2;-OP(O)R°2;-OP(O)(OR°)2;SiR°3;-(C 1~4 Linear or branched alkylene)ON(R°)2; or -(C 1~4 linear or branched alkylene)C(O)ON(R°)2.

[0180] Each R° is independently hydrogen, C 1~6 Aliphatic, -CH2Ph, -O(CH2) 0~1Ph, -CH2- (a 5-6 membered heteroaryl ring), or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; or notwithstanding the above definition, two independent occurrences of R° together with their intervening atoms form a 3-12 membered saturated, partially unsaturated or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur (which may be substituted by a divalent substituent on a saturated carbon atom of R° selected from =O and =S); or each R° is selected from halogen, -(CH2) 0~2 R ● , -(Halo R ● ), -(CH2) 0~2 OH, -(CH2) 0~2 OR ● , -(CH2) 0~2 CH(OR ● )2;-O(HaloR ● ), -CN, -N3, -(CH2) 0~2 C(O)R ● , -(CH2) 0~2 C(O)OH, -(CH2) 0~2 C(O)OR ● , -(CH2) 0~2 S.R. ● , -(CH2) 0~2 SH, -(CH2) 0~2 NH2, -(CH2) 0~2 NHR ● , -(CH2) 0~2 NR ● 2, -NO2, -SiR ● 3. -OSiR ● 3. -C(O)SR ● , -(C 1~4 Linear or branched alkylene)C(O)OR ● , or -SSR ● and optionally substituted with monovalent substituents independently selected from:

[0181] Each R ● are independently 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, where each R ● is unsubstituted or, if preceded by halo, is substituted only with one or more halogens, or the optional substituents on a saturated carbon are =O, =S, =NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2~3 O- or -S(C(R * 2)) 2~3 S- or the divalent substituents attached to adjacent substitutable carbons of the "optionally substituted" group are -O(CR * 2) 2~3 O-, where R * Each independent occurrence of is hydrogen, C 1~6 It is selected from aliphatic or unsubstituted 5-6 membered saturated, partially unsaturated or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0182] R * C 1~6 If aliphatic, R * is halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or -NO2, where each R ● are independently 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; ● is unsubstituted or, if preceded by halo, substituted only with one or more halogens.

[0183] The optional substituents on a substitutable nitrogen are independently: -R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CH2C(O)R † , -S(O)2R † , -S(O)NR † 2. -C(S)NR † 2. -C(NH)NR † 2, or -N(R † )S(O)2R † where each R † are independently hydrogen, C 1~6 an aliphatic, unsubstituted -OPh, or an unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; or R † two independent occurrences of together with their intervening atom(s) form an unsubstituted 3-12 membered saturated, partially unsaturated or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, where R † C 1~6 If aliphatic, R † is halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or -NO2 as necessary, and each R ● are independently 1~4Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; ● is unsubstituted or, if preceded by halo, substituted only with one or more halogens.

[0184] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., within the scope of sound medical judgment, and is commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxybutanol ... These include sil-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like.

[0185] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N+ (C 1~4 Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Further pharma- ceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations, formed where appropriate using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkylsulfonate, and arylsulfonate.

[0186] Unless otherwise stated, a structure depicted herein is also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of that structure, such as the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Thus, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the compounds of the invention are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. In addition, unless otherwise stated, a structure depicted herein is also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, hydrogen is replaced by deuterium or tritium, or carbon is replaced by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 7 13 C- or 14 Compounds having the structures of the invention, including those replaced with C-enriched carbons, are within the scope of the invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or as therapeutic agents according to the invention.

[0187] Synthesis of compounds The compounds described herein, such as compounds of formula I, IA, or IB, and pharma- ceutically acceptable salts thereof, can be synthesized using methods known in the art, such as those described in U.S. Patent No. 9,789,131, which is incorporated herein by reference in its entirety. For example, such compounds can be generally prepared according to Scheme I below. Scheme I [ka]

[0188] In Scheme I above, X, R 1 , R 2 , R 2A , P.G. 1 , P.G. 2 , P.G. 3 , and P.G. 4 Each of, either alone or in combination, is as defined and described in the embodiments herein.

[0189] General principles of organic chemistry and synthesis are well known in the art and are described, for example, in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999; "March's Advanced Organic Chemistry", 5 th Ed., Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2001, and "Comprehensive Organic Synthesis", 2 nd Ed., Ed.: Knochel, P. and Molander, GA, Elsevier, Amsterdam: 2014, the entire contents of each of which are incorporated herein by reference.

[0190] In step S-1, the formula R 1A thiol or alcohol of -XH is coupled with an adenine nucleobase of formula E. The coupling is carried out in the presence of a suitable base. Alternatively, 1 The corresponding thiol or alcohol metal salt of -XM, where M is a metal atom, such as sodium or potassium, is coupled with an adenine nucleobase of formula E.

[0191] LG of formula E 1 The group is a suitable leaving group. Suitable leaving groups are well known in the art, for example, as described in the above references. Such leaving groups include, but are not limited to, halogen, alkoxy, sulfonyloxy, optionally substituted alkylsulfonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and diazonium moieties. Examples of suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyl (mesyl), tosyl, triflate, nitro-phenylsulfonyl (nosyl), and bromo-phenylsulfonyl (brosyl). For example, LG 1 may be chloro, fluoro, or triflate. In certain embodiments, LG 1 In the above formula I or IB, -XR 1 If is a halogen, step S-1 is omitted (LG 1 is a halogen, e.g., chloro, and does not need to undergo any chemical transformation).

[0192] In step S-2, the adenine 2-halo, 2-thioether or 2-ether nucleobase D is protected to give the N-protected adenine 2-halo, 2-thioether or 2-ether nucleobase of formula C.

[0193] PG of formula C and A 1The group is a suitable amino-protecting group. Suitable amino-protecting groups are well known in the art and are described in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3 rd edition, John Wiley & Sons, 1999, which is incorporated herein by reference in its entirety. 2A Suitable amino protecting groups in combination with the )-moiety include, but are not limited to, aralkylamines, carbamates, allylamines, amides, and the like. 1 Exemplary groups include t-butyloxycarbonyl (BOC), ethyloxycarbonyl, methyloxycarbonyl, trichloroethyloxycarbonyl, allyloxycarbonyl (Alloc), benzyloxocarbonyl (CBZ), allyl, benzyl (Bn), fluorenylmethylcarbonyl (Fmoc), acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, phenylacetyl, trifluoroacetyl, benzoyl, and the like. 1 is an acid labile amino protecting group. PG 1 is the bond to -N(R 2A )-moiety may be an acid labile carbamate. Typically, PG 1 is BOC.

[0194] Those skilled in the art will recognize that R 2 is hydrogen, R of nucleobase C 2A It will be appreciated that R may be hydrogen (from the addition of a single protecting group to nucleobase D) or a suitable amino protecting group (from the addition of a second protecting group to nucleobase D), depending on the reaction conditions (e.g., the stoichiometry of nucleobase D to protecting group reagent). 2A can be hydrogen or a suitable amino protecting group, e.g., BOC. In some cases, PG 1 and R 2A are BOCs, respectively.

[0195] In step S-3, the N-protected adenine 2-halo, 2-thioether or 2-ether nucleobase of formula C undergoes coupling with a protected (N)-methanocarba sugar analog B to yield the (N)-methanocarba nucleoside analog A. The coupling may be carried out under Mitsunobu-type conditions.

[0196] PG of formula B and A 2 , P.G. 3 , and P.G. 4 Each of the groups is independently a suitable hydroxyl protecting group. Suitable hydroxyl protecting groups are well known in the art and are described in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3 rd edition, John Wiley & Sons, 1999, which is incorporated herein by reference in its entirety. 2 , P.G. 3 , and P.G. 4Each of may be selected from esters, ethers, silyl ethers, alkyl ethers, aryl alkyl ethers, and alkoxy alkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates. Specific examples include formates, benzoylformates, chloroacetates, trifluoroacetates, methoxyacetates, triphenylmethoxyacetates, p-chlorophenoxyacetates, 3-phenylpropionates, 4-oxopentanoates, 4,4-(ethylenedithio)pentanoates, pivalates (trimethylacetyl), crotonates, 4-methoxy-crotonates, benzoates, p-benzylbenzoates, 2,4,6-trimethylbenzoates, or carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl. Examples of such silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers. Alkyl ethers include methyl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers. Examples of arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, trityl, 2- and 4-picolyl.

[0197] For example, P.G. 2 , P.G. 3 , and P.G. 4 Each of may be an acid labile hydroxyl protecting group.

[0198] In some cases, P.G. 4 together with the oxygen atom to which it is attached is a silyl ether or an arylalkyl ether. Alternatively, PG 4 is trityl or dimethoxytrityl.

[0199] PG 2 and P.G. 3 can combine with the oxygen atom to which they are attached to form diol protecting groups, such as cyclic acetals or ketals. Such groups include methylene, ethylidene, benzylidene, isopropylidene, cyclohexylidene, and cyclopentylidene, silylene derivatives such as di-t-butylsilylene and 1,1,3,3-tetraisopropyldisiloxanylidene derivatives, cyclic carbonates, and cyclic boronates.

[0200] In step S-4, the (N)-methanocarbanucleoside analog A is deprotected to give a compound of formula I, IA, or IB. 1 , P.G. 2 , P.G. 3 , and P.G. 4 It will be appreciated that the conditions required to deprotect each of the PGs may be the same or different. 1 , P.G. 2 , P.G. 3 , and P.G. 4 If necessary, a deprotection step can be performed with or without isolation of the intermediate, where P-G 1 , P.G. 2 , P.G. 3 , and P.G. 4 One or more (but not all) of the following have been deprotected:

[0201] Exemplary Treatment Methods In some embodiments, the present invention relates to a method for treating a neurodegeneration caused by traumatic brain injury (TBI), concussion, stroke (e.g., acute ischemic stroke (AIS)), partial or complete spinal cord transection, malnutrition, toxic neuropathies, cerebral meningismus, neurodegeneration caused by genetic disorders, age-related neurodegeneration, vascular diseases, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), cardiovascular diseases, autoimmune diseases, allergic diseases, transplant rejection, graft versus host disease, ocular hypertension, glaucoma, odor sensitivity, olfactory disorders, type 2 diabetes, pain control, respiratory diseases, defects in CNS function, learning disabilities, cognitive disorders, ear disorders, Meniere's disease, endolymphatic hydrops, progressive hearing loss, dizziness, vertigo, tinnitus, radiation, The present invention provides a method for treating an injury, disease, or condition selected from collateral brain damage associated with cancer therapy, migraine treatment, sleep disorders in the elderly, epilepsy, schizophrenia, symptoms experienced by recovering alcoholics, damage to neurons or nerves of the peripheral nervous system during surgery, gastrointestinal conditions, pain mediated by the CNS, migraine, depression, mood or behavior changes, dementia, vagal behavior, suicidality, tremors, Huntington's disease, loss of motor coordination, hearing loss, speech disorders, dry eye, masked facies, attention deficit, memory loss, cognitive difficulties, vertigo, dysarthria, dysphagia, eye abnormalities or disorientation, or addiction, comprising the step of administering to a patient a compound as described herein or a pharma- ceutically acceptable salt thereof or a composition comprising same. In some embodiments, the present invention provides a method of treating an injury, disease, or condition selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, or a cardiac or cardiovascular disease, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0202] In some embodiments, the compound acts as an agonist of the A3 adenosine receptor (A3R). In some embodiments, the compound is a partial A3R agonist. In some embodiments, the compound is a biased A3R agonist. In some embodiments, the compound acts by dual agonism at the A3 adenosine receptor and the A1 adenosine receptor (A1R). In some embodiments, the compound acts as an agonist of the A1 adenosine receptor (A1R). In some embodiments, the compound is a partial A1R agonist. In some embodiments, the compound is a biased A1R agonist.

[0203] In some embodiments, the present invention provides a method of treating an injury, disease, or condition selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, or a cardiac or cardiovascular disease, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0204] In some embodiments, the present invention provides a method of treating a brain or central nervous system (CNS) injury or condition selected from traumatic brain injury (TBI) or stroke, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharmacologic acceptable salt thereof, or a composition comprising same.

[0205] In some embodiments, the present invention provides a method of treating or ameliorating traumatic brain injury (TBI), radiation injury, stroke, migraine, heart disease or cardiovascular disease, or a neurodegenerative disorder, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0206] In some embodiments, the present invention provides a method of treating or ameliorating traumatic brain injury (TBI), radiation injury, stroke, migraine, heart disease or cardiovascular disease, or a neurodegenerative disorder, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0207] In some embodiments, the present invention provides a method of treating an injury, disease, or condition selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, or a cardiac or cardiovascular disease, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharmacologic acceptable salt thereof, or a composition comprising same.

[0208] In some embodiments, the injury, disease, or condition is TBI.

[0209] In some embodiments, the TBI is selected from a concussion, a blast injury, a combat-related injury, or a mild, moderate or severe blow to the head.

[0210] In some embodiments, the injury, disease, or condition is a stroke selected from ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, or transient ischemic attack (TIA).

[0211] In some embodiments, neuroprotection or neurorepair in the patient is increased compared to an untreated patient.

[0212] In some embodiments, the neurodegenerative disease is selected from Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), or a neurodegenerative condition caused by a virus, alcoholism, tumor, toxin, or repetitive brain injury.

[0213] In some embodiments, the neurodegenerative disease is Parkinson's disease.

[0214] In some embodiments, the injury, disease, or condition is Alzheimer's disease, migraine headaches, brain surgery, or neurological side effects associated with cancer chemotherapy.

[0215] In some embodiments, the recovery time following TBI, stroke, cardiac ischemia, or myocardial infarction is shortened compared to untreated patients.

[0216] In some embodiments, the cardiac or cardiovascular disease is selected from cardiac ischemia, myocardial infarction, cardiomyopathy, coronary artery disease, arrhythmias, myocarditis, pericarditis, angina, hypertensive heart disease, endocarditis, rheumatic heart disease, congenital heart disease, or atherosclerosis.

[0217] In some embodiments, the cardiac or cardiovascular disease is cardiac ischemia or myocardial infarction.

[0218] In some embodiments, the compound or composition is administered chronically to treat stroke, cardiac ischemia, or myocardial infarction, for the period after the injury has occurred until it has resolved.

[0219] In some embodiments, the present invention provides a method of increasing neuroprotection or neurorepair in a patient in need thereof suffering from TBI or stroke, comprising administering to the patient an effective amount of a compound described herein or a pharmacologic acceptable salt thereof, or a composition comprising same.

[0220] In some embodiments, the compound or a pharma- ceutically acceptable salt thereof is administered orally, intravenously, or parenterally.

[0221] In some embodiments, the compound or composition is administered within 24 hours of the TBI or stroke.

[0222] In some embodiments, the compound or composition is administered within 8 hours of the TBI or stroke.

[0223] In some embodiments, the compound or composition is administered during at least the first 8-48 hours after TBI or stroke.

[0224] In some embodiments, the present invention provides a method of treating cardiac or cardiovascular disease, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0225] In some embodiments, the patient is suffering from cardiac ischemia or myocardial infarction.

[0226] In some embodiments, the compound or composition increases cardioprotection or regeneration of damaged cardiac tissue in a patient.

[0227] In some embodiments, the compound or composition shortens the recovery period following cardiac ischemia or myocardial infarction in a patient compared to an untreated patient.

[0228] In some embodiments, the present invention provides a method for the preparation of a (i) Radiation-induced brain injury or collateral brain injury associated with radiation cancer therapy or migraine treatment; (ii) migraine headaches, (iii) a condition associated with brain injury or a neurodegenerative condition; or (iv) an autoimmune disease or condition, glaucoma, an ear disorder, progressive hearing loss, tinnitus, epilepsy, or pain (e.g., CNS-mediated pain, neuropathic pain, inflammatory pain, or acute pain). 1. A method for treating an injury, disease, disorder, or condition selected from the group consisting of: Methods are provided that include the step of administering to a patient in need thereof an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0229] In some embodiments, the compound or composition increases neuroprotection or neurorepair in a patient compared to an untreated patient.

[0230] In some embodiments, the condition associated with brain injury or neurodegenerative condition is selected from epilepsy, migraine, collateral brain damage associated with radiation cancer treatment, depression, mood or behavioral changes, dementia, erratic behavior, suicidality, tremors, Huntington's disease, loss of motor coordination, hearing loss, speech disorders, dry eyes, masked facies, attention deficit, memory loss, cognitive difficulties or impairments, defects in CNS function, learning disabilities, vertigo, dysarthria, dysphagia, eye abnormalities, or disorientation.

[0231] In some embodiments, the present invention provides a method of increasing cardioprotection or regeneration of damaged cardiac tissue in a patient in need thereof suffering from cardiac ischemia or myocardial infarction, comprising administering to the patient an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0232] In some embodiments, the present invention provides a method of treating a disease, disorder, or condition selected from cognitive impairment, deficits in CNS function, learning disabilities, and memory loss, comprising administering to a subject in need thereof an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a pharma-ceutically acceptable composition thereof.

[0233] In some embodiments, the disease, disorder, or condition is a cognitive disorder.

[0234] In some embodiments, the disease, disorder, or condition is a defect in CNS function.

[0235] In some embodiments, the disease, disorder, or condition is a learning disability.

[0236] In some embodiments, the disease, disorder, or condition is memory loss.

[0237] In some embodiments, the subject has suffered from one or more traumatic brain injuries (TBI(s)), and the disease, disorder, or condition is associated with the TBI(s).

[0238] In some embodiments, the subject has suffered from one or more strokes, and the disease, disorder, or condition is associated with one or more strokes.

[0239] In some embodiments, the subject has suffered from one or more of ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, or transient ischemic attack (TIA).

[0240] In some embodiments, the subject has Alzheimer's disease, and the disease, disorder, or condition is associated with Alzheimer's disease.

[0241] In some embodiments, the methods provided herein improve cognitive or neurological function as measured by an increase in score of between about 1% and 40% on the delayed verbal recall task of the Wechsler Memory Scale-Revised.

[0242] In some embodiments, the methods provided herein improve scores on the delayed verbal recall task of the Wechsler Memory Scale-Revised by about 5-10%, 10-20%, 15-30%, 20-30%, 30-40%, or between 5-30%.

[0243] In some embodiments, the methods increase synaptic plasticity, improve hippocampal long-term potentiation, improve cognitive function, reduce cognitive impairment, and / or improve or restore memory or learning.

[0244] In some embodiments, the methods increase synaptic plasticity, improve hippocampal long-term potentiation, improve cognitive function, attenuate cognitive impairment, prevent or delay cognitive decline, reduce plaque burden, enhance beta-amyloid clearance, and / or improve or restore memory or learning.

[0245] In some embodiments, the methods improve or enhance cognitive or neurological function by improving synaptogenesis.

[0246] In one aspect, the invention provides a method of improving cognitive or neurological function in a subject having Alzheimer's disease, comprising administering to a subject in need thereof an effective amount of a disclosed compound, e.g., I-1, or a pharma- ceutically acceptable salt or composition thereof. In some embodiments, the improvement in cognitive or neurological function is measured as an increase in score of between about 1%-40%, or about 5-10%, 10-20%, 15-30%, 20-30%, 30-40%, or 5-30% on the delayed verbal recall task of the Wechsler Memory Scale-Revised.

[0247] Surprisingly, it has been found that certain purine nucleoside mono-, di-, and triphosphates, such as the phosphates of the nucleosides disclosed herein, are dephosphorylated in vivo and exist primarily as nucleosides, i.e., are not substantially phosphorylated in vivo. Without wishing to be bound by theory, it is believed that such dephosphorylation is carried out by ectonucleotidases, enzymes involved in the dephosphorylation of nucleotides, present both on the surface of cell membranes and in circulation in blood and plasma (see Ziganshin et al. Pflugers Arch. (1995) 429:412-418). It is often extremely difficult to predict which nucleotide analogs are substrates for ectonucleotidases and therefore are expected to be dephosphorylated in vivo. In some embodiments, the dephosphorylated compounds are responsible for therapeutic efficacy. Thus, in some embodiments, the corresponding phosphorylated monophosphate, diphosphate, or triphosphate or phosphate ester, such as its alkyl or phenyl ester, are prodrugs or precursors of the drug responsible for therapeutic efficacy.

[0248] In some embodiments, the compounds of the present invention can cross the blood-brain barrier (BBB). The term "blood-brain barrier" or "BBB" as used herein refers to the BBB in the strict sense and the blood-spinal barrier. The blood-brain barrier, which is composed of the endothelium, basement membrane and glial cells of the brain blood vessels, acts to limit the penetration of substances into the brain and cerebrospinal fluid (CSF). In some embodiments, the brain / plasma ratio of the total drug is at least about 0.01 after administration (e.g., oral or intravenous administration) to a patient. In some embodiments, the brain / plasma ratio of the total drug is at least about 0.03. In some embodiments, the brain / plasma ratio of the total drug is at least about 0.06. In some embodiments, the brain / plasma ratio of the total drug is at least about 0.1. In some embodiments, the brain / plasma ratio of the total drug is at least about 0.2.

[0249] Prototypical adenosine A3 agonists, such as Cl-IB-MECA and MRS5698, are lipophilic compounds with low solubility and cLogP values ​​typically higher than 2. This lipophilicity is a major factor contributing to the high plasma protein binding, high brain binding, and low free fraction of drug available to interact with A1 and / or A3 receptors in the brain. In some embodiments, for example in neurological and neurodegenerative conditions, the physicochemical properties of the compounds of the present invention are substantially different, and these and related compounds are hydrophilic compounds with cLogP<0, resulting in high solubility, low plasma and brain binding, and high unbound drug concentrations available to interact with A1 and / or A3 receptors.

[0250] Thus, in some embodiments, the compound has a cLogP of less than about 0.8, less than about 0.7, less than about 0.6, less than about 0.5, less than about 0.4, less than about 0.3, less than about 0.2, less than about 0.1, less than about 0.05, less than about 0.01, or less than about 0.005. In some embodiments, the compound has a cLogP of less than 0, e.g., less than about -0.1, less than about -0.2, less than about -0.3, less than about -0.4, less than about -0.5, less than about -0.6, less than about -0.7, less than about -0.8, or less than about -0.9, or less. In some embodiments, the compound has an unbound fraction in plasma of about 0.5 to 0.9. In some embodiments, the compound has an unbound fraction in plasma of about 0.6 to 0.85, 0.7 to 0.8, or about 0.75. In some embodiments, the compound has an unbound fraction in the brain of at least about 0.02, or at least about 0.03, at least about 0.04, at least about 0.05, at least about 0.06, at least about 0.07, at least about 0.08, at least about 0.09, at least about 0.1, at least about 0.12, at least about 0.15, or at least about 0.17, or higher. In some embodiments, the compound has an unbound fraction in plasma of about 0.6-0.85, 0.7-0.8, or about 0.75, and / or an unbound fraction in the brain of at least 0.08.

[0251] Uses of the Compounds and Pharmaceutically Acceptable Compositions Thereof As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment is administered after one or more symptoms have developed. In other embodiments, treatment is administered in the absence of symptoms. For example, treatment is administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment is also continued after symptoms have resolved, for example to prevent, delay, or reduce the severity of their recurrence. Brain, CNS, cardiovascular, and other injuries and conditions

[0252] In some embodiments, the present invention provides a new approach to prevent and / or treat brain damage associated with acute brain trauma, as well as longer-term brain and CNS diseases, and heart and cardiovascular diseases and conditions. In one aspect, the present invention provides a method of treating such injuries, diseases, and conditions by utilizing the neuroprotective and neurorepair effects mediated by astrocytes, now understood as the crucial natural caretaker cells of neurons, and astrocyte mitochondria, which provide a significant portion of the brain's energy. In another aspect, the present invention provides a method of treating such injuries, diseases, and conditions by the cardioprotective and regenerative effects mediated by A3R receptors. With regard to the neuroprotective and neurorepair effects, without wishing to be bound by theory, it is believed that the selective enhancement of astrocyte energy metabolism mediated by A3R and / or P2Y1 receptors promotes the caretaker functions of astrocytes, such as their neuroprotective and neurorepair functions, which in turn enhances the resistance of neurons and other cells to both acute injuries and long-term stress. In some cases, it may be advantageous to achieve a biased, i.e., selective or preferential, activation of one or more pathways mediated by A3R and / or P2Y1 and / or A1R receptors, where one or more undesirable pathways are not activated or are activated to a lesser extent. In addition to or as an alternative to astrocytes, the neuroprotective or neurorepair functions of glia, microglia, neurons, endothelial cells, and other brain and / or CNS cell types may be activated.Thus, in one aspect, the present invention provides compounds and methods of use thereof for treating, ameliorating, or promoting recovery from certain conditions of the brain or central nervous system (CNS), e.g., brain injury, e.g., by increasing the neuroprotective and / or neurorepair effects mediated by astrocytes, glia, microglia, neurons, endothelial cells, or other cells of the brain and / or CNS, comprising administering to a patient in need thereof an effective amount of a compound as described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0253] Astrocytes play a crucial role in supporting and protecting neurons, critically affecting the outcome of brain damage, such as brain damage resulting from ischemic injury. The central role that astroglial mitochondria themselves play in these brain functions is less understood. For example, inhibition of astroglial mitochondria leads to increased swelling and necrotic cell death. Neurons are permanently damaged by recurrent propagating depolarization only if astroglial mitochondrial function fails, and astroglial mitochondria are responsible for the extracellular K that causes the propagating depolarization. + Activation of purinergic receptors on astrocytes enhances mitochondrial citric acid cycle function and increases mitochondrial Ca2+ levels, which increases respiration and ATP production. 2+Thus, in one aspect, the present invention relates to the discovery that activation of astrocyte purinergic receptors enhances brain cell survival signaling pathways, allowing both astrocyte and neuron survival during oxidative stress. Furthermore, activated astrocytes produce and provide reduced glutathione, a very important antioxidant that helps both astrocyte and neuron resistance to oxidative stress. Thus, in one aspect, the present invention provides a method of modulating astrocyte purinergic receptors to promote the survival and viability of one or more cell types in the brain of a patient after oxidative stress, such as oxidative stress caused by brain injury, ischemia-reperfusion, or neurodegenerative conditions, comprising administering to a patient in need thereof a compound as described herein or a pharma- ceutical acceptable salt thereof, or a composition comprising the same.

[0254] In some embodiments, activation of astrocytes is achieved by contacting the disclosed compounds with one or more purinergic receptors, e.g., adenosine receptors (ARs), e.g., receptors associated with or expressed by astrocytes, thereby modulating the activity of the one or more receptors. In some embodiments, the compounds activate adenosine receptors on astrocytes, e.g., A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52, A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A71, A72, A73, A74, A75, A76, A77, A78, A79, A79, A81, A82, A93, A94, A95, A96, A97, A98, A99, A100, A99, A111, A121, A131, A141, A151, A162, A173, A182, A199, A199, A101, A111, A121, 2A , A 2Band A3 activate astrocytes to treat one or more of the disclosed diseases or conditions. In some embodiments, the disclosed compounds affect one or more astrocyte functions after administration to a patient in need thereof. In some embodiments, the astrocyte functions are selected from glutamate uptake, reactive gliosis, swelling, or release of neurotrophic and neurotoxic factors that act to ameliorate metabolic stress and its consequences. In some embodiments, the compounds are AR agonists. In some embodiments, the purinergic receptor is the A3 adenosine receptor (A3R). In some embodiments, the compounds are A3R agonists. In some embodiments, the compounds are partial agonists or biased agonists or biased partial agonists at the A3 receptor (A3R), for example, the human A3 receptor (hA3R). In some embodiments, the compounds act as agonists at the A1 adenosine receptor (A1R). In some embodiments, the compounds are biased agonists at the A1 and / or A3 receptors. In some embodiments, the compounds act through dual agonism at the A3R and the A1R.

[0255] In another aspect, the present invention provides a method for treating or ameliorating brain injury, disease, or condition, such as brain injury resulting from TBI or progressive neurodegenerative disorder, in a patient in need thereof, comprising administering to the patient an effective amount of a compound described herein, or a pharmacologic acceptable salt thereof, or a composition comprising the same.In some embodiments, the subject suffers from TBI, concussion, stroke, partial or complete spinal cord transection, or malnutrition.In other embodiments, the subject suffers from toxic neuropathies, cerebral meningitis, neurodegeneration caused by genetic disorders, age-related neurodegeneration, or vascular disease, or another disease disclosed in U.S. Patent No. 8,691,775, which is incorporated herein by reference. In some embodiments, the present invention provides a method for treating or ameliorating brain injury, disease, or condition, such as brain injury resulting from TBI or progressive neurodegenerative disorder, in a patient in need thereof, comprising administering to the patient an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A1R and / or A3R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist at the A1 receptor. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist at the A3 receptor. In some embodiments, the compound acts by dual agonism at the A3R and A1R. In some embodiments, the compound is one of the compounds depicted in Table 1, or a pharmaceutically acceptable salt thereof.

[0256] In another aspect, the present invention provides a method for promoting or increasing neuroprotection, neurorepair or neuroregeneration in a patient suffering from a disease or condition, comprising administering to the patient an effective amount of a compound as described herein, or its pharmacologic acceptable salt or a composition comprising it.In some embodiments, the patient suffers from a neurodegenerative disease or condition.In some embodiments, the patient suffers from TBI or stroke.

[0257] Traumatic brain injury Traumatic brain injury (TBI) is a distressing and common medical condition that is predicted to be the third leading cause of morbidity and mortality worldwide by 2020. There are no approved treatments for TBI, and most TBI patients are discharged from the hospital without receiving any pharmacological treatment (Witt 2006). Repetitive TBI, e.g., concussion, can trigger age-related neurodegeneration that results in a range of symptoms and disabilities over decades (McKee 2013). TBI can result from sports-related injuries, motor vehicle accidents, falls, explosive impacts, physical assaults, etc. Injuries range in complexity and severity, from "mild" concussions with brief alterations in mental status, cognitive difficulties, or loss of consciousness, to "severe" concussions with prolonged unconsciousness and / or amnesia following injury. In the United States, approximately 1.7 million people annually sustain injuries resulting in TBI and seek medical intervention (USCSF and CDC), and the CDC estimates that an additional 1.6 to 3.8 million concussion incidents occur annually in sports and other recreational activities that do not result in a hospital or emergency department visit (CDC, Langlois 2006). Approximately 5 to 10% of athletes will sustain a concussion each sports season (Sports Concussion Institute 2012). Football is the sport with the highest concussion risk for men (75% chance of concussion), while soccer is the sport with the highest concussion risk for women (50% chance of concussion). TBI is the leading cause of death and disability in children and young adults (CDC), the majority of whom typically sustain military-related injuries. Approximately 20% of U.S. military personnel deployed since 2003 have had at least one sustained TBI (Chronic Effects of Neurotrauma Consortium (CENC), Warden 2006, Scholten 2012, Taylor 2012, Gavett 2011, Guskiewicz 2005, Omalu 2005). Combined indirect and direct medical costs related to TBI are estimated at $77 billion annually (UCSF and CDC).At least 5 million Americans require ongoing daily assistance with activities as a result of TBI (CDC and Thurman 1999).

[0258] In one aspect herein, a method for treating or promoting recovery from TBI is provided, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In some embodiments, the TBI is selected from trauma to the brain (e.g., concussion, blast injury, combat-related injury), or trauma to the spinal cord (e.g., partial or complete spinal cord transection). In some embodiments, the TBI results from mild, moderate, or severe impact to the head, includes open or closed head wound, or results from penetrating or non-penetrating impact to the head. In some embodiments, the present invention provides a method for treating or promoting recovery from TBI, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharma-ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A3R agonist. In some embodiments, the present invention provides a method for treating or promoting recovery from TBI, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at the A3 receptor. In some embodiments, the compound acts by dual agonism at the A3R and A1R. In some embodiments, the compound acts as an agonist of the A1 adenosine receptor (A1R). In some embodiments, the compound is one of the compounds listed in Table 1, or a pharma- ceutically acceptable composition comprising the same.

[0259] stroke Stroke occurs when blood vessels that transport oxygen and nutrients to the brain are destroyed by ischemic occlusion or by hemorrhagic rupture of intracerebral vessels, causing the death of neurons, glia, and endothelial cells in the destroyed area of ​​the brain. The outcome of a stroke depends on the location and width of the damage, and the effects of that damage are observed in the body functions regulated by the damaged brain area. Stroke can cause unilateral or bilateral paralysis, speech and language disorders, memory loss, behavioral changes, and even death. Stroke is the fourth leading cause of death in the United States and the leading cause of disability in adults. Approximately 800,000 people experience a new or recurrent stroke each year. Every day, more than 2,000 Americans suffer a stroke, and more than 400 of these incidents result in death. Stroke accounted for approximately 1 in 19 deaths in the United States in 2010. An estimated 6.8 million Americans age 20 and older have had a stroke (AHA and Go, 2014). As of 2010, the annual direct and indirect costs of stroke were estimated at $36.5 billion. Within minutes of a stroke, a core of brain tissue is permanently damaged due to lack of blood flow. Between this damaged core and normal brain tissue is a region of tissue known as the penumbra, tissue under graded stress due to reduced blood flow and partial disruption of energy metabolism. Over the first 24-48 hours after the stroke incident, stress on neuronal and glial cells in the penumbra resolves, either by partial recovery or further cell death.

[0260] In one aspect, the present invention provides a method of neuroprotective treatment in stroke patients, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In some embodiments, such treatment saves as much of the penumbra as possible, and / or limits further acute tissue damage, and / or promotes neuronal recovery. In another aspect, a method of treating stroke or promoting recovery from stroke is provided, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In another aspect, a method of promoting or increasing neuroprotection, neuroregeneration, or neurorepair in a patient suffering from stroke is provided, comprising administering to a patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In another aspect, a method for treating stroke or promoting recovery from stroke is provided, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A3R agonist. In another aspect, a method for treating stroke or promoting recovery from stroke is provided, comprising administering to a patient in need thereof an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at the A3 receptor. In some embodiments, the compound acts by dual agonism at the A3R and A1R. In some embodiments, the compound acts as an agonist at the A1 adenosine receptor (A1R). In some embodiments, the compound is one of the compounds set forth in Table 1, or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0261] In some embodiments, the stroke is selected from ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, and transient ischemic attack (TIA). In some embodiments, the stroke is ischemic, e.g., acute ischemic stroke (AIS). In some embodiments, the stroke is hemorrhagic. In some embodiments, the compound is administered within 48 hours of the stroke. In some embodiments, the compound is administered within 24 hours of the stroke. In some embodiments, the compound is administered within 16 hours of the stroke. In some embodiments, the compound is administered within 8 hours, 4 hours, 2 hours, or 1 hour of the stroke. In some embodiments, the compound is administered for at least the first 1-72 hours after the stroke. In some embodiments, the compound is administered for at least the first 8-52 hours after the stroke. In some embodiments, the compound is administered for at least the first 8-48 hours after the stroke. In some embodiments, the compound is administered for at least the first 24-48 hours after the stroke. In some embodiments, the compounds are administered chronically to treat strokes, should they occur, hi some embodiments, the compounds are administered chronically to treat transient ischemic attacks (TIAs).

[0262] In some embodiments, the compounds are administered chronically to treat ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, transient ischemic attack (TIA), or to treat patients at increased risk of stroke, e.g., patients who have had a previous stroke and are at risk for further stroke, e.g., patients over the age of 40, 45, 50, 55, 60, 65, 70, 75, or 80 years of age.

[0263] In some embodiments, the compounds treat ischemia-reperfusion injury caused by stroke.

[0264] In certain embodiments, for the treatment of stroke and related conditions, recanalization procedures such as thrombolysis with recombinant tissue plasminogen activator (r-tPA) or mechanical thrombectomy are used in combination with the disclosed methods of treating stroke or related conditions.

[0265] Neurodegenerative diseases Neurodegenerative diseases are incurable, progressive, and ultimately debilitating syndromes resulting from the progressive degeneration and / or death of neurons in the brain and spinal cord. Neurodegeneration leads to movement disorders (ataxia) and / or cognitive impairment (dementia) and includes a variety of diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and chronic traumatic encephalopathy (CTE). Many neurodegenerative diseases are primarily genetic in origin, but other causes can include viruses, alcoholism, tumors or toxins, and, as is now becoming apparent, repetitive brain injury.

[0266] Neurons accumulate cellular damage over time due to the aforementioned factors, which is generally believed to be the reason why many neurodegenerative diseases associated with prolonged cellular stress, such as Alzheimer's and Parkinson's, occur in older individuals. Dementia is the main outcome of neurodegenerative diseases, with AD accounting for approximately 60-70% of cases (Kandale 2013). As discussed above, activating neuroprotective and neurorepair mechanisms can ameliorate the progression of one or more neurodegenerative diseases. Thus, in one aspect, the present invention provides a method of treating or promoting recovery from a neurodegenerative disease, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.

[0267] In one aspect, the present invention provides a method for promoting neuroprotection or neurorepair in a patient suffering from a neurodegenerative disease, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In some embodiments, a method for promoting neuroprotection or neurorepair in a patient suffering from a neurodegenerative disease is provided, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A3R agonist. In some embodiments, a method for promoting neuroprotection or neurorepair in a patient suffering from a neurodegenerative disease is provided, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at the A3 receptor. In some embodiments, the compound acts by dual agonism at the A3R and the A1R. In some embodiments, the compound acts as an agonist of the A1 adenosine receptor (A1R). In some embodiments, the compound is a compound listed in Table 1, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.

[0268] Alzheimer's Disease (AD) An estimated 5.2 million Americans of all ages were affected by AD in 2014. 11% of the population age 65 and older has AD (Alzheimer's Association). By 2050, the number of people age 65 and older with AD is expected to nearly triple to a projected 13.8 million. In the United States, the cost of providing care to AD patients is approximately $214 billion per year. 70% of this cost is borne by Medicare and Medicaid. At current trends, these costs can be expected to grow to $1.2 trillion per year by 2050.

[0269] The activation of astrocytes and promotion of neuroprotection and neurorepair according to the present invention provides a new treatment option for AD.Therefore, in one aspect herein, a method for treating AD or promoting neuroprotection or neurorepair in a patient suffering from AD is provided, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.In some embodiments, the present invention provides a method for treating AD or promoting neuroprotection or neurorecovery in a patient suffering from AD, comprising administering to the patient an effective amount of a compound described herein, or a pharma-ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A3R agonist.In some embodiments, the present invention provides a method for treating AD or promoting neuroprotection or neurorecovery in a patient suffering from AD, comprising administering to the patient an effective amount of a compound described herein, or a pharma-ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at A3 receptor. In some embodiments, the compound acts by dual agonism at A3R and A1R. In some embodiments, the compound acts as an agonist at A1 adenosine receptor (A1R). In some embodiments, the compound is a compound listed in Table 1, or a pharmaceutically acceptable salt thereof, or a composition comprising the same.

[0270] In some embodiments, beneficial effects resulting from the methods of treating AD provided herein include, but are not limited to, one or more of improved cognitive function, reduced cognitive impairment, reduced plaque burden, enhanced clearance of beta amyloid, increased synapse formation, and improved memory.

[0271] Parkinson's Disease (PD) As many as one million Americans live with PD, and approximately 60,000 new Americans are diagnosed each year, not including the thousands of cases that go undetected (Parkinson's Disease Foundation). The total combined direct and indirect costs of PD, including medical procedures, social security costs, and lost benefits, are estimated to be nearly $25 billion annually in the United States (Parkinson's Disease Foundation and Huse 2005).

[0272] The activation of neuroprotection and neurorepair according to the present invention provides a new treatment option for PD.Therefore, in one aspect herein, a method for treating PD or promoting neuroprotection or neurorepair in a patient suffering from PD is provided, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.In some embodiments, the present invention provides a method for treating PD or promoting neuroprotection or neurorecovery in a patient suffering from PD, comprising administering to the patient an effective amount of a compound described herein, or a pharma-ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A3R agonist.In some embodiments, the present invention provides a method for treating PD or promoting neuroprotection or neurorecovery in a patient suffering from PD, comprising administering to the patient an effective amount of a compound described herein, or a pharma-ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at A3 receptor. In some embodiments, the compound acts by dual agonism at A3R and A1R. In some embodiments, the compound acts as an agonist at A1 adenosine receptor (A1R). In some embodiments, the compound is one of the compounds listed in Table 1, or a pharmaceutically acceptable salt thereof or a composition comprising it.

[0273] Multiple sclerosis (MS) More than 400,000 people in the United States have MS. In young adults, MS is the most prevalent disease of the central nervous system (Multiple Sclerosis Foundation). Astrocytes have the potential to reverse the destruction of nerve cell myelin coating caused by MS by promoting neurorepair effects and healing in the damaged CNS of MS patients.

[0274] Thus, the activation of CNS neuroprotection and neurorepair according to the present invention provides a new treatment option for MS. Thus, in one aspect herein, a method for treating MS or promoting neuroprotection or neurorepair in a patient suffering from MS is provided, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In some embodiments, the present invention provides a method for treating MS or promoting neuroprotection or neurorecovery in a patient suffering from MS, comprising administering to the patient an effective amount of a compound described herein, or a pharma-ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A3R agonist. In some embodiments, the present invention provides a method for treating MS or promoting neuroprotection or neurorecovery in a patient suffering from MS, comprising administering to the patient an effective amount of a compound described herein, or a pharma-ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at A3 receptor. In some embodiments, the compound acts by dual agonism at A3R and A1R. In some embodiments, the compound acts as an agonist at A1 adenosine receptor (A1R). In some embodiments, the compound is one of the compounds listed in Table 1, or a pharmaceutically acceptable salt thereof or a composition comprising it.

[0275] Amyotrophic lateral sclerosis (ALS) / Lou Gehrig's disease Approximately 5,600 people are diagnosed with ALS each year in the United States, and as many as 30,000 Americans may have the disease at any one time (ALS Association). Activation of astrocytes can provide a stimulus for the recovery and repair of neurons and their connections in ALS patients.

[0276] Thus, in one aspect herein, a method for treating ALS or promoting neuroprotection or neurorestoration in a patient suffering from ALS is provided, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.In yet another embodiment, a method for stimulating the recovery and repair of neurons and their connections in an ALS patient is provided, comprising administering to the patient an effective amount of a compound described herein, or a pharma-ceutically acceptable salt thereof, or a composition comprising the same.In some embodiments, the present invention provides a method for treating ALS or promoting neuroprotection or neurorestoration in a patient suffering from ALS, comprising administering to the patient an effective amount of a compound described herein, or a pharma-ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A3R agonist. In some embodiments, the present invention provides a method for treating ALS or promoting neuroprotection or neurorecovery in a patient suffering from ALS, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at the A3 receptor. In some embodiments, the compound acts by dual agonism at the A3R and A1R. In some embodiments, the compound acts as an agonist of the A1 adenosine receptor (A1R). In some embodiments, the compound is one of the compounds listed in Table 1, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.

[0277] Chronic Traumatic Encephalopathy (CTE) CTE (a form of tauopathy) is a progressive neurodegenerative disease found in individuals who have suffered one or more severe impacts to the head (often multiple times or repeated over time). CTE is most frequently diagnosed in professional athletes from American football, soccer, hockey, professional wrestling, stunt performance, bull riding and rodeo performance, motocross, and other contact sports who have experienced brain trauma and / or repeated concussions. A subset of CTE sufferers has chronic traumatic encephalomyopathy (CTEM), characterized by motor neuron disease symptoms similar to ALS. Progressive muscle weakness and abnormal movement and gait are thought to be early signs of CTEM. Stage 1 symptoms of CTE include progressive attention deficit, disorientation, dizziness, and headaches. Stage 2 symptoms include memory loss, social instability, erratic behavior, and impaired judgment. In stages three and four, patients suffer from progressive dementia, bradykinesia, tremors, mask-like facies, vertigo, speech disorders, hearing loss, and suicidal tendencies, and may further include dysarthria, dysphagia, and eye abnormalities such as ptosis.

[0278] Thus, in one aspect herein, a method is provided for treating or preventing CTE or promoting neuroprotection or neurorestoration in a patient suffering from CTE, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In yet another embodiment, a method is provided for stimulating the recovery and repair of neurons and their connections in a patient suffering from CTE, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In some embodiments, the compound treats one or more symptoms of stage 1, stage 2, stage 3, or stage 4 of CTE. In some embodiments, the present invention provides a method for treating CTE or promoting neuroprotection or neurorestoration in a patient suffering from CTE, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A3R agonist. In some embodiments, the present invention provides a method for treating CTE or promoting neuroprotection or neurorecovery in a patient suffering from CTE, comprising administering to the patient an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same, wherein the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at the A3 receptor. In some embodiments, the compound acts by dual agonism at the A3R and A1R. In some embodiments, the compound acts as an agonist of the A1 adenosine receptor (A1R). In some embodiments, the compound is one of the compounds listed in Table 1, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.

[0279] On a microscopic scale, the pathology includes neuronal cell death, tau deposition, TAR DNA-binding protein 43 (TDP43) beta amyloid deposition, white matter changes, and other abnormalities. Tau deposition includes the increased presence of dense neurofibrillary tangles (NFTs), neurites, and glial tangles, which are composed of astrocytes and other glial cells. Thus, in some embodiments, the method treats, enhances clearance, or prevents neuronal cell death, tau deposition, TAR DNA-binding protein 43 (TDP43) beta amyloid deposition, white matter changes, and other abnormalities associated with CTE.

[0280] In some embodiments, the present invention provides for the chronic administration of a compound disclosed herein, such as a biased agonist, partial agonist or biased partial agonist of A3R, or a dual agonist at A3R and A1R, or a biased agonist, partial agonist or biased partial agonist of P2Y1, for treating a neurodegenerative disease, such as one of the diseases described herein. In some embodiments, the present invention provides for the chronic administration of a compound disclosed herein, such as a biased agonist, partial agonist or biased partial agonist of A1R, for treating a neurodegenerative disease, such as one of the diseases described herein.

[0281] cardiovascular disease The disclosed compounds are also useful in treating various cardiovascular diseases and conditions.In some embodiments, the present invention provides a method for treating heart disease (cardiac disease) or cardiovascular disease, such as cardiac ischemia, myocardial infarction, cardiomyopathy, coronary artery disease, arrhythmia, myocarditis, pericarditis, angina pectoris, hypertensive heart disease, endocarditis, rheumatic heart disease, congenital heart disease, or atherosclerosis, comprising administering an effective amount of the compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.In some embodiments, the disclosed compounds modulate ATP-sensitive potassium channels, for example, via biased agonism, partial agonism, or biased partial agonism at the A3R receptor, or dual agonism at A3R and A1R.In some embodiments, the disclosed compounds modulate ATP-sensitive potassium channels, for example, via biased agonism, partial agonism, or biased partial agonism at the A1R receptor.

[0282] In some embodiments, the cardiac or cardiovascular disease is cardiac ischemia or myocardial infarction.

[0283] In some embodiments, the present invention provides a method of promoting or increasing cardioprotection, cardiac repair, or cardiac regeneration in a patient suffering from a cardiac (heart) or cardiovascular disease or condition, comprising administering to the patient an effective amount of a disclosed compound, such as one of the compounds set forth in Table 1 or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0284] In some embodiments, the cardiac (heart disease) or cardiovascular disease from which the patient is suffering is cardiac ischemia, myocardial infarction, cardiomyopathy, coronary artery disease, arrhythmia, myocarditis, pericarditis, angina pectoris, hypertensive heart disease, endocarditis, rheumatic heart disease, congenital heart disease, or atherosclerosis.

[0285] In some embodiments, the compound acts as an agonist of the A3 adenosine receptor (A3R). In some embodiments, the compound acts as a dual agonist of the A3R and the A1 adenosine receptor (A1R). In some embodiments, the compound acts as an agonist of the A1R.

[0286] Other disorders Compounds that modulate beneficial effects such as neuroprotection, for example by increasing astrocyte mitochondrial activity, also have the potential to treat various other diseases. For example, due to the role of astrocytes in neuroprotection disclosed in the present invention, activation of astrocytes, for example via modulation of A3R and / or A1R, is useful for treating various diseases and conditions discussed below.

[0287] Thus, in some embodiments, the invention provides a method of treating neurodegeneration in a patient suffering from a disease or condition, comprising administering to the patient an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0288] In some embodiments, the invention provides a method of promoting or increasing neuroprotection, neurorepair, or neuroregeneration in a patient suffering from a disease or condition, comprising administering to the patient an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0289] In some embodiments, the disease or condition is selected from autoimmune diseases, allergic diseases, and / or transplant rejection and graft-versus-host disease (for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, for example, WO2007 / 20018, which is incorporated herein by reference). In other embodiments, the disease or condition is selected from ocular hypertension and / or glaucoma (for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, for example, WO2011 / 77435, which is incorporated herein by reference). In other embodiments, the disease or condition is selected from odor hypersensitivity and / or olfactory disorders (for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, for example, EP1624753, which is incorporated herein by reference). In other embodiments, the disease or condition is type 2 diabetes (see, e.g., U.S. Patent Application Publication No. 2010 / 0256086, incorporated herein by reference, for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions).

[0290] In other embodiments, the disease or condition is selected from a respiratory disease and / or a cardiovascular (CV) disease (see, e.g., FASEB J. (2013) 27:1118.4 (Meeting Abstract), incorporated herein by reference, for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions). In other embodiments, the disease or condition is selected from defects in CNS function, learning disabilities and / or cognitive disorders (for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, e.g., Neuropsychopharmacology. 2015 Jan;40(2):305-14. doi: 10.1038 / npp.2014.173. Epub 2014 Jul 15. "Impaired cognition after stimulation of a P2Y1 receptor in the rat medial prefrontal cortex," Koch, H. et al. PMID: 25027332, incorporated herein by reference). In other embodiments, the disease or condition is selected from neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, and / or amyotrophic lateral sclerosis (for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, for example, U.S. Patent No. 8,691,775, which is incorporated herein by reference). In other embodiments, the disease or condition is selected from ear disorders, Meniere's disease, endolymphatic hydrops, progressive hearing loss, dizziness, vertigo, tinnitus, incidental brain damage associated with radiation cancer treatment and / or migraine treatment (for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, for example, U.S. Patent Application Publication No. 2009 / 0306225, UY31779, and U.S. Patent No. 8,399,018, each of which is incorporated herein by reference).In other embodiments, the disease or condition is selected from pathological sleep disturbance, depression, sleep disorders of the elderly, Parkinson's disease, Alzheimer's disease, epilepsy, schizophrenia, and / or symptoms experienced by recovering alcoholics (see, e.g., U.S. Patent Application Publication No. 2014 / 0241990, which is incorporated herein by reference for the use of certain nucleoside and nucleotide compounds in treating these conditions). In other embodiments, the disease or condition is selected from injury to neurons or nerves of the peripheral nervous system during surgery (see, e.g., U.S. Patent No. 8,685,372, which is incorporated herein by reference for the use of certain nucleoside and nucleotide compounds in treating these conditions). In other embodiments, the disease or condition is cancer, e.g., prostate cancer (for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, e.g., Biochem Pharmacol. 2011 August 15; 82(4): 418-425. doi:10.1016 / j.bcp.2011.05.013. "Activation of the P2Y1 Receptor Induces Apoptosis and Inhibits Proliferation of Prostate Cancer Cells," Qiang Wei et al., incorporated herein by reference).In other embodiments, the disease or condition is selected from one or more gastrointestinal conditions, such as constipation and / or diarrhea (for use of certain nucleoside and nucleotide compounds in treating these conditions, see, e.g., Acta Physiol (Oxf). 2014 Dec;212(4):293-305. doi: 10.1111 / apha.12408. "Differential functional role of purinergic and nitrergic inhibitory cotransmitters in human colonic relaxation," Mane N1, Gil V, Martinez-Cutillas M, Clave P, Gallego D, Jimenez M., and Neurogastroenterol. Motil. 2014 Jan;26(1):115-23. doi: 10.1111 / nmo.12240. Epub 2013 Oct 8. "Calcium responses in subserosal interstitial cells of the guinea-pig proximal colon," Tamada H., Hashitani H. PMID: 24329947).

[0291] In other embodiments, the disease or condition is selected from brain cancer, e.g., glioblastoma (for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, e.g., Purinergic Signal. 2015 Sep;11(3):331-46. doi: 10.1007 / s11302-015-9454-7. Epub 2015 May 15. "Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells." D'Alimonte, I. et al. PMID: 25976165, incorporated herein by reference). In other embodiments, the disease or condition is selected from gastrointestinal disorders, e.g., diarrhea (for the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, e.g., Acta Physiol (Oxf). 2014 Dec;212(4):293-305. doi: 10.1111 / apha.12408. "Differential functional role of purinergic and nitrergic inhibitory cotransmitters in human colonic relaxation," Mane N., Gil V, Martinez-Cutillas M, Clave P, Gallego D, Jimenez M., which is incorporated herein by reference).In other embodiments, the disease or condition is a cognitive disorder (for the use of certain nucleoside and nucleotide compounds in the treatment of this condition, see, e.g., Neuropsychopharmacology. 2015 Jan;40(2):305-14. doi: 10.1038 / npp.2014.173. Epub 2014 Jul 15. "Impaired cognition after stimulation of P2Y1 receptors in the rat medial prefrontal cortex," Koch H, Bespalov A, Drescher K, Franke H, Kruegel U. PMID: 25027332, which is incorporated herein by reference).

[0292] In some embodiments, the present invention provides a method for treating diseases or conditions associated with brain injury or neurodegenerative conditions, such as epilepsy, migraine, collateral brain damage associated with radiation cancer treatment, depression, mood or behavior changes, dementia, erratic behavior, suicidality, tremor, Huntington's chorea, loss of motor coordination, hearing loss, speech disorder, dry eye, masked face, attention deficit, memory loss, cognitive difficulties, vertigo, dysarthria, dysphagia, eye abnormalities, or disorientation, comprising administering to a patient in need thereof an effective amount of the disclosed compound. In some embodiments, the compound is an A3R agonist. In some embodiments, the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at the A3 receptor. In some embodiments, the compound acts by dual agonism at A3R and A1R. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at A1 receptor.In some embodiments, the compound is one of the compounds listed in Table 1, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.

[0293] In further embodiments, the present invention provides a method for treating a neurodegenerative disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, and prion disease in a patient in need thereof, comprising administering an effective amount of a compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In some embodiments, the compound is an A3R agonist. In some embodiments, the compound is an A1R agonist. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at the A3 receptor. In some embodiments, the compound acts by dual agonism at the A3R and A1R. In some embodiments, the compound is a biased agonist, partial agonist, or biased partial agonist or antagonist at the A1 receptor. In some embodiments, the compound is one of the compounds listed in Table 1, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same.

[0294] In some embodiments, the improvement in cognitive or neurological function is measured as an increase in score of between about 1% and 20% on the delayed verbal recall task of the Wechsler Memory Scale-Revised. For example, the improvement in cognitive function can be measured as an increase in score of between about 1% and 10%, or between about 1% and 5%, or between about 5% and 15%.

[0295] In some embodiments, the present invention provides a method of treating a brain or central nervous system (CNS) injury or condition selected from traumatic brain injury (TBI) or stroke, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharmacologic acceptable salt thereof, or a composition comprising same.

[0296] In some embodiments, the brain or central nervous system (CNS) injury or condition is a TBI. In some embodiments, the TBI is selected from a concussion, a blast injury, a combat-related injury, or a mild, moderate, or severe blow to the head.

[0297] In some embodiments, the compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising same, is administered within 24 hours of the TBI or stroke.

[0298] In some embodiments, the compound described herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising same, is administered within 8 hours of the TBI or stroke.

[0299] In some embodiments, a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same, is administered during at least the first 8 to 48 hours after TBI or stroke.

[0300] In some embodiments, the brain or central nervous system (CNS) injury or condition is a stroke.

[0301] In some embodiments, the compounds described herein or pharma- ceutically acceptable salts thereof, or compositions comprising same, are administered chronically to treat stroke, for the period after stroke onset until it resolves.

[0302] In some embodiments, neuroprotection or neurorepair in the patient is increased compared to an untreated patient.

[0303] In some embodiments, the compound is a biased partial agonist at human A3 adenosine receptor (A3R). In some embodiments, the compound acts by dual agonism at A3R and A1R. In some embodiments, the compound is a biased partial agonist at human A1 adenosine receptor (A1R).

[0304] In some embodiments, the A3R is partially agonized in a manner biased towards the neuroprotective function of the A3R receptor.

[0305] In some embodiments, the compounds described herein or pharma- ceutically acceptable salts thereof, or compositions comprising same, are administered orally, intravenously, or parenterally.

[0306] In one aspect, the present invention provides a method of increasing neuroprotection or neurorepair in a patient suffering from TBI or stroke, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharmacologic acceptable salt thereof, or a composition comprising same.

[0307] In some embodiments, neuroprotection or neurorepair shortens the recovery period following TBI or stroke compared to untreated patients.

[0308] In some embodiments, the compound is a biased partial agonist at human A3 adenosine receptor (A3R), and A3R is partially agonized in a manner biased toward the neuroprotective function of A3R receptor. In some embodiments, the compound acts by dual agonism at A3R and A1R. In some embodiments, the compound is a biased partial agonist at human A1 adenosine receptor (A1R), and A1R is partially agonized in a manner biased toward the neuroprotective function of A1R receptor. In some embodiments, the compound acts as an agonist at A1R.

[0309] In some embodiments, the compounds described herein or pharma- ceutically acceptable salts thereof, or compositions comprising same, are administered orally, intravenously, or parenterally.

[0310] In one aspect, the present invention provides a method of treating an injury, disease, or condition selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, or a cardiac or cardiovascular disease, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharmacologic acceptable salt thereof, or a composition comprising same.

[0311] In some embodiments, the injury, disease, or condition is a TBI. In some embodiments, the TBI is selected from a concussion, a blast injury, a combat-related injury, or a mild, moderate, or severe blow to the head.

[0312] In some embodiments, the injury, disease, or condition is a stroke selected from ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, or transient ischemic attack (TIA).

[0313] In some embodiments, the neurodegenerative disease is selected from Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), or a neurodegenerative condition caused by a virus, alcoholism, tumor, toxin, or repetitive brain injury.

[0314] In some embodiments, the injury, disease, or condition is Parkinson's disease.

[0315] In some embodiments, the injury, disease, or condition is Alzheimer's disease, migraine headaches, brain surgery, or neurological side effects associated with cancer chemotherapy.

[0316] In some embodiments, the cardiac or cardiovascular disease is selected from cardiac ischemia, myocardial infarction, cardiomyopathy, coronary artery disease, arrhythmias, myocarditis, pericarditis, angina, hypertensive heart disease, endocarditis, rheumatic heart disease, congenital heart disease, or atherosclerosis.

[0317] In some embodiments, the cardiac or cardiovascular disease is cardiac ischemia or myocardial infarction.

[0318] In some embodiments, the compounds described herein or pharma- ceutically acceptable salts thereof, or compositions comprising same, are administered chronically to treat stroke, cardiac ischemia, or myocardial infarction for the period after injury has occurred until it has resolved.

[0319] In some embodiments, neuroprotection or neurorepair in the patient is increased compared to an untreated patient.

[0320] In some embodiments, the A3R is agonized in a manner biased towards the neuroprotective function of the A3R receptor by preferentially activating intracellular calcium mobilization with little or no activation of other A3R-mediated pathways, or by preferentially activating Gq11-mediated intracellular calcium mobilization, Gi-mediated modulation of cAMP production, or Gi-mediated phosphorylation of ERK1 / 2 and Akt.

[0321] In some embodiments, the A3R is partially agonized in a manner biased toward the cardioprotective function of the A3R receptor by preferentially activating intracellular calcium mobilization with little or no activation of other A3R-mediated pathways, or by preferentially activating Gq11-mediated intracellular calcium mobilization, Gi-mediated modulation of cAMP production, or Gi-mediated phosphorylation of ERK1 / 2 and Akt.

[0322] In some embodiments, the methods increase neuroprotection or neurorepair in patients suffering from neurological side effects associated with or resulting from cancer chemotherapy or brain surgery.

[0323] In some embodiments, the compounds described herein or pharma- ceutically acceptable salts thereof, or compositions comprising same, are administered orally.

[0324] In one aspect, the present invention provides a method of increasing neuroprotection or neurorepair in a patient suffering from TBI or stroke, thereby treating TBI or stroke, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharmacologic acceptable salt thereof, or a composition comprising same.

[0325] In one aspect, the present invention provides a method of increasing cardioprotection or regeneration of damaged cardiac tissue in a patient suffering from cardiac ischemia or myocardial infarction, thereby treating cardiac ischemia or myocardial infarction, comprising administering to a patient in need thereof an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0326] In some embodiments, the recovery time following TBI, stroke, cardiac ischemia, or myocardial infarction is shortened compared to untreated patients.

[0327] In some embodiments, the A3R is partially agonized in a manner biased towards the neuroprotective function of the A3R receptor.

[0328] In some embodiments, the A3R is partially agonized in a manner biased towards the cardioprotective function of the A3R receptor.

[0329] In some embodiments, the compounds described herein or pharma- ceutically acceptable salts thereof, or compositions comprising same, are administered orally.

[0330] In some embodiments, the compounds are biased agonists of the A3R, with improved cardioprotective function compared to full A3R agonists.

[0331] In some embodiments, the compounds are biased agonists of A3R that have improved cardioprotective function compared to full A3R agonists by preferentially activating one or more of the following A3R-mediated pathways: activation of Gq11-mediated intracellular calcium mobilization, Gi-mediated modulation of cAMP production, Gi-mediated phosphorylation of ERK1 / 2 and Akt, or modulation of beta-arrestin activation.

[0332] In some embodiments, the compounds are biased agonists of the A3R, which have improved cardioprotective properties compared to full A3R agonists by preferentially activating intracellular calcium mobilization with little or no activation of other A3R-mediated pathways.

[0333] In some embodiments, the compounds are partial agonists of the A3R, with improved cardioprotective function compared to full A3R agonists.

[0334] Addictive Disorders The disclosed compounds are also useful for treating addiction, addictive behavior, behavioral addiction, obsessive-compulsive disorders and behaviors, and related conditions.

[0335] The use of certain compounds in the treatment of such addictions, behaviors, and disorders is described in WO / 2019 / 157317, the contents of which are incorporated herein by reference.

[0336] Cocaine self-administering mice show significantly higher glutamate levels in the VTA (ventral tegmental area) of the brain. The VTA, particularly VTA dopamine neurons, play several functions in reward systems, motivation, cognition, and drug addiction, and may be the focus of several psychiatric disorders. The elevated glutamate levels are believed to be due, at least in part, to a loss of glutamate uptake into astrocytes. Without wishing to be bound by theory, it is believed that reduced glutamate availability has a negative effect on astrocyte function, and this loss of function affects neuronal activity and drug-seeking behavior. Now, compounds disclosed herein have been found to treat or prevent relapse in addicted individuals, for example, by reversing such loss of astrocyte function. Such loss of astrocyte function may be due, in part, to a decrease in the expression of glutamate transporter (GLT-1) in astrocytes. Because astrocytes metabolize glutamate to generate ATP, this likely impairs glutamate uptake and weakens astrocyte oxidative metabolism and downstream ATP-dependent processes, thereby compromising their ability to maintain an optimal environment for VTA neuronal activity.

[0337] Thus, in one aspect, the present invention provides a method for preventing, ameliorating, treating, or promoting recovery from addiction, addictive behavior, behavioral addiction, brain reward system disorder, obsessive-compulsive disorder, or related conditions, comprising administering to a subject in need thereof an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0338] In some embodiments, the addiction is to an addictive substance, hi some embodiments, the addictive substance is a prescription drug or a recreational drug.

[0339] In some embodiments, the addictive substance is selected from alcohol, nicotine, stimulants, cannabinoid agonists, or opioid agonists. In some embodiments, the addictive substance is selected from heroin, cocaine, alcohol, inhalants, opioids, nicotine, amphetamines, or synthetic analogs, salts, compositions, or combinations thereof.

[0340] In some embodiments, the amphetamine is selected from bupropion, cathinone, MDMA, or methamphetamine.

[0341] In some embodiments, the prescription or recreational drug is selected from a cannabinoid agonist or an opioid agonist.

[0342] In some embodiments, the addiction is an alcohol or nicotine addiction.

[0343] In some embodiments, the subject is a polydrug abuser.

[0344] In some embodiments, the prescription or recreational drug is selected from cocaine, heroin, bupropion, cathinone, MDMA, or methamphetamine morphine, oxycodone, hydromorphone, fentanyl, or combinations thereof.

[0345] In some embodiments, the disclosed compounds increase the energy metabolism mediated by astrocytes, e.g., astrocyte mitochondria. In some embodiments, the compounds reverse the loss of glutamate uptake into astrocytes caused by substances with potential for abuse. In some embodiments, the compounds at least partially reverse the reorganization of the brain reward system caused by addiction. In some embodiments, such effects are mediated by adenosine A3 receptors in the brain or CNS, e.g., astrocyte A3R in the VTA, or microglial A3R.

[0346] In another aspect, the present invention provides a method for preventing, ameliorating, treating, or promoting recovery from addiction, addictive behavior, behavioral addiction, brain reward system disorder, obsessive-compulsive disorder, or related conditions by increasing energy metabolism mediated by astrocytes, glia, microglia, neurons, endothelial cells, or other cells of the brain and / or CNS, comprising administering to a subject in need thereof an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0347] In some embodiments, the method treats or prevents the relapse of addiction or addictive behavior in a subject.In some embodiments, the subject is addicted to one or more addictive substances, such as addictive drugs (drugs that have potential for abuse).As described below, such drugs include prescription drugs and recreational drugs, such as heroin, cocaine, nicotine, or opioid agonists.

[0348] In another aspect, the present invention provides a method for treating or preventing withdrawal caused by addiction to one or more addictive substances or drugs, comprising administering to a subject in need thereof an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising the same. In some embodiments, the compound reduces withdrawal symptoms in an addicted individual in withdrawal. In some embodiments, the compound treats withdrawal in an addicted individual in withdrawal. In some embodiments, the method further comprises co-administering another drug for treating withdrawal, and providing counseling, e.g., psychotherapy, as necessary. In some embodiments, the method further comprises cognitive behavioral therapy. In some embodiments, the method further comprises digital therapy. Digital therapy includes, for example, reSET or reSET-O (Pear Therapeutics).

[0349] In some embodiments, the present invention provides a method of treating or preventing relapse of obsessive-compulsive disorder or compulsive behavior, comprising administering to a subject in need thereof an effective amount of a compound described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0350] In some embodiments, the obsessive-compulsive disorder is obsessive-compulsive disorder (OCD), Tourette's syndrome, trichotillomania, anorexia, bulimia, anxiety disorder, psychosis, or post-traumatic stress disorder.

[0351] According to another aspect, the present invention provides a method for treating one or more behavioral addictions and addictive behaviors or disorders, comprising administering to a subject in need thereof the compound described herein or its pharma- ceutically acceptable salt, or a composition comprising the same.Behavioral addictions and addictive disorders result from the addiction felt by brain chemicals (e.g., serotonin, adrenaline, epinephrine, etc.) released during certain activities.Such disorders are known in the art, and include gambling, sex addiction, pornography addiction, eating disorders, shopping addiction, rage / anger, workaholism, exercise addiction, risk-taking addiction (e.g., kleptomania and pyromania), perfectionism, internet or gaming addiction, and compulsive use of electronic devices, such as emailing and checking social media, to name a few.

[0352] In some embodiments, activation of astrocytes is achieved by contacting the disclosed compounds with one or more purinergic receptors, e.g., adenosine receptors (ARs), e.g., receptors associated with or expressed by astrocytes or microglia, thereby modulating the activity of the one or more receptors. In some embodiments, the compounds bind to adenosine receptors on astrocytes, e.g., A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A30, A31, A32, A33, A34, A35, A36, A37, A38, A39, A40, A41, A42, A43, A44, A45, A46, A47, A48, A49, A50, A51, A52, A53, A54, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A71, A72, A73, A74, A75, A75, A76, A77, A78, A79, A79, A81, A82, A93, A94, A95, A96, A97, A98, A99, A100, A99, A1100, A120, A130, A140, A150, A160, A171, A181, A199, A1100, 2A , A 2Band activate astrocytes by their effects on A3 to treat one or more of the disclosed diseases or conditions. In some embodiments, the disclosed compounds, after being administered to a subject in need thereof, affect one or more functions, for example, glutamate uptake, which has an effect on astrocyte energy metabolism or neuronal function, thus treating one or more of the disclosed diseases or conditions. In some embodiments, the compounds are AR agonists. In some embodiments, the purinergic receptor is adenosine A3 receptor (A3R). In some embodiments, the compounds are A3R agonists. In some embodiments, the compounds are partial agonists or biased agonists or biased partial agonists at A3 receptors (A3R), for example human A3 receptors (hA3R). In some embodiments, the compounds are biased antagonists at A3 receptors. In some embodiments, the compounds act by dual agonism at A3R and A1R. In some embodiments, the compounds are A1R agonists. In some embodiments, the compound is one of the compounds set forth in Table 1 or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

[0353] As used herein, the term "addiction" includes physical or psychological dependence on a substance, unless otherwise specified.Addiction may involve withdrawal symptoms, or mental or physical pain, when the substance is discontinued.Addiction includes drug preference, drug dependence, habit formation, neurological and / or synaptic changes, development of brain reward system disorders, behavioral changes, or other signs or symptoms of addiction in a subject.

[0354] As used herein, the term "addictive drug" or "drug with potential for abuse" includes drugs and other substances, such as nicotine, that are known to cause clinical, behavioral, or neurological manifestations of addiction or compulsive behavior, regardless of whether they have been approved by a regulatory agency for the treatment of a disease. In some embodiments, addictive drugs include nicotine, cannabinoid agonists, stimulants, or opioid agonists. "Addictive substances" refers to addictive drugs and other abused substances, such as alcohol. Thus, examples of addictive substances include heroin, cocaine, alcohol, opiates, nicotine, inhalants, amphetamines, and their synthetic analogs.

[0355] Pain Conditions and Disorders The disclosed compounds are also useful for treating pain, pain disorders, and related conditions.Thus, in one aspect, the present invention provides a method for treating, preventing, promoting recovery from, or improving a pain condition or disorder, comprising administering to a subject in need thereof an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.In some embodiments, the compound is one of the compounds described in Table 1, or a pharmaceutically acceptable salt thereof.

[0356] In some embodiments, the pain condition or disorder is pain control (pain management, e.g., chronic pain management).For the use of certain nucleoside and nucleotide compounds in the treatment of this and related conditions, see, for example, U.S. Patent Application Publication No. 2010 / 0256086, which is incorporated herein by reference.

[0357] In other embodiments, the pain condition or disorder is selected from CNS-mediated pain, such as neuropathic pain, inflammatory pain, or acute pain. For the use of certain nucleoside and nucleotide compounds in the treatment of these conditions, see, for example, Br J Pharmacol. 2010 Mar;159(5):1106-17. doi: 10.1111 / j.1476-5381.2009.00596.x. Epub 2010 Feb 5. "A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain." Ando RD1, Mehesz B, Gyires K, Illes P, Sperlagh B. PMID: 20136836, which is incorporated herein by reference.

[0358] In some embodiments, the painful condition or disorder is a migraine headache.

[0359] In some embodiments, the pain condition or disorder is neuropathic pain, inflammatory pain, or acute pain.See, for example, Tosh, DK; Padia, J.; Salvemini, D.; Jacobson, KA Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3adenosine receptor agonist that protects against chronic neuropathic pain. Purinergic Signalling 2015, 11, 371-387.

[0360] In some embodiments, the pain condition or disorder is a central pain syndrome, peripheral neuropathy, corneal neuropathic pain, post-stroke pain, or pain caused by multiple sclerosis.

[0361] In another aspect, the present invention provides a method for treating pain, comprising administering to a subject in need thereof an effective amount of a disclosed compound, e.g., I-1, or a pharma- ceutically acceptable salt thereof, or a pharma-ceutically acceptable composition thereof.

[0362] In some embodiments, the pain is neuropathic pain. In some embodiments, the pain is inflammatory pain. In some embodiments, the pain is acute pain. In some embodiments, the pain is chronic pain. In some embodiments, the pain is nociceptive pain. In some embodiments, the pain is non-inflammatory musculoskeletal pain, fibromyalgia syndrome (FMS), or myofascial pain syndrome (MPS).

[0363] In some embodiments, the pain is selected from musculoskeletal pain, fibromyalgia, myofascial pain, pain during menstruation, pain during osteoarthritis, pain during rheumatoid arthritis, pain during gastrointestinal inflammation, pain during myocardial inflammation, pain during multiple sclerosis, pain during neuritis, pain during AIDS, pain during chemotherapy, tumor pain, headache, chronic pain syndrome (CPS), central pain, trigeminal neuralgia, shingles, stamp pain, phantom pain, temporomandibular joint disorders, nerve injury, migraine, postherpetic neuralgia, neuropathic pain encountered as a result of injury, amputation infection, metabolic or degenerative disorders of the nervous system, neuropathic pain associated with diabetes, pseudoesthesia, hypothyroidism, uremia, vitamin deficiency or alcoholism, acute pain following injury, postoperative pain, pain during acute gout, and pain from surgery.

[0364] In some embodiments, the musculoskeletal pain is neck and shoulder pain and / or spasms, back pain, sciatica, chest pain, or thigh muscle pain.

[0365] In some embodiments, the pain is or is associated with otitis externa (OE), otitis media (OM), mastoiditis, bullous myringitis, eustachian tube catarrh, labyrinthitis, facial neuritis, temporal bone osteoradionecrosis, disembarkation disease, temporal bone fracture, or temporomandibular joint disease.

[0366] Pharmaceutically acceptable compositions According to another embodiment, the present invention provides a composition comprising the disclosed compound and a pharma- ceutically acceptable carrier, adjuvant or vehicle.In certain embodiments, the composition of the present invention is formulated for administration to a patient in need of such composition.In some embodiments, the composition of the present invention is formulated for oral administration to a patient.

[0367] The term "biological sample" as used herein includes, but is not limited to, cell cultures or extracts thereof; biopsies or extracts thereof obtained from mammals; and blood, saliva, urine, feces, semen, tears, CSF, or other bodily fluids, or extracts thereof.

[0368] The term "subject" or "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.

[0369] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound that is formulated together.The pharmaceutically acceptable carrier, adjuvant, or vehicle that can be used in the composition of the present invention includes, but is not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylate, wax, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.

[0370] "Pharmaceutically acceptable derivative" means any non-toxic salt, ester, salt of an ester, or other derivative of a compound of the invention which, upon administration to a recipient, is capable of providing, directly or indirectly, a compound of the invention, or an inhibitory active metabolite or residue thereof.

[0371] The compounds and compositions according to the method of the present invention are administered using any amount and any route of administration effective for treating or reducing the severity of the disorders provided above. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the specific drug, its mode of administration, and the like. The compounds of the present invention are preferably formulated into unit dosage forms for ease of administration and uniformity of dosage. The expression "unit dosage form" as used herein refers to a physically separate pharmaceutical unit suitable for the patient to be treated. However, it will be understood that the total daily usage of the compounds and compositions of the present invention will be determined by the attending physician within the scope of sound medical judgment. The specific effective dosage level for any particular patient or organism will vary depending on a variety of factors, including the disorder and severity of the disorder to be treated; the activity of the specific compound used; the specific composition used; the age, weight, general health, sex, and diet of the patient; the time of administration, route of administration, and excretion rate of the specific compound used; duration of treatment; drugs used in combination or simultaneously with the specific compound used, and similar factors well known in the medical field.

[0372] The pharma- ceutically acceptable compositions of the present invention can be administered to humans and other animals orally, rectally, parenterally, intravesically, intravaginally, intraperitoneally, topically (as powders, ointments, or drops), bucally, as oral or nasal sprays, etc., depending on the severity of the infection being treated. In certain embodiments, the compounds of the present invention are administered orally or parenterally at a dosage level of about 0.01 mg to about 50 mg, preferably about 0.01 mg to about 25 mg, per kg of subject body weight per day, one or more times per day to obtain the desired therapeutic effect. In certain embodiments, the compounds of the present invention are administered orally or parenterally at a dosage level of about 0.01 mg to about 50 mg, or about 0.01 mg to about 25 mg, or about 0.05 mg to about 10 mg, or about 0.05 mg to about 5 mg, or about 0.1 mg to about 2.5 mg, per kg of subject body weight per day, one or more times per day to obtain the desired therapeutic effect.

[0373] Liquid dosage forms for oral administration include, but are not limited to, pharma- ceutically acceptable emulsions, liposomes, microemulsions, solutions, suspensions, syrups and elixirs.In addition to the active compounds, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing and emulsifying agents, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.In addition to inert diluents, oral compositions may also contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents and aromatics.

[0374] Injectable preparations, for example, injectable sterile aqueous or oily suspensions, can be formulated using suitable dispersing or wetting agents and suspending agents according to known techniques. Injectable sterile preparations can also be injectable sterile solutions, suspensions or emulsions in non-toxic parenterally acceptable diluents or solvents, for example, as a solution in 1,3-butanediol. Acceptable vehicles and solvents that can be used include water, Ringer's solution, USP and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any non-irritating fixed oil can be used, including synthetic mono- or diglycerides. In addition, fatty acids, such as oleic acid, are used in the preparation of injectables.

[0375] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[0376] In order to prolong the effect of the compounds of the present invention, it is often desirable to delay the absorption of the compound from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends on its rate of dissolution, which in turn may depend on the size and crystalline form of the crystals. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers, such as polylactide-polyglycolide. Depending on the ratio of the compound to the polymer and the nature of the particular polymer used, the release rate of the compound can be controlled. Examples of other biodegradable polymers include poly(orthoesters), poly(anhydrides), and cyclodextrins and modified cyclodextrins (e.g., SBE-bCD). Injectable depot formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[0377] Compositions for rectal or vaginal administration are preferably suppositories, which can be prepared by mixing the compounds of the invention with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol or a suppository wax, which is solid at ambient temperature but liquid at body temperature and therefore will melt in the rectum or vaginal cavity and release the active compound.

[0378] The solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.In such solid dosage forms, the active compound is mixed with at least one inert pharma- ceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate, and / or a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders, such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants, such as glycerol, d) disintegrants, such as agar, calcium carbonate, and / or glycerol. In the case of capsules, tablets and pills, the dosage form may also contain buffering agents.

[0379] Solid compositions of a similar type can also be used as fillers for soft and hard filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols. Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They can optionally contain opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type can also be used as fillers for soft and hard filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.

[0380] The active compound may be in microencapsulated form with one or more excipients as described above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings, release-controlling coatings, and other coatings well known in the pharmaceutical formulation art. In such solid dosage forms, the active compound may be mixed with at least one inert diluent, such as sucrose, lactose, or starch. Such dosage forms can also contain additional substances other than inert diluents, as is customary, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms can also contain buffering agents. They can optionally contain opacifying agents, and can be of a composition that they release the active ingredient(s) only or preferentially in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0381] Dosage forms for topical or transdermal administration of the compounds of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active components are mixed under sterile conditions with a pharma- ceutically acceptable carrier and any necessary preservatives or buffers, if required. Ophthalmic formulations, ear drops, and eye drops are also contemplated within the scope of the present invention. In addition, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. This rate can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.

[0382] The compounds of the present invention can also be administered topically, for example, directly to the eye, for example, as eye drops or eye ointments. Eye drops typically contain an effective amount of at least one compound of the present invention and a carrier that can be safely applied to the eye. For example, eye drops are in the form of an isotonic solution, and the pH of the solution is adjusted so as not to cause irritation to the eye. In many cases, the epithelial barrier prevents molecules from penetrating the eye. Therefore, most currently used ophthalmic drugs are supplemented with some form of penetration enhancer. These penetration enhancers act by loosening the tight junctions of the top epithelial cells (Burstein, 1985, Trans Ophthalmol Soc UK 104(Pt 4): 402-9; Ashton et al., 1991, J Pharmacol Exp Ther 259(2): 719-24; Green et al., 1971, Am J Ophthalmol 72(5): 897-905). The most commonly used penetration enhancer is benzalkonium chloride (Tang et al., 1994, J Pharm Sci 83(1): 85-90; Burstein et al, 1980, Invest Ophthalmol Vis Sci 19(3): 308-13), which also acts as a preservative against microbial contamination. It is typically added to a final concentration of 0.01-0.05%.

[0383] Combination with other therapeutic agents Depending on the specific condition to be treated, additional therapeutic agents that are usually administered to treat that condition can also be present in the composition of the present invention.As used herein, additional therapeutic agents that are usually administered to treat a specific disease or condition are known as "suitable for the disease or condition being treated".In addition, standard therapies, including surgery or the use of medical devices, can be advantageously added to the treatment methods described herein.

[0384] In certain embodiments, a provided compound or composition thereof is administered to a patient in need thereof in combination with other therapeutic agents, such as tissue plasminogen activator, blood thinners, statins, ACE inhibitors, angiotensin II receptor blockers (ARBs), beta blockers, calcium channel blockers or diuretics.

[0385] In certain embodiments, tissue plasminogen activators used in combination with compounds or compositions of the invention include, but are not limited to, alteplase, desmoteplase, reteplase, tenecteplase, or any combination of the above.

[0386] In certain embodiments, for the treatment of stroke and related conditions, recanalization procedures such as thrombolysis with recombinant tissue plasminogen activator (r-tPA) or mechanical thrombectomy are used in combination with the disclosed methods of treating stroke or related conditions.

[0387] In certain embodiments, anticoagulants used in combination with the compounds or compositions of the invention include, but are not limited to, warfarin, heparin, apixabam, clopidogrel, aspirin, rivaroxaban, dabigatran, or any combination of the above.

[0388] In certain embodiments, statins used in combination with the compounds or compositions of the invention include, but are not limited to, atorvastatin, rosuvastatin, fluvastatin, lovastatin, pravastatin, simvastatin, and pitavastatin, cerivastatin, mevastatin, or any combination of the above.

[0389] In certain embodiments, ACE inhibitors used in combination with the compounds or compositions of the invention include, but are not limited to, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril benazepril, or any combination of the above.

[0390] In certain embodiments, angiotensin II receptor blockers (ARBs) used in combination with the compounds or compositions of the invention include, but are not limited to, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, fimasartan, or any combination of the above.

[0391] In certain embodiments, beta blockers used in combination with the compounds or compositions of the invention include, but are not limited to, atenolol, bisoprolol, betaxolol, carteolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, oxprenolol, penbutolol, pindolol, propranolol, timolol, or any combination of the above.

[0392] In certain embodiments, calcium channel blockers used in combination with the compounds or compositions of the present invention include, but are not limited to, dihydropyridines, amlodipine, cilnidipine, clevidipine, felodipine, isradipine, lercanidipine, levamlodipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, diltiazem, verapamil, or any combination of the above.

[0393] In certain embodiments, diuretics used in combination with the compounds or compositions of the present invention include, but are not limited to, loop diuretics, thiazide diuretics, thiazide-like diuretics and potassium-sparing diuretics, or any combination of the above.

[0394] In certain embodiments, loop diuretics used in combination with the compounds or compositions of the invention include, but are not limited to, bumetanide, ethacrynic acid, furosemide, torsemide, or any combination of the above.

[0395] In certain embodiments, thiazide diuretics used in combination with the compounds or compositions of the invention include, but are not limited to, epithizide, hydrochlorothiazide and chlorothiazide, bendroflumethiazide, methyclothiazide, polythiazide, or any combination of the above.

[0396] In certain embodiments, thiazide-like diuretics used in combination with the compounds or compositions of the present invention include, but are not limited to, indapamide, chlorthalidone, metolazone, or any combination of the above.

[0397] In certain embodiments, potassium-sparing diuretics used in combination with the compounds or compositions of the invention include, but are not limited to, amiloride, triamterene, spironolactone, eplerenone, or any combination of the above.

[0398] In certain embodiments, provided compound or its composition is administered to the patient in need thereof in combination with mechanical thrombus removal device.In certain embodiments, mechanical thrombus removal device is stroke thrombus removal device or cerebral aneurysm coil embolization device.In certain embodiments, such device includes but is not limited to coil retriever, suction device, or stent retriever.

[0399] In certain embodiments, combinations of two or more therapeutic agents may be administered together with a compound or composition of the invention. In certain embodiments, combinations of three or more therapeutic agents may be administered together with a compound or composition of the invention.

[0400] These additional drugs can be administered separately from the composition containing the compound of the present invention as part of a multiple dose regimen.Alternatively, these drugs can be part of a single dosage form, mixed together with the compound of the present invention in a single composition.When administered as part of a multiple dose regimen, the two active agents can be delivered simultaneously, sequentially, or within a certain period of each other, usually within 5 hours of each other.

[0401] As used herein, the terms "combination", "combined" and related terms refer to simultaneous or sequential administration of a therapeutic agent according to the present invention.For example, a compound of the present invention can be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms, or together in a single unit dosage form.Thus, the present invention provides a single unit dosage form that includes a compound of the present invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0402] The amounts of both the provided compound and additional therapeutic agent (in compositions containing additional therapeutic agents described above) that can be combined with the carrier materials to produce a single dosage form will vary depending on the host treated and the particular mode of administration. Preferably, the compositions of the present invention should be formulated so that a dosage of between 0.01-100 mg of the compound of the present invention per kg of body weight per day can be administered.

[0403] In those compositions that include an additional therapeutic agent, the additional therapeutic agent and the compound of the present invention may act synergistically. Thus, the amount of the additional therapeutic agent in such compositions is less than that required in a monotherapy that utilizes only that therapeutic agent. In such compositions, the additional therapeutic agent may be administered at a dosage between about 0.001-100 mg per kg of body weight per day, or about 0.001 mg to about 500 μg, or about 0.005 mg to about 250 μg, or about 0.01 mg to about 100 μg of the additional therapeutic agent per kg of body weight per day.

[0404] The amount of additional therapeutic agent present in the compositions of the invention will not exceed the amount that would normally be administered in a composition containing that therapeutic agent as the only active agent. Preferably, the amount of additional therapeutic agent in the compositions of the present disclosure will be in the range of about 50% to 100% of the amount that would normally be present in a composition containing that agent as the only therapeutically active agent.

[0405] In one embodiment, the present invention provides a composition comprising a compound of the present invention and one or more additional therapeutic agents. The therapeutic agent can be administered together with the compound of the present invention, or before or after the compound of the present invention. Suitable therapeutic agents are described in further detail below. In certain embodiments, the compound of the present invention can be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours before the therapeutic agent. In other embodiments, the compound of the present invention can be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours after the therapeutic agent.

[0406] In some embodiments, the present invention provides a medicament comprising at least one compound of the invention, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

[0407] All features of each of the aspects of the invention apply mutatis mutandis to all other aspects.

[0408] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only, and are not to be construed as limiting this invention in any manner. EXAMPLES

[0409] As shown in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures: While the general methods are directed to the synthesis of certain compounds of the invention, it will be understood that the following general methods, as well as other methods known to those of skill in the art, are applicable to all compounds as described herein, and each subclass and species of these compounds. Example 1 Adenosine A1R / A3R agonist I-1 (AST-004) reduces cerebral infarction in a non-human primate model of stroke Nonstandard Abbreviations and Acronyms A1R, adenosine A1 receptor A2aR, adenosine A2a receptor A2bR, adenosine A2b receptor A3R, adenosine A3 receptor ADC, apparent diffusion coefficient AIS, acute ischemic stroke AR, adenosine agonist ASL, arterial spin labeling CBF, cerebral blood flow COMP, group treated with the composite of all drugs CSF, cerebrospinal fluid Cmax, maximum concentration DWI, diffusion weighted imaging Emax, maximum effect FLAIR, fluid-attenuated inversion-recovery HE, hemotoxylin-eosin staining HERMES, Highly Effective Reperfusion Using Multiple Endovascular Devices MABP, mean arterial blood pressure MRI, magnetic resonance imaging MCA, middle cerebral artery MCAO, middle cerebral artery occlusion MRA, magnetic resonance angiography NDS, neurological deficit score NHP, non-human primate PEG, polyethylene glycol PI, prediction interval PK / PD, Pharmacokinetics / Pharmacodynamics r-tPA, recombinant tissue plasminogen activator RO, receptor occupancy SEM, standard error of the mean SMTP-7, Stachybotrys microspora triprenylphenol-7 STAIR, Stroke Management Academic-Industry Roundtable tMCAO, transient middle cerebral artery occlusion

[0410] introduction Current acute ischemic stroke (AIS) treatments are limited to recanalization by thrombolysis or thrombectomy (Ref. 1). These treatments focus on restoring blood flow and oxygenation of hypoperfused tissues. However, thrombolytic agents are only given to fewer than 5% of AIS patients within a limited time window after occlusion, whereas thrombectomy requires access to the site of occlusion and is currently available in fewer than 20% of AIS patients (Ref. 2).

[0411] There is a major unmet need for pharmacological therapies that are both neuroprotective and administrable for the majority of AIS patients with recanalization (Ref. 3). The vast majority of previous preclinical neuroprotection programs focused on efficacy evaluation in rodent models, with limited insight into drug distribution, target engagement, and pharmacological response, and likely resulting in neutral or negative findings during clinical trials (Ref. 4). For these reasons, the International Stroke Treatment Academic-Industry Discussion Group (STAIR) has issued detailed guidelines for preclinical testing of potential AIS therapies, including evaluation of efficacy in both lissencephalic and gyrencephalic species (Ref. 5). To date, we are aware of only two drugs that meet the STAIR guidelines and have been evaluated in both rodent and nonhuman primate (NHP) stroke models prior to the initiation of clinical trials: the postsynaptic density protein-95 inhibitor nerinetide and the plasminogen modulator SMTP-7 (Refs. 6-9).

[0412] In this study, we followed STAIR recommendations to evaluate the effects of a combined adenosine A1R / A3R receptor agonist, I-1, in a cynomolgus monkey model of transient middle cerebral artery occlusion (tMCAO) (refs. 10-12). In rodent stroke models, activation of central adenosine A1R or A3R results in robust brain protection defined by smaller brain lesion volumes compared to vehicle treatment (refs. 13-20). However, previous rodent studies have utilized treatment before the onset of occlusion, which raises concerns regarding the translatability of findings to clinical settings (ref. 13).

[0413] The study was designed to closely follow the average timeline for clinical study interventions in human AIS patients described in HERMES (ref. 21). Significant efficacy in terms of inhibition of lesion growth rate and reduction in overall lesion size was observed, but no adverse effects on core physiological parameters were evident. Furthermore, clear relationships were observed between observed efficacy and I-1 (AST-004) cerebrospinal fluid and plasma drug concentrations and estimated brain A1R / A3R receptor occupancy.

[0414] animal A total of 25 adult male Macaca fascicularis macaques, ranging in age from 47 to 83 months and weighing from 2.7 to 5.4 kg, were used in this study.

[0415] The study was conducted in a completely randomized (despite replacement subjects, see below) and blinded fashion. Subjects were randomized prior to treatment introduction. Allocation concealment was maintained throughout the study as separate blinded investigators were utilized for MCAO surgery, treatment introduction, and subsequent imaging and efficacy endpoint analysis. This was the first efficacy study of its type utilizing this primate model of transient MCAO with extensive imaging endpoints. Thus, we could not anticipate the size of potential treatment outcomes that would be necessary for a priori power and sample size calculations. The data generated in this exploratory study will allow us to perform power and size calculations for future efficacy studies.

[0416] Animal Quarantine and Stabilization Prior to arrival at the animal facility, the macaques were tested and were negative for Salmonella spp., Shigella spp., Yersinia spp., M. tuberculosis and Cercopithecium herpesvirus 1 (B virus). Individual health certification was obtained for each macaque from the distributor (EBS, Inc., Hashimoto, Japan). Upon arrival, the macaques used in this study were quarantined and observed for 14 days. Veterinarians and animal care staff performed daily cursory visual checks of each macaque assessing body condition, overall behavior, appetite, and excretion. Any physical, behavior, appetite or excretory abnormalities should be recorded in each macaque's individual health record and may result in exclusion. No such abnormalities were observed in the macaques used in this study during the quarantine period or during housing within the general colony. An exclusion criterion was abnormal cerebral anatomy (based on T2-weighted images), but subjects were not required to be excluded on this criterion.

[0417] anesthesia Macaques were initially sedated with ketamine HCl (10 mg / kg, im) and treated with atropine sulfate (0.05 mg / kg, im). Macaques were intubated, immobilized with vecuronium bromide at 0.04–0.16 mg / kg (iv) and artificially ventilated. During the surgical procedure, animals were maintained on 0.8% isoflurane in a 7:3 mixture of NO and O. Prior to transient middle cerebral artery occlusion (tMCAO), the concentration of isoflurane was reduced to 0.5–0.6% and continued until 4 h postischemia. End-tidal CO, body temperature, heart rate and blood pressure were monitored during surgery. During magnetic resonance imaging (MRI), macaques were anesthetized with 0.5–0.6% isoflurane. Sugammadex (8 mg / kg, iv) was administered to reverse the effects of vecuronium. Postoperative antibiotics (enrofloxacin 5 mg / kg im twice daily for up to 4 days after surgery), analgesics (buprenorphine 0.01 mg / kg im twice daily for up to 4 days after surgery) and prednisolone (1 mg / kg im once after surgery then bidaily for the following 4 days) were administered and animals were observed during recovery from anesthesia. Animals showing signs of severe pain or distress at any time as determined by the attending veterinarian and his staff were scheduled to be euthanized, although this was not required.

[0418] Middle cerebral artery occlusion and reperfusion Under deep anesthesia, the right eyeball was removed and the orbital contents were dissected and removed using a surgical microscope (KOM300, Konan Medical Inc., Hogo, Japan). A window approximately 10 mm in diameter was opened at the base of the skull just anterior to the foramen of the optic canal, allowing identification of the main trunk of the right middle cerebral artery (MCA) just below the dura. After opening the dura, tMCAO was performed using two microvascular clips (Sugita TII, 17-001-81, Mizuho Medical, Tokyo, Japan), one placed on the proximal part of the main MCA trunk and the other on its distal to preorbital branch. Four hours after tMCAO, these clips were removed. After visual confirmation of recanalization of MCA blood flow, the burr hole was closed using Clearfil New Bond (Kuraray Noritake Dental, Inc., Tokyo, Japan), and the orbital cavity was closed by best veterinary practice.

[0419] Assessment of physiological parameters Body weight, core temperature, mean arterial blood pressure (MABP), heart rate, pO2, pCO2, sO2 and blood pH were assessed before and after tMCAO at specified intervals with respect to the normal physiological ranges reported for each parameter (refs. 22-23).

[0420] Transient middle cerebral artery occlusion and reperfusion Transorbital transient MCA occlusion (tMCAO) was performed using two microvascular clips, one placed on the proximal part of the main MCA trunk and the other on the distal preorbital branch (References 10, 11, 24). Four hours after MCA occlusion, these clips were removed for recanalization. After visual confirmation of restoration of MCA blood flow, the burr hole was closed using Clearfil New Bond (Kuraray Noritake Dental, Inc., Tokyo, Japan), and the orbital cavity was closed according to best veterinary practices.

[0421] Magnetic resonance imaging Serial coronal magnetic resonance imaging (MRI) of the brain (3 mm slice thickness) was performed at 0.5, 1.5, 1.8, 3.5, 6.0, 24 and 120 h after occlusion. Imaging sequences were: (i) diffusion-weighted imaging (DWI), arterial spin labeling (ASL), (ii) magnetic resonance angiography (MRA), and (iii) fluid-attenuated inversion recovery (FLAIR) T2-weighted imaging. Apparent diffusion coefficient (ADC) maps, cerebral blood flow (CBF), and perfusion defects were generated with FuncTool Performance (GE Healthcare, Milwaukee, WI, USA) available on the MRI scanner console. Inhibition of the volume of the lesion was considered the primary efficacy endpoint. Penumbra volume (mm 3 ) was calculated by subtracting the volume of the lesion differentiated from the DWI diffusion map from the calculated total perfusion defect.

[0422] Measurement of lesion volume, perfusion defect, and penumbra volume Measurement details The infarct (lesion) area (mm 2 ) were marked using OsiriX version 8.0.2 (Pixmeo SARL, Bernex, Switzerland). Infarcts were demarcated manually using DWI maps. Lesion volumes (mm 3 ) was calculated as the sum of the product of the infarct area and slice thickness (3 mm) for each section. No adjustment was made for potential edema when calculating infarct area and volume. Perfusion defect (mm 3 ) was calculated from the ASL maps as a reduction to <30% and <50% of the contralateral corresponding area. For clarity, the perfusion defect includes both the penumbra volume (hypo-oxygenated tissue) and the lesion volume (necrotic tissue). Penumbra volume (mm 3 ) was calculated by subtracting the volume of the lesion differentiated from the DWI diffusion map from the calculated total perfusion defect.

[0423] Controlling for edema effects in volumetric data sets In general, we did not observe any major edema increase in imaging after reperfusion in any of the subjects included in this study and final analysis.Nevertheless, the volume data of lesions from these subjects included in final analysis was controlled for the potential effect of edema using the Gerriets method.The analysis confirmed that the effect of edema on volume data was less than 1% and did not affect any of the analyses performed.

[0424] Exclusion of subjects based on lesion volume At 1.5 h after occlusion, the infarct volume in each macaque was calculated from DWI and fitted with a linear regression model based on lesion volumes obtained over time from three macaques with 3 h of occlusion and six macaques with 4 h of occlusion (medical history data, animals not included in this study). log(lesion volume, mm 3 ) = 5.141 + 0.641 × (time after MCA occlusion, hours) The 90% prediction interval (PI) is determined by: PI = mean ± t 0.1,df=n-1 ×RSD×sqrt(1+1 / n) The residual standard deviation (RSD) was 0.614, the number of observations (n) was 57, and the t-value (two-tailed test) for n-1 degrees of freedom and the significance level (t 0.1,d.f.=n-1 ) was 1.68. Thus, 1.5 hours after occlusion, the mean (90% PI) lesion volume was 447.0 mm 3 Macaques with calculated infarct volumes falling either below or above the 90% PI were removed from treatment at that time and excluded from the study.

[0425] Drug administration and pharmacokinetic sampling Macaques received a bolus dose of vehicle (40% PEG400 in 0.9% saline) or I-1 into the saphenous vein 2 hours after occlusion (2 hours prior to restoration of MCA blood flow), immediately followed by a 22-hour intravenous infusion. This dosing regimen was designed to rapidly achieve and maintain predetermined plasma and cerebrospinal fluid (CSF) steady-state concentrations of I-1 based on its pharmacokinetics previously determined in untreated and MCA-occluded macaques (Tables A-C below). [Table A] [Table B] [Table C]

[0426] During MRI, vehicle or I-1 was infused into the saphenous vein via a syringe pump (TOP5500E, TOP Corp., Tokyo, Japan). Infusion following MRI was maintained via a programmable portable IPRECIO® dual infusion pump (DMP-100; Primetech Corp., Tokyo, Japan) transferred to the jugular line, both of which were secured to the jacket. Methods for pharmacokinetic sampling and bioanalytical analysis of plasma and CSF are described below.

[0427] Drug administration and pharmacokinetic sampling Blood samples (1.0 mL) were drawn into heparinized tubes from either the contralateral cephalic or femoral vein at 3, 6, 24, 48, 72, and 5 days after occlusion. Heparinized blood was centrifuged at 1,800 × g for 10 min at 4 °C. In the same animals, 0.3–0.5 mL of cerebrospinal fluid (CSF) was drawn at 6 and 24 h after occlusion. Macaques were sedated with ketamine (10 mg / kg, im) and CSF was collected via puncture of the cisterna magna. Plasma and CSF samples were snap frozen in liquid nitrogen and stored at −70 °C until shipment for further processing. Samples were shipped on dry ice. Plasma and CSF concentrations of I-1 were determined by LC / MS / MS utilizing a standard curve (performed by Bio Research Department, Kamakura Techno-Science, Inc., Kanagawa, Japan). The lower limits of quantitation for compound I-1 were 1.0 ng / mL and 0.1 ng / mL for plasma and CSF, respectively.

[0428] Assessment of neurological deficits At 24 hours and 5 days after occlusion, neurological deficits were scored using the Neurological Deficit Score (NDS) as described elsewhere. (25) The NDS was considered a secondary efficacy endpoint.

[0429] Exclusion criteria and replacement targets Exclusion criteria were based on a comparison of infarct volume to the 90% prediction interval (PI) made from the lesion volume in a pilot study. Based on these exclusion criteria, two macaques were found to have infarct volumes outside the 90% PI and were excluded and replaced. Subjects who died during the study were also replaced. Three subjects died following complications from the MCAO surgery and were replaced. Other exclusion criteria included limitations in overall health status prior to study entry and violation of species-specific ranges of biological parameters at three consecutive time points. No animals had to be excluded based on these criteria.

[0430] statistics Means and standard error of the mean (SEM) were calculated using Microsoft Excel 2016 (Microsoft Corporation). Statistical analysis was performed using SAS Analytical Pro version 9.4 (SAS Institute, Tokyo, Japan) and EXSUS version 8.1 (CAC Croit Corp., Tokyo, Japan). Additional statistical analysis was performed using Prism 4.02 (GraphPad Software, San Diego, CA). Prior to the t-tests of the complex and control groups, F-tests were performed to confirm equal variance between the control and complex groups. Next, t-tests, equal variances, were performed on the complex group versus the control group, and if the endpoint was positive, the individual dose groups were tested and the associations discussed. These individual analyses did not change the conclusions about the statistical significance of the complex and are considered descriptive analyses rather than tests of hypotheses. Statistical significance was set at p<0.05, with a trend towards statistical significance defined as 0.05≦p<0.1.

[0431] result Physiological parameters and baseline measurements Physiological parameters were measured before tMCAO (baseline) and throughout the study. There were no clinically relevant differences between vehicle-treated and I-1-treated groups for any parameter at baseline or during the study. All parameters remained primarily within normal physiological ranges with occasional small, transient deviations that did not trigger preset exclusion criteria.

[0432] I-1 retards ischemic lesion growth I-1 administration resulted in a rapid decline in the lesion growth rate (i.e., a decrease in slope) compared to both the vehicle and growth rates prior to I-1 treatment. The slope of lesion growth was calculated as a measure of the lesion growth rate compared to the linear phase of the lesion growth curve during the periods prior to drug initiation (0.5-1.8 h) and after drug initiation (1.8-6.0 h) (Figure 1A,B). During the period prior to drug initiation, the slope of lesion growth did not differ between the vehicle- and I-1-treated groups. However, after the initiation of I-1 treatment, the slope of the composite group was less than that of the vehicle group (p=0.004). The slope of lesion growth for the I-1 dose groups was less than that of the vehicle-treated group with statistical significance achieved in the mid- and high-dose groups (p=0.02) as well as a trend observed in the low-dose group (p=0.06). In addition, when the post-drug slope of lesion growth was compared with the pre-drug slope by itself, the rate of increase in the composite group after I-1 treatment was significantly less than the rate of increase before I-1 treatment (p<0.0001). Similar results were observed in the medium and high dose groups (p<0.002 and p<0.009, respectively; Fig. 1C). These data suggested that I-1 activation of adenosine A1 and A3 receptors resulted in a significant reduction in the rate of lesion growth following tMCAO.

[0433] I-1 preserves the penumbra and reduces overall stroke volume Initial measurements of cerebral perfusion defects were determined 0.5 hours after occlusion. As assessed by contralateral cerebral blood flow of either <30% or <50% (11,26-28), early MCAO perfusion defects were not significantly different between vehicle-treated or either I-1-treated groups (p = 0.63-0.97).

[0434] In general, penumbra volume (calculated by the 30% perfusion defect minus the volume of the lesion) decreased during the ischemic period across all groups (Figure 2). In the vehicle group, penumbra volume decreased by an average of 71% (604.5 mm 3 In contrast, the I-1 treated complex decreased by 48% (296.0 mm 3 / h; p=0.01). Penumbra volume preservation was greatest in the low dose group (p=0.001) compared to the vehicle group. The other I-1 treatment groups showed lower mean penumbra rate decline compared to the vehicle group, although high intersubject variability may have prevented statistical significance in the mid and high dose groups (p≧0.3).

[0435] The reduction in the rate of lesion growth with I-1 treatment resulted in a significant inhibition of total lesion volume measured by DWI (Fig. 3A,B). After 24 h of occlusion, total lesion volume tended to be 20% smaller in the I-1 complex compared to vehicle treatment (p=0.07; Fig. 3C). However, total lesion volume in the I-1 complex was 30% smaller than that of the vehicle group after 120 h of occlusion (p=0.05). Furthermore, the greatest inhibition of total lesion volume was observed with medium (p=0.04) and high (p=0.02) treatments (Fig. 3D). Findings about total lesion volume at 120 h were confirmed by histological lesion volume assessed in brain sections stained with HE (Fig. 4).

[0436] Pharmacokinetics and Pharmacodynamics of I-1 Plasma and CSF The I-1 dose levels in this study were designed to target specific plasma and CSF concentrations of I-1 based on previous analysis of the pharmacokinetics of I-1 in untreated and tMCAO monkeys, related to estimated brain adenosine A1 and A3 receptor occupancy (Table B). Using a combined bolus / infusion regimen, the average plasma and CSF concentrations of I-1 were within 2-fold of the target at all dose levels (Table, Fig. 5A, B and Table C) and remained within the entire infusion period. Plasma concentration-time analysis confirmed the advantage of this dosing regimen in maintaining targeted concentrations compared to a single intravenous bolus, where I-1 plasma concentrations were below the bioanalytical limit of quantification 8 hours after dosing. Good correlation existed between I-1 plasma and CSF concentrations, showing a plasma / CSF ratio of approximately 10 (Fig. 5C).

[0437] Comparison of mean I-1 plasma and CSF concentrations with the primary efficacy endpoint of % inhibition of lesion volume was performed using semi-log Emax When analyzed by plot, they showed a linear relationship (Figure 5D). These analyses also showed that E max When plotted on a curve, it shows a linear relationship between inhibition of lesion volume and brain A1R / A3R occupancy (Figure 5E).

[0438] Secondary endpoints The study did not have adequate power and duration to statistically evaluate neurological deficits following tMCAO. However, preliminary evaluations were performed 1 and 5 days after occlusion to identify any potential trends in neurological function. From days 1 to 5 of the study, improved but not statistically significant (p=0.11) neurological function was observed in the I-1-treated complex compared to the vehicle-treated group (Figure 6).

[0439] Consideration This study demonstrated the cerebroprotective efficacy of I-1, a dual agonist for human A1R and A3R (ref. 12), in an NHP model of 4-h transient cerebral ischemia. Compared with vehicle treatment, I-1 treatment reduced total infarct volume 24 h and 5 days after MCA occlusion. In addition to reducing total infarct volume, I-1 treatment slowed the rate of infarct volume expansion over time. Our findings suggest a cerebroprotective effect of I-1 and are supported by the finding that penumbra volume reduction was reduced under I-1 treatment. Taken together, the findings suggest A1R / A3R activation as a potential cerebroprotective strategy that can be utilized to prevent brain tissue necrosis, ultimately improving functional outcomes following AIS.

[0440] Timely reperfusion of occluded vessels minimizes brain tissue death and neurological impairment following AIS (Ref. 29). For example, recanalization techniques by thrombolysis with recombinant tissue plasminogen activator (r-tPA) or mechanical thrombectomy offer a radical change in AIS treatment, but are limited to a relatively narrow time window (<4.5 hours for r-tPA) and to select patient populations exhibiting large penumbra / core mismatches and accessible clots in large operable vessels (Ref. 29). A significant risk of cerebral hemorrhage is associated with delayed r-tPA treatment, making r-tPA a contraindication for use in nonthrombotic strokes. This limits its use to a low percentage of stroke patients. Procedures that protect brain tissue from hypoxic injury and are not limited to these narrow time windows would be of enormous value in stroke treatment. Furthermore, a procedure with the potential to immediately delay penumbra decline before recanalization would widen the therapeutic time window for both thrombolysis and thrombectomy, increasing the number of patients eligible for these interventions and reducing the severity of AIS (Ref. 3).

[0441] Basic Considerations and Pharmacokinetics Extracellular brain adenosine concentrations are significantly increased after the onset of ischemic stroke (References 30, 31). Activation of four G protein-coupled adenosine receptors, A1R, A2aR, A2bR and A3R, plays an important role in both neuroprotection and neurodegeneration (Reference 32). Activation of A2aR can lead to neurodegeneration through glutamate receptor-mediated pathways. Activation of A2bR can lead to neurodegeneration through promotion of neuroinflammation, although investigations to date on this receptor are inconsistent with examples of both A2bR agonism and antagonism leading to brain protection (References 33, 34). Neuroprotective effects are observed following activation of A1R and A3R (References 13-20, 35). To date, several reasons have limited progress in the development of high-affinity adenosine receptor agonism-based therapies for AIS. First, data suggest that A1R and A3R are susceptible to rapid desensitization by potent agonists, including their endogenous ligand adenosine (Refs. 36, 37). Second, high-affinity full A1R agonists have unacceptable peripheral cardiovascular side effects, including bradycardia and hypotension, due to vascular A1R activation (Refs. 38, 39). Furthermore, clinical evaluation of high-affinity A3R agonists in the AIS could be limited by problematic chemical properties of presynthesized nucleoside ligands, including poor brain distribution (Refs. 40-43), low unbound brain concentrations that prevent adequate target engagement (Refs. 44, 45), as well as the aforementioned tendency to rapidly desensitize the receptor. An ideal AR agonist should exhibit excellent distribution in brain tissue and avoid potential adverse cardiovascular effects, traits that could also mitigate the possibility of receptor desensitization, e.g., with either lower affinity or partial agonism. Therefore, the present study not only evaluated the potential cerebroprotective effects of I-1 but also closely monitored subjects for any adverse cardiovascular side effects that may occur following systemic administration.

[0442] I-1 showed good brain distribution, as well as high free fractions in both plasma and brain tissue. CSF drug concentrations are an established surrogate for brain concentrations of unbound drugs that interact with central receptor targets (refs. 46, 47). Unbound brain concentrations and resulting brain receptor occupancies at A1R and A3R can be estimated using receptor affinity data and a single mass action equation (refs. 48, 49). In a previous study in neonatal pigs, we showed that I-1 CSF concentrations were equivalent to unbound I-1 brain extracellular fluid concentrations as determined via an in situ equilibrium dialysis probe (ref. 35). Thus, during the 22-h infusion of I-1, sufficient CSF concentrations were available to provide central A1R and A3R coverage in macaques. Measurable concentrations of I-1 were found in plasma for 24 h following cessation of medium and high-dose infusions, suggesting the prolonged presence of significant I-1 concentrations in the brain.

[0443] I-1 administration did not result in significant changes in MABP or heart rate as would be expected with systemic administration of a full A1R agonist (refs. 38, 39). In addition, pre-set physiological criteria were not violated for changes in body temperature, MABP pressure, heart rate, pO2, pCO2, sO2, or pH. Incidental deviations of these parameters from normal ranges are associated with stroke or procedure, as such deviations were observed in both vehicle- and I-1-treated macaques. These data suggest a lack of significant adverse side effects following sustained activation of A1R and A3R, further suggesting that I-1 may be safely evaluated in human patients.

[0444] I-1-mediated brain protection The penumbra will eventually become infarcted tissue if timely revascularization does not occur. Thus, slowing the loss of preserved or viable tissue in the penumbra during occlusion is an important objective of current cerebroprotectants (ref. 3). Potential cerebroprotectants have already been tested in rodent models of tMCAO, but few have examined the effects of these agents in the penumbra, due in part to the limited access to small animal MRI required to visualize the diffusion-perfusion mismatch. Studies in larger animals, including NHPs, have mostly relied on the final volume of the lesion as a neuroanatomical indicator of neuroprotection (refs. 7, 24). This study utilized the change in penumbra volume over time as an indicator of cerebroprotection. The smaller infarct volumes observed at 24 hours and 5 days following I-1 treatment manifest as a reduced rate of penumbra volume loss over time. Indeed, we observed reduced penumbra volume loss in the combined and low-dose groups (p<0.01). There were smaller mean differences in penumbra volume reduction in all other I-1 treatment groups, but these differences were not statistically significant. Nevertheless, the data obtained are very promising but may require larger cohorts for validation.

[0445] A reduction in the rate of lesion growth is a strong indicator of brain protection. After occlusion but before treatment (0.5-1.8 h after occlusion, before infusion), the rate of lesion growth between vehicle and I-1-treated groups was similar. However, compared to vehicle treatment, the rate of lesion growth after the initiation of I-1 treatment was significantly lower. In turn, the reduction in the rate of infarct growth resulted in significantly smaller infarct volumes at day 5. Future studies using higher resolution in vivo imaging studies or absolute quantification of cerebral blood flow could identify specific neuroanatomical regions in the penumbra during tMCAO that would benefit from therapeutic intervention (ref. 50).

[0446] Because there is high sequence homology between NHP and human A1R and A3R (51) and the affinity of I-1 for human A1R and A3R is similar (12), it is expected that the calculated receptor occupancy values ​​should be very similar for adenosine receptors in both NHP and human brain. max In the plot, a linear relationship was observed across the I-1 dose regimens utilized in this study. max Because relationships are typically sigmoidal, these linear relationships present the intriguing possibility that maximal efficacy of I-1 was not achieved in this study. Further studies should determine whether even higher levels of efficacy of I-1 can be achieved in the NHP tMCAO model, as a function of matrix concentration and receptor occupancy, E max It is necessary to establish what is reached.

[0447] limit Several limitations of this study should be noted. First, the relatively small sample size. We selected a minimal sample in an attempt to reduce the number of animals used. Nevertheless, statistically significant positive outcomes were achieved in the primary outcome measures, suggesting a relatively large effect size. Second, there was high intersubject variability in many of the reading parameters. This may be due to the small sample size in the treatment subgroups combined with the relatively large variance of individual data that may have "masked" statistical significance. The larger variance of data is typically for large animal models that draw from mixed populations and better reflect clinical reality (Reference 52). Therefore, we can assume that the external validity of our study is good, although it means that at the same time that certain endpoints may require larger group sizes for complete evaluation. Third, the overall observation period was relatively short. Although further changes may occur in some endpoints, including NDS, in the long term, the primary and other important MRI-based efficacy outcomes will benefit from the selected configuration. Confirmation of our results in larger cohorts, primarily targeting functional outcomes as well as long-term lesion construction, may be justified.

[0448] conclusion In summary, this study investigated the effects of A1R / A3R activation via I-1, a novel adenosine A1R / A3R receptor agonist, in an NHP model of AIS with recanalization. Efficacy was observed in key outcome measures including rate of infarct volume growth, total lesion volume, and penumbra volume preservation. The efficacy observed in these neuroanatomical outcome measures is comparable to I-1 concentrations in plasma and CSF and further aligns with estimated brain A1R / A3R receptor occupancy. Importantly, estimates of receptor occupancy associated with efficacy in this non-human primate model can be utilized to identify dose levels for human clinical trials that obtain similar levels of receptor occupancy, thus enhancing the likelihood of translation to human stroke trials and ensuring that pharmacological approaches are fully evaluated. These findings justify further preclinical and clinical investigation of A1R and A3R activation as a novel brain protective strategy. Positive outcomes for safety parameters also justify early clinical safety and efficacy trials in human patients. References

[0449] 1. Powers WJ. Acute ischemic stroke. N Engl J Med. 2020;383:252-260

[0450] 2. Herpich F, Rincon F. Management of acute ischemic stroke. Crit Care Med. 2020;48:1654-1663

[0451] 3. Savitz SI, Baron JC, Fisher M, Stair X Consortium. Stroke Treatment Academic Industry Roundtable X: Brain cytoprotection therapies in the reperfusion era. Stroke. 2019;50:1026-1031

[0452] 4. Albers G, Ashwood, T, Barone, FC, Basta, SL, Bogousslavsky, J, Buchan, AM, Cady, WJ, Chan, PH, Clemens, JA, Cox, BF, Craddock, RE, Cramer, SC. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-2758

[0453] 5. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244-2250

[0454] 6. Bratane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M. Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke. 2011;42:3265-3270

[0455] 7. Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483:213-217

[0456] 8. Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, Poppe AY, Buck BH, Field TS, Dowlatshahi D, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (Escape-NA1): A multicentre, double-blind, randomised controlled trial. Lancet. 2020;395:878-887

[0457] 9. Suzuki E, Nishimura N, Yoshikawa T, Kunikiyo Y, Hasegawa K, Hasumi K. Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys. Pharmacol Res Perspect. 2018;6:e00448

[0458] 10. Hudgins WR, Garcia JH. Transorbital approach to the middle cerebral artery of the squirrel monkey: A technique for experimental cerebral infarction applicable to ultrastructural studies. Stroke. 1970;1:107-111

[0459] 11. Takamatsu H, Tsukada H, Kakiuchi T, Nishiyama S, Noda A, Umemura K. Detection of reperfusion injury using pet in a monkey model of cerebral ischemia. J Nucl Med. 2000;41:1409-1416

[0460] 12. Liston TE, Hinz S, Muller CE, Holstein DM, Wendling J, Melton RJ, Campbell M, Korinek WS, Suresh RR, Sethre-Hofstad DA, et al. Nucleotide P2Y1 receptor agonists are in vitro and in vivo prodrugs of A1 / A3 adenosine receptor agonists: Implications for roles of P2Y1 and A1 / A3 receptors in physiology and pathology. Purinergic Signal. 2020;16:543-559

[0461] 13. Chen GJ, Harvey BK, Shen H, Chou J, Victor A, Wang Y. Activation of adenosine a3 receptors reduces ischemic brain injury in rodents. J Neurosci Res. 2006;84:1848-1855

[0462] 14. Fedorova IM, Jacobson MA, Basile A, Jacobson KA. Behavioral characterization of mice lacking the A3 adenosine receptor: Sensitivity to hypoxic neurodegeneration. Cell Mol Neurobiol. 2003;23:431-447

[0463] 15. Bjorklund O, Shang M, Tonazzini I, Dare E, Fredholm BB. Adenosine A1 and A3 receptors protect astrocytes from hypoxic damage. Eur J Pharmacol. 2008;596:6-13

[0464] 16. Martire A, Lambertucci C, Pepponi R, Ferrante A, Benati N, Buccioni M, Dal Ben D, Marucci G, Klotz KN, Volpini R, et al. Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia. J Neurochem. 2019;149:211-230

[0465] 17. Von Lubitz DK, Lin RC, Melman N, Ji XD, Carter MF, Jacobson KA. Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol. 1994;256:161-167

[0466] 18. Bischofberger N, Jacobson KA, von Lubitz DK. Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann N Y Acad Sci. 1997;825:23-29

[0467] 19. Bozdemir E, Vigil, F.A., Bugay, V., Chun, S.H., Espinoza, L., Lorenzo, D., Holstein, D.M., Elliot, R., Sprague, C., Rule, G., Cavazos, J.E., Shapiro, M.S., Zamora, D., Brenner, R. and Lechleiter, J.D. Protective role of adora3 agonist AST-004 in blast and blunt TBI models. Military Health System Research Symposium. 2019

[0468] 20. Sayre NL, Holstein, D., Stoveken, B.J., Sprague, S., Digicaylioglu, M., Liston, T., Korinek, W.S. and Lechleiter, J.D. Novel treatment reduces short and long term impacts of single and repetitive concussions in mice. Chronic Traumatic Encephalopathy (CTE) Conference. 2017

[0469] 21. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Davalos A, Majoie CB, van der Lugt A, de Miquel MA, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: A meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723-1731

[0470] 22. Yao JA, Feldman HS, Illenberger A, Littell T, Schnee L, Yates D. Evaluation of electrocardiograms recorded in cynomolgus monkeys with short- and long-term intracardiac lead implantations. J Pharmacol Toxicol Methods. 2009;60:185-192

[0471] 23. National Centre for the Replacement Refinement and Reduction of Animals in Research. The macaque website - physiological indicators. www.nc3rs.org.uk / macaques / welfare-assessment / physiological-indicators / . 2021.

[0472] 24. Takamatsu H, Tsukada H, Noda A, Kakiuchi T, Nishiyama S, Nishimura S, Umemura K. FK506 attenuates early ischemic neuronal death in a monkey model of stroke. J Nucl Med. 2001;42:1833-1840

[0473] 25. Kito G, Nishimura A, Susumu T, Nagata R, Kuge Y, Yokota C, Minematsu K. Experimental thromboembolic stroke in cynomolgus monkey. J Neurosci Methods. 2001;105:45-53

[0474] 26. Sun Z, Zhang X, Zhang Y, Guo H, Zhang J, Yu C. Estimation of the ischemic penumbra based on CT perfusion a pilot study. Acad Radiol. 2010;17:1535-1542

[0475] 27. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, et al. The desmoteplase in acute ischemic stroke trial (dias): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73

[0476] 28. Bivard A, McElduff P, Spratt N, Levi C, Parsons M. Defining the extent of irreversible brain ischemia using perfusion computed tomography. Cerebrovasc Dis. 2011;31:238-245

[0477] 29. Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, Sonnenberg FA, Schulman S, Vandvik PO, Spencer FA, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e601S-e636S

[0478] 30. Phillis JW, Smith-Barbour, M., O’Regan, M.H., and Perkins, L.M. Amino acid and purine release in rat brain following temporary middle cerebral artery occlusion. Neurochemical Research. 1994;19:1125-1130

[0479] 31. Laghi Pasini F, Guideri F, Picano E, Parenti G, Petersen C, Varga A, Di Perri T. Increase in plasma adenosine during brain ischemia in man: A study during transient ischemic attacks, and stroke. Brain Res Bull. 2000;51:327-330

[0480] 32. Melani A, Pugliese AM, Pedata F. Adenosine receptors in cerebral ischemia. Int Rev Neurobiol. 2014;119:309-348

[0481] 33. Gu L, Huang B, Shen W, Gao L, Ding Z, Wu H, Guo J. Early activation of nSMase2 / ceramide pathway in astrocytes is involved in ischemia-associated neuronal damage via inflammation in rat hippocampi. J Neuroinflammation. 2013;10:109

[0482] 34. Li Q, Han X, Lan X, Hong X, Li Q, Gao Y, Luo T, Yang Q, Koehler RC, Zhai Y, et al. Inhibition of tPA-induced hemorrhagic transformation involves adenosine a2b receptor activation after cerebral ischemia. Neurobiol Dis. 2017;108:173-182

[0483] 35. Kilbaugh T, Liston, T., Stolow, M., Hanlon, L., Bozdemir, E., Holstein, D., Kurbanov, A., Tunca, C., Poe, R., Lorenzo, D., Sethre-Hofstad, D., Lechleiter, J., and Margulies, S. Protective role of AST-004 in piglet model of blunt tbi - abstract. J. Neurotrauma. 2019;36:10384

[0484] 36. Klaasse EC, Ijzerman AP, de Grip WJ, Beukers MW. Internalization and desensitization of adenosine receptors. Purinergic Signal. 2008;4:21-37

[0485] 37. Mundell S, Kelly E. Adenosine receptor desensitization and trafficking. Biochim Biophys Acta. 2011;1808:1319-1328

[0486] 38. Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev. 1990;70:761-845

[0487] 39. Roelen H, Veldman N, Spek AL, von Frijtag Drabbe Kunzel J, Mathot RA, AP IJ. N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors. J Med Chem. 1996;39:1463-1471

[0488] 40. Brodie MS, Lee K, Fredholm BB, Stahle L, Dunwiddie TV. Central versus peripheral mediation of responses to adenosine receptor agonists: Evidence against a central mode of action. Brain Res. 1987;415:323-330

[0489] 41. Gervitz LM, Lutherer LO, Hamilton ME, Fowler JC. Lack of central effects of peripherally administered adenosine A(1) agonists on synaptic transmission in the rat hippocampus. Brain Res. 2002;951:141-145

[0490] 42. Schaddelee MP, Read KD, Cleypool CG, Ijzerman AP, Danhof M, de Boer AG. Brain penetration of synthetic adenosine A1 receptor agonists in situ: Role of the rENT1 nucleoside transporter and binding to blood constituents. Eur J Pharm Sci. 2005;24:59-66

[0491] 43. Tosh DK, Rao H, Bitant A, Salmaso V, Mannes P, Lieberman DI, Vaughan KL, Mattison JA, Rothwell AC, Auchampach JA, et al. Design and in vivo characterization of A1 adenosine receptor agonists in the native ribose and conformationally constrained (n)-methanocarba series. J Med Chem. 2019;62:1502-1522

[0492] 44. Tosh DK, Padia J, Salvemini D, Jacobson KA. Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective a3 adenosine receptor agonist that protects against chronic neuropathic pain. Purinergic Signal. 2015;11:371-387

[0493] 45. Wzorek J, Bednarek R, Watala C, Boncler M. Binding of adenosine derivatives to carrier proteins may reduce their antiplatelet activity. Biochem Pharmacol. 2020;174:113827

[0494] 46. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos. 2006;34:1443-1447

[0495] 47. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos. 2009;37:787-793

[0496] 48. Liu X, Vilenski O, Kwan J, Apparsundaram S, Weikert R. Unbound brain concentration determines receptor occupancy: A correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos. 2009;37:1548-1556

[0497] 49. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD. Receptor occupancy and brain free fraction. Drug Metab Dispos. 2009;37:753-760

[0498] 50. Werner P, Saur D, Zeisig V, Ettrich B, Patt M, Sattler B, Jochimsen T, Lobsien D, Meyer PM, Bergh FT, et al. Simultaneous PET / MRI in stroke: A case series. Journal of Cerebral Blood Flow & Metabolism. 2015;35:1421-1425

[0499] 51. van der Putten C, Zuiderwijk-Sick EA, van Straalen L, de Geus ED, Boven LA, Kondova I, AP IJ, Bajramovic JJ. Differential expression of adenosine A3 receptors controls adenosine A2a receptor-mediated inhibition of TLR responses in microglia. J Immunol. 2009;182:7603-7612

[0500] 52. Herrmann AM, Meckel S, Gounis MJ, Kringe L, Motschall E, Mulling C, Boltze J. Large animals in neurointerventional research: A systematic review on models, techniques and their application in endovascular procedures for stroke, aneurysms and vascular malformations. J Cereb Blood Flow Metab. 2019;39:375-394

[0501] 53. Gerriets T, Stolz E, Walberer M, Muller C, Kluge A, Bachmann A, Fisher M, Kaps M, Bachmann G. Noninvasive quantification of brain edema and the space-occupying effect in rat stroke models using magnetic resonance imaging. Stroke. 2004;35:566-571.

[0502] Example 2 Determination of I-1 CSF concentrations in the Phase I SAD / MAD study In this discussion, we summarize the rationale for obtaining CSF concentrations of I-1 in clinical single ascending dose (SAD) and multiple ascending dose (MAD) studies, and how the information is used to estimate target central receptor occupancy and phase II doses.

[0503] The challenge of GPCR agonism versus antagonism The majority of drug discovery and development focuses on some form of receptor antagonism or enzyme inhibition, i.e., blocking the effects of endogenous ligands. Due to the propensity of enzymes and receptors to have large reserves, endogenous ligands can be used to block the effects of ECs. 50or E max To have an effect, they only need to interact with a relatively low percentage of the receptor population. What this means is that drug receptor antagonists or enzyme inhibitors need to block a high percentage of the drug target active sites to block the effect of the endogenous ligand. In other words, they need to have a high receptor occupancy to have the desired therapeutic effect. The exact percentage of antagonism / inhibition required can vary widely depending on the target, tissue, and disease state. In general, however, this requirement for high receptor occupancy of antagonists / inhibitors forces medicinal chemists to design for high affinity to ensure not only broad coverage of the active sites, but also to ensure that it can be achieved at a reasonable dose and reasonable cost of goods.

[0504] Conversely, for receptor agonists, a smaller percentage of receptor occupancy may be effective in producing the desired therapeutic outcome. In some cases, a low percentage of receptor occupancy may still result in a higher EC due to the large receptor reserve of many receptors. 50 or E max You can get the effect. This EC 50 The receptor occupancy associated with is as low as <1% for some agonists. The required receptor occupancy can vary widely between species, tissues, and diseases due to differences in agonist affinity, efficacy, receptor-effector coupling, etc.

[0505] Receptor occupancy is the first step for a pharmacological effect to result in efficacy (or toxicity), so understanding receptor occupancy at / near target sites is crucial for setting effective doses.

[0506] Challenges of Measuring Target Engagement in CNS Programs Subsequently, if we can determine the receptor occupancy in the target organ / compartment that is associated with efficacy, we can use that number to guide dose selection. In many therapeutic areas, sampling of appropriate target tissues is relatively uncomplicated. For drug targets in well-perfused organs, the plasma concentration of the drug can be easily used to estimate the receptor occupancy in the target organ.

[0507] CNS drug targeting is a special challenge in this area. This is due to the blood-brain and blood-spinal cord barriers that can prevent distribution of drugs to the CNS compartment. The degree of distribution of unbound drug from blood or plasma to the brain is difficult to predict and can vary by species. The field of CNS drug discovery / development is replete with failed drug candidates that were advanced based on the assumption of a brain-free fraction, distribution of drugs to the brain or the idea that plasma drug concentrations correlated with brain drug concentrations.

[0508] For these reasons, Liu and his colleagues at Pfizer began evaluating how to predict receptor occupancy in the brain. Liu X, et al., "Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration," Drug Metab Dispos. 2006;34:1443-144;Liu X, et al., "Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos. 2009;37:787-793;and Liu X, et al., "Unbound brain concentration determines receptor occupancy: A correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats," Drug Metab Dispos. 2009;37:1548-1556. First, they showed that CSF drug concentrations were much better predictors of brain unbound drug concentrations than total or unbound plasma drug concentrations, especially for more hydrophilic compounds such as I-1. Second, they showed that brain unbound drug concentrations could be used to predict brain receptor occupancy. Since it is not possible to obtain brain biopsies from human volunteers, the next question was whether CSF drug concentrations could also be used to predict brain receptor occupancy.Studies such as Liu's indicate that CSF drug concentrations are a reasonable surrogate for the unbound brain drug concentrations needed to estimate brain receptor occupancy, and are superior to the plasma concentrations relied upon to date.

[0509] Thus, the determination of CSF concentrations of a compound, e.g., I-1, enables clinical studies. All investigations to this point indicate that plasma drug concentrations are poor predictors of brain receptor occupancy, and CSF drug concentrations are suboptimal to experimentally determined brain unbound extracellular fluid concentrations.

[0510] Receptor occupancy calculation Receptor occupancy is a mass action relationship.

number

[0511] The percentage of receptors occupied by an agonist or antagonist is a function of drug concentration and drug affinity for the receptor target. The challenge is that the drug concentration at the target site (in this case brain and CSF) can vary from species to species as can the affinity of the drug target. The affinity of I-1 for its receptor target can vary as much as 5-fold between species. Therefore, it is necessary to determine the affinity of I-1 for its target as well as the concentration of I-1 in the relevant matrix for each species and at each administered dose. Since plasma concentrations have been shown to be not useful for predicting receptor occupancy of brain targets, the only matrix available is CSF.

[0512] I-1 receptor occupancy to date We have used this approach with great success in preclinical species to date: mice, rats, neonatal pigs, and non-human primates. This study not only demonstrates the approach of dose selection based on estimated brain receptor occupancy, but also shows why we need to make these decisions in each species, including humans.

[0513] In our rodent mouse and rat efficacy studies, we were able to directly determine the unbound drug concentration in the brain at effective doses. In their efficacy models, the estimated receptor occupancy associated with efficacy was about 1% or less. This indicates that the rodent brain may have a very large receptor reserve for drug targets.

[0514] Using this estimate of receptor occupancy, we proceeded with a study in neonatal pigs targeting doses that would obtain unbound brain and CSF concentrations that would provide receptor occupancy similar to that associated with efficacy in rodent models. In pigs, we have the advantage of performing a pharmacokinetic study that includes collection of CSF, cerebral equilibrium dialysis, which directly determines brain unbound extracellular fluid concentrations, plasma concentrations, and final brain total concentrations. This was an important study because it showed that I-1 concentrations in the CSF were equivalent to unbound brain extracellular fluid concentrations. This was an important study that validated the use of I-1 CSF concentrations to estimate brain receptor occupancy. In the pig efficacy study, we achieved efficacy with an estimated receptor occupancy of approximately 2%.

[0515] We next proceeded to an important preclinical stroke efficacy model in non-human primates. In a preliminary efficacy pharmacokinetic study, plasma and CSF pharmacokinetic data were obtained. I-1 CSF concentrations were combined with receptor affinity data to estimate receptor occupancy, and the combination of CSF concentrations and associated receptor occupancy was used to set dose regimens for efficacy studies.

[0516] In monkeys, we observed efficacy beginning to occur with estimated receptor occupancy in the range of 3-4%. We also observed a correlation between unbound plasma concentrations and CSF drug concentrations, but had we not collected CSF and determined I-1 CSF concentrations, we would not have known what that correlation was. If we were to conduct additional primate efficacy studies, we would not need to obtain CSF concentrations, since we would know the relationship between unbound plasma and CSF drug concentrations. It is important to note that in these preclinical efficacy studies, unbound plasma concentrations grossly over-predicted brain receptor occupancy, leading us to dose below the threshold for I-1 efficacy.

[0517] Intended Clinical Application Through our preclinical pharmacokinetic and efficacy studies, we have demonstrated the value of determining I-1 CSF or brain unbound drug concentrations and using these data to estimate brain receptor occupancy for dose setting and interspecies transfer. Our intention is to extend the implementation to human clinical trials to set doses for Phase II.

[0518] Our objectives are to: To determine I-1 concentrations in CSF at each Phase I dose level Future studies will determine the relationship between unbound plasma I-1 and CSF concentrations so that we can predict CSF exposure solely from plasma concentration data. To determine how CSF drug concentrations accumulate with repeated dosing and, most importantly, to determine the dose of I-1 in humans that provides CSF drug concentrations that result in receptor occupancy associated with efficacy in preclinical models to date.

[0519] After determining the latter, we use it to set the mid-dose of our Phase II study. Knowing that there may be species differences in receptor-effector coupling, we set doses above and below this target dose to increase the chance of observing efficacy at a range of receptor occupancies around the targeted receptor occupancy. Due to the high failure rate and expense of conducting clinical trials, the approach we outline above provides an important solution to the need for better predictability in evaluating new drug candidates, such as I-1 and the related compounds mentioned above.

[0520] Example 3 Plasma and brain pharmacokinetics of I-25 (R-PIA) and brain-free fraction in rats The compound R-phenylisopropyl adenosine (R-PIA) is 6 -substituted adenosine analogs. Roucher and coworkers studied the effects of R-PIA administration in a rat model of cerebral ischemia, and MacGregor and coworkers studied its effects on kainic acid-induced hippocampal lesions in rats and on the neurological effects. See Roucher, P., et al., J Cereb Blood Flow Metab. 1991 May;11(3):453-8;MacGregor, DG, et al., Br J Pharmacol. 1993 Sep; 110(1): 470-476;MacGregor, DG, et al., Br J Pharmacol. 1993 Jun; 109(2): 316-321. R-PIA is a high affinity A1R agonist with similarly good A3R affinity. Its A1R K i is 1.2 nM, and its A3R K i The affinity of 158 nM. However, it also has an A2a affinity of 220 nM. A2a agonism has been shown to have neurodegenerative effects in previous studies.

[0521] Roucher reported that the rat was exposed to reversible forebrain ischemia before, during, and 30 min after ischemia in vivo. 31The metabolic effects of R-PIA were studied by P NMR spectroscopy. R-PIA had no effect on cerebral metabolism before ischemia. During 30 min of ischemia, R-PIA reduced the decline in phosphocreatine (43 + / - 11% of control levels at the end of ischemia vs. 27 + / - 9% in the reference group) and ATP (58 + / - 12% vs. 40 + / - 23%) as well as the increase in inorganic phosphate (672 + / - 210% vs. 905 + / - 229%). The intracellular acidosis induced by ischemia was also reduced in the treated group (pH of 6.40 + / - 0.10 vs. 6.30 + / - 0.10). Recirculation was associated with a more rapid recovery of PCr, ATP, Pi, and pHi control levels in the treated group than in the reference group. It was concluded that adenosine protects against ischemic injury by a mechanism involving metabolic protection.

[0522] As part of this study, we first replicated the original Roucher results. As shown in Figure 7, at a dose of 0.02 mg / kg, R-PIA showed partial reversal of the decline in ATP during ischemia. Roucher did not describe the pharmacokinetics, brain concentrations, or target engagement of R-PIA.

[0523] Therefore, the inventors 31 The same study using P-ATP was performed to measure receptor engagement in the brain associated with beneficial ATP effects. The estimated RO% was 16% RO for A1R and 1% RO for A3R. The significance of this result is that for the agonist R-PIA, A1R and A3R receptor occupancies in the range of 1-16% led to a significant reversal of ATP decline in this rodent model of cerebral ischemia. The estimated receptor occupancy for compound I-1 associated with significant efficacy in NHP stroke studies was also 1-15% (low, medium, and high doses).

[0524] These results continue to support the hypothesis that A1R / A3R agonism at relatively low receptor occupancy results in sustained brain ATP generation and efficacy. Thus, dosing with A1R / A3R agonists, such as R-PIA and compound I-1, at doses that result in estimated brain receptor occupancy in the range of 15% is expected to be effective in both animals and humans.

[0525] Example 4 Pharmacokinetics of compounds after intraperitoneal administration to mice Examples 1 and 2 of U.S. Patent No. 9,789,131, which is incorporated herein by reference, describe assays for determining the plasma and brain concentrations of certain compounds after intraperitoneal administration to mice at doses used in mouse photothrombosis and traumatic brain injury models.The compounds described herein can be evaluated using such assays or similar variations thereof.

[0526] Example 5 Plasma and brain binding of test compounds in mice Example 3 of U.S. Patent No. 9,789,131, incorporated herein by reference, describes an assay for determining the plasma and brain free fractions of certain compounds, such as I-1. The compounds described herein can be evaluated using such an assay or similar variations thereof.

[0527] Example 6 In vitro stability and metabolism of test compounds in mouse and human blood and plasma Example 4 of U.S. Patent No. 9,789,131, incorporated herein by reference, describes an assay for determining the in vitro stability and metabolic fate of certain compounds, such as I-1, in mouse and human blood and plasma. The compounds described herein can be evaluated using such an assay or similar variations thereof.

[0528] Example 7 Neuroprotective efficacy of test compounds following TBI in mice Example 5 of US Patent No. 9,789,131, which is incorporated herein by reference, describes an assay for determining the effectiveness of certain compounds, such as I-1, in inducing neuroprotection in mice subjected to traumatic brain injury (TBI). Compounds described herein can be evaluated using such an assay or similar variations thereof. The assay procedure is reproduced below.

[0529] the purpose This study is designed to determine the neuroprotective efficacy of a test compound in mice subjected to traumatic brain injury (TBI) and compare mice without traumatic brain injury treated with the test compound and Cl-IB-MECA, a full agonist of the adenosine A3 receptor.

[0530] method Chemicals: Test compounds are prepared as described above. Cl-IB-MECA is commercially available from Tocris Biosciences (Bristol, UK) and several other vendors. All other chemicals can be obtained from commercial vendors, such as Sigma-Aldrich (St. Louis, MO).

[0531] Animals and traumatic brain injury (TBI): TBI is performed using a controlled closed skull injury model as described by Talley-Watts et al. 2012 (J. Neurotrauma 30, 55-66). A pneumatic impact device is used to produce moderate TBI, with the skull and dura remaining intact, according to the methods described herein. To achieve this, C57BL / 6 mice are anesthetized with isoflurane (3% induction, 1% maintenance) in 100% oxygen. A temperature-controlled heated operating table is used to maintain body temperature at 37°C. Using sterile surgical techniques, a small midline incision is made in the scalp. A 5 mm stainless steel disk is placed on the skull and secured using superglue between bregma and lambda on the somatosensory cortex on the right parietal bone. The mouse is then placed on the table directly under the pneumatic impact tip. A calibrated impulse is delivered at 4.5 m / sec at a depth of 2 mm, thereby causing moderate injury to the mouse. The scalp incision is closed using 4-0 nylon braided suture, and the incision is applied with antibiotic ointment. The mouse is placed in a Thermo-Intensive Care Unit (Braintree Scientific model FV-1; 37°C; 27% O2) and monitored until fully awake and free to move about. Thirty minutes after injury or sham (uninjured), the mouse is treated with either vehicle (saline), test compound, or control (Cl-IB-MECA). Exemplary doses of test compound and Cl-IB-MECA are 0.16 mg / kg and 0.24 mg / kg, respectively, which are equivalent to approximately equimolar doses of 0.5 μmol / kg, respectively.

[0532] Western blot analysis for GFAP: At selected survival times, mice are anesthetized under isoflurane and sacrificed. Brains are removed and placed on ice for dissection into impacted and non-impacted hemispheres. Isolated tissues are rapidly homogenized using a Wheaton glass dounce (20 strokes) in homogenization buffer (0.32 M sucrose, 1 mM EDTA, 1 M Tris-HCL, pH=7.8) chilled on ice. Homogenates are transferred to 2 mL tubes and centrifuged at 1000 g for 10 min at 4° C., and the supernatants are collected and analyzed. Protein concentrations are determined by BCA assay using a 1:50 dilution. 100 μg protein is removed as an aliquot for each sample, Laemmli buffer containing β-mercaptoethanol is added, and samples are placed in a 95° C. heat block for 3 min. Samples are loaded onto a 12% gel and run at 80V for 20 minutes followed by 130V for 40 minutes. Samples are transferred to nitrocellulose membranes at 100V for 1 hour. Membranes are blocked with 5% milk in TBS-T for 30 minutes. GFAP (1:1000-Imgenex IMG-5083-A) is added and left at 4°C overnight. Membranes are washed 3 times with TBS-T for 10 minutes. Secondary antibody for GFAP (donkey anti-rabbit HRP conjugated (ImmunoJackson Laboratories; 711-035-152; 1:20000) is applied for 1 hour at room temperature. Membranes are washed 15 minutes (3 times) with TBS-T and developed using the Western Lightning Plus-ECL kit (PerkinElmer, Inc.) according to the manufacturer's instructions.

[0533] result Effective compounds (I-1 is known to be effective in this model) would be expected to reduce GFAP expression in mouse brains after TBI. Glial fibrillary acidic protein (GFAP) expression is used as a biomarker for reactive gliosis after TBI (Talley-Watts et al. 2012; Sofroniew, 2005). Western blot analysis is performed on GFAP expression in sham, TBI or TBI test compound treated mice sacrificed 7 days after injury. First, Western blot analysis confirms that TBI induces a significant increase in GFAP expression in both the ipsilateral (center impacted) and contralateral sides of the brain 7 days after injury. GFAP expression is significantly lower in blots from mice treated with test compounds, such as I-1 (injected within 30 minutes of initial trauma). For loading control, beta-actin Western blot is used. Data are typically averaged from three separate experiments and represent the relative changes in GFAP / actin ratios (band intensity measured using Image J software).

[0534] Effective compounds (I-1 is known to be effective in this model) can be expected to reduce GFAP levels in mouse plasma after TBI. GFAP levels in plasma were also used as a biomarker for TBI due to the breakdown of the blood-brain barrier (BBB) ​​after trauma. Consequently, we also collect plasma samples from TBI mice on day 7. GFAP levels are easily detected by Western blot analysis on day 7.

[0535] Compound I-1 is a low affinity (4900 nM) agonist of A3 receptor in mice. In contrast, Cl-IB-MECA is a high affinity (0.18 nM) agonist in mice, and the difference in affinity between these two compounds is approximately 25,000-fold. However, in mouse models of photothrombotic stroke and TBI, I-1 shows significant efficacy, which is blocked by the A3 antagonist MRS1523, while Cl-IB-MECA is inactive (stroke) or weakly active. One potential explanation for this surprising result is based on the ADME / PK data we have generated for I-1 and Cl-IB-MECA. Cl-IB-MECA is a lipophilic compound (cLogP approximately 2.5), highly bound to plasma proteins (free fraction 0.002), and highly bound non-specifically to brain tissue (free fraction 0.002). I-1 is a highly hydrophilic compound (cLogP<0) with a very large unbound fraction in plasma (0.74) and brain (0.13). Only unbound drug is available for distribution across membranes and interaction with receptors. Thus, despite I-1's lower receptor affinity, the fraction of I-1 available to interact with A3 receptors in these mouse models is at least 1000-fold greater than Cl-IB-MECA. These significant differences in the physicochemical properties and ADME / PK characteristics of the compounds may contribute to the nontrivial efficacy of I-1 and other compounds described herein compared to Cl-IB-MECA (and MRS5698, another lipophilic and highly binding / high affinity full A3R agonist) in these mouse models. An alternative explanation is that compounds such as I-1 and other compounds shown in Table 1 act as dual A3 and A1 agonists or selective A1 agonists. Example 8 Neuroprotective Efficacy of AST-004 Following Stroke in Mice Examples 6 and 7 of US Patent No. 9,789,131, which is incorporated herein by reference, describe an assay for determining the effectiveness of certain compounds, such as I-1, in inducing neuroprotection in mice that have undergone stroke.Compounds described herein can be evaluated using such assay or similar variations thereof.The assay procedure is reproduced below.

[0536] the purpose This study is designed to determine the neuroprotective efficacy of test compounds in mice subjected to stroke, with or without the A3 receptor antagonist MRS1523, compared to the full A3R agonists MRS5698 and Cl-IB-MECA. MRS1523 has the following structure: [ka]

[0537] method Chemicals: Test compounds are prepared as described above. Cl-IB-MECA, MRS5698 and MRS2365 are commercially available from Tocris Bioscience (Bristol, UK) and several other vendors. All other chemicals can be obtained from Sigma-Aldrich (St. Louis, MO).

[0538] Photothrombosis-induced stroke: Photothrombosis is performed as described by Zheng et al 2010 (PloS One 5 (12): e14401). Briefly, Rose Bengal is a fluorescent dye that, when injected into the vasculature and excited, generates singlet oxygen that damages the endothelial wall and induces local thrombosis (blood clots). Using this technique, mice are given a tail vein injection of 0.1 mL of sterile Rose Bengal (RB, Sigma, USA) in artificial cerebrospinal fluid (aCSF). The RB concentration is 20 mg / mL. The cortical area is centered in the imaging field and illuminated with a green laser (543 nm, 5 mW) using a 0.8-NA 40x water immersion objective (Nikon, Tokyo). The formation of blood clots is monitored in real time until the targeted vessel or downstream capillaries are firmly occluded. Stable blood clots are then identified by non-fluorescent vessel segmentation terminating in hyperfluorescent regions. In control experiments, neither laser irradiation nor Rose Bengal itself resulted in the formation of blood clots. Treatments at doses such as 0.5 μmol / kg are administered by intraperitoneal injection (ip). For experiments using the A3 receptor antagonist MRS1523, mice are administered intraperitoneal injections (2 mg / kg) at 0 and 2 hours to ensure receptor antagonism throughout the course of the study.

[0539] Animals and photothrombosis-induced stroke: Stroke is performed as described by Zheng et al 2010 (PloS One 5 (12): e14401). Female C57Bl / 6 mice (4-6 months old) are used in this study. From the method of this paper, mice are anesthetized with 3% isoflurane with 100% oxygen via a nose cone and then maintained with 1% isoflurane. Anesthesia depth is monitored and regulated according to vital signs, pinch withdrawal, and eye blinks. Body temperature is maintained at 37°C by a feedback-controlled heating pad (Gaymar T / Pump). Vital signs including oxygen saturation, respiratory rate, and heart rate are continuously monitored by using a MouseOx system (...

Claims

1. 1. A method of treating an injury, disease, or disorder selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, a cardiac or cardiovascular disease, addiction, an addictive disorder, and a condition associated with TBI, stroke, or said neurodegenerative condition, comprising administering to a subject in need of treatment for said injury, disease, or disorder an ADP of the brain or CNS for a period of time sufficient to treat said condition. 1 R and / or A 3 A in an amount effective to achieve 0.01-40% receptor occupancy (%RO) at R 1 Receptor (A 1 R) and / or A 3 Receptor (A 3 R), or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

2. For efficacy in treating an injury, disease, or disorder selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, a cardiac or cardiovascular disease, and a condition associated with TBI, stroke, or said neurodegenerative condition, 1 R.A. 3 R or Dual A 1 R / A 3 A method for screening for an A R agonist, comprising administering to a subject in need thereof an amount of the A R agonist. 1 R.A. 3 R or Dual A 1 R / A 3 administering an A R agonist, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same; and 1 Receptor (A 1 R) and / or A 3 Receptor (A 3 R) determining percent receptor occupancy (% RO).

3. The above A 1 R.A. 3 R or Dual A 1 R / A 3 R agonists stimulate A 1 R and / or A 3 3. The method of claim 2, wherein the method is effective to treat the injury, disease, or disorder when R reaches 0.01-40% RO.

4. The above A 1 R.A. 3 R or Dual A 1 R / A 3 R agonists stimulate A 1 R and / or A 3 3. The method of claim 1 or 2, wherein the method is effective to treat the injury, disease, or disorder when R reaches 1-15% RO.

5. A method for determining an effective dose for treating an injury, disease, or disorder selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, a heart disease or cardiovascular disease, addiction, an addictive disorder, and a condition associated with TBI, stroke, or said neurodegenerative condition, comprising administering to a subject in need thereof an amount of A 1 R.A. 3 R or Dual A 1 R / A 3 administering an A R agonist, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same; and 1 Receptor (A 1 R) and / or A 3 Receptor (A 3 R) determining percent receptor occupancy (% RO).

6. 1. A method of predicting efficacy or predicting an effective dose for treating an injury, disease, or disorder selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, a cardiac or cardiovascular disease, addiction, an addictive disorder, and a condition associated with TBI, stroke, or said neurodegenerative condition, comprising administering to a subject in need thereof an amount of A 1 R.A. 3 R or Dual A 1 R / A 3 administering an A R agonist, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same; and 1 Receptor (A 1 R) and / or A 3 Receptor (A 3 R) determining percent receptor occupancy (% RO).

7. 1. A method of optimizing a treatment regimen for an injury, disease, or disorder selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, a cardiac or cardiovascular disease, addiction, an addictive disorder, and a condition associated with TBI, stroke, or said neurodegenerative condition, comprising administering to a subject in need thereof an amount of A 1 R.A. 3 R or Dual A 1 R / A 3 administering an A R agonist, or a pharma- ceutically acceptable salt thereof, or a composition comprising the same; and 1 Receptor (A 1 R) and / or A 3 Receptor (A 3 R) determining percent receptor occupancy (% RO).

8. The method of any one of claims 1 to 7, wherein the injury, disease or disorder is stroke.

9. A method of treating stroke, comprising administering to a subject in need of stroke treatment an anti-angiogenic agent to the brain or CNS for a period of time sufficient to treat the stroke. 1 Receptor (A 1 R) and / or A 3 Receptor (A 3 R) in an amount effective to achieve 0.01-40% receptor occupancy (% RO) of the following compound: 【Chemical 36】 or a pharma- ceutically acceptable salt thereof, or a composition comprising same.

10. 10. The method of claim 9, wherein the stroke is selected from ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, and transient ischemic attack (TIA).

Citation Information

Patent Citations

  • Compounds and methods for treating neurological and cardiovascular conditions

    JP2019515920A

  • Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists

    US20030092668A1